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ABSTRACT
INFLUENCE OF BILBERRY-DERIVED ANTHOCYANIDINS ON KEY REGULATORS OF
COLORECTAL CANCER DEVELOPMENT

Ashley Marie Mudd
August 24th 2018
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths within the United
States.

A variety of factors including exposure to environmental carcinogens, such as

benzo[a]pyrene (B[a]P), dysbiosis of the gut microbiome and hereditary influences, including
APC mutations, have been shown to lead to an increased risk of developing colorectal
cancer. Given the recent alarming rise in cases of colorectal cancer diagnosed in individuals
under the age of 40, further insight into developing novel and effective prevention and
treatment strategies are warranted. The family of plant pigments known as the anthocyanins
has been identified with a variety of health benefits including chemopreventive and
therapeutic effects. However, a limitation to current clinical applications of anthocyanins is
the high doses that are required. In order to overcome this barrier we tested the active
moiety, anthocyanidins, native bilberry mixture of anthocyanidins (Anthos), at various doses
for chemopreventive and therapeutic effects against colorectal cancer both in vitro and in
vivo. Anthos treatment led to favorable modulation of several key contributors to the
development of CRC including Src/EGFR pathway, Phase I/II enzyme expression and the
inflammatory microenvironment, with special emphasis on the expression of PD-L1, a key
immune checkpoint protein both in vitro and in vivo using an ApcMin/+ ETBF mouse tumor
model. These results provide a promising outlook on the impact of berry Anthos for treatment
and prevention of bacteria and B[a]P-driven colorectal cancer. Results from this study also
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provide novel mechanistic insight into the chemopreventive and therapeutic activities of
Anthos.
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CHAPTER 1:
PREFACE, BACKGROUND & INTRODUCTION
Preface
Previously thought to have been a disease on the decline, colorectal cancer
(CRC) has recently made a comeback in younger individuals. Of these cases of
CRC, the majority are in the distal and rectal regions. The exact cause(s) for this
alarming uptick have yet to be identified. Given this alarming rise, there is an
urgent need for research in both the prevention and treatment of CRC. With this
in mind, the focus of my doctoral research has been to utilize berry-derived
Anthos and exosomal formulation of Anthos (ExoAnthos) for the prevention and
treatment of a bacterially-driven model of CRC. Similar to the majority of
individuals that have been diagnosed with CRC in the younger generations, this
model develops tumors in the distal colon. A major component of the work
presented here has been to unravel the highly interrelated and complex
mechanism of action for how Anthos achieves highly significant reductions in
tumor burden as well as to determine how Anthos exerts protection against the
ubiquitous environmental carcinogen benzo[a]pyrene (B[a]P). Although, it should
be noted that gaining a complete understanding for how Anthos functions would
need a lifetime in research rather than the finite span that defines an individual’s
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time as a graduate student. Thus, the picture presented here is but a small albeit
compelling piece of the overall puzzle.
CRC
Classified as the third most common form of cancer diagnosed in men and
women, CRC is the third leading class for cancer-related deaths within the United
States. In fact, according to the American Cancer Society, an estimated 140,250
individuals will be diagnosed and 50,630 will die from CRC in the US in 2018
alone. Therefore, given the prevalence and lethality of CRC, there is an urgent
need for investigating not only chemotherapeutic alternatives but also
chemopreventive strategies for this disease.
Influences on the development of CRC
It is estimated that cases of CRC will increase by approximately 60% or 2.2
million new cases and 1.1 million deaths by 2030 [1]. Several factors have been
found to impact an individual’s chance of developing CRC including age, race,
gender [2], lifestyle and diet [3]. According to the American Cancer Society, the
lifetime risk of developing CRC is about 1 in 22 (4.49%) for men and 1 in 24
(4.15%) for women. The highest incidence rates have been found in countries
with high or very high human health indexes (HDI) such as North America,
Europe, Australia and New Zealand and the lowest incidence rates have been
found in Africa and South-Central Asia [4]. It should also be noted that although
the rates of CRC have been increasing recently in other parts of Asia, India has
maintained a low incidence of CRC.
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Figure 1: Distribution of estimated new cases of cancer and cancer deaths for
2018 by site, figure from American Cancer Society, Cancer Facts & Figures
2018.
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The low rate of CRC in this region has been hypothesized to be linked to variety
of factors such as the widespread consumption of fruits and vegetables,
vegetarianism and the use of spices such as turmeric (curry powder), which is
rich in the protective phytochemical, curcumin [5, 6]. The important role of one’s
diet on the likelihood of developing CRC was previously identified in a casecontrol study in Greece which found that individuals who consumed a diet that
was high meat/low vegetable versus high vegetable/low meat showed a risk ratio
of about 8 [7]. Additional, more recent studies assessing the influence of dietary
vegetable and particularly fruit intake on CRC prevention have found similar
protective benefits in individuals from Sweden, China, South Korea and the
United States [8-11] Overall, these epidemiological findings highlight the
protective role that vegetable and particularly fruit consumption may have against
the development of CRC and may be associated with the geographic differences
in incidence noted above.
Although the incidence of CRC has been decreasing since the mid to late 1980s
for individuals over 55 years old, a recent study has found a rather disconcerting
uptick in the CRC incidence for individuals below 55 years old in the US [12]. A
particularly concerning trend was noted for younger individuals, with individuals
born circa 1990 having a risk of developing colon cancer that is double that of an
individual born circa 1950 and for rectal cancer the risk was four-fold higher.
Moreover, a greater number of the younger cases were found in the distal colon
as opposed to the proximal colon. This is somewhat surprising considering that
tumors in the distal colon have been decreasing overall in recent years, while
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tumors of the proximal colon have become more common in the 55 years or
older portion of the population [12]. The exact causes for this recent increase in
younger individuals have yet to be defined. However, a number of factors have
been shown to contribute to the development of CRC. The below summary
provides an overview of some of the key environmental as well as genetic factors
that are related to the topic of this dissertation and that have been found to
impact the development of CRC.
The impact of diet and lifestyle on CRC risk
The important role that diet and lifestyle play not only on one’s overall health but
on the chance of developing CRC has been found in a number of studies.
Furthermore, it should be noted that chronic inflammation has been shown to be
a significant etiological factor in the development of colorectal adenocarcinoma
[13]. It has been shown in both males and females that a link exists between
consuming a high inflammatory diet, i.e. a diet rich in animal fat, alcohol et cetera
and low in fruits and vegetables, and developing CRC [3]. Moreover, results from
the same study also supported the benefits of an anti-inflammatory diet, which
include plant-based foods which are a rich source of phytochemicals, over a proinflammatory diet, which includes fried foods, highly processed foods etc., as a
means of decreasing the risk of developing CRC [3]. Additionally, coffee, which
contains a variety of bioactive compounds including polyphenols, melanoidins,
diterpenes, is believed to also lower the risk of developing CRC [14].
Epidemiological studies comparing coffee drinkers vs. non-drinkers showed a
26% lower odds of developing CRC [14]. There also appeared to be a dose5

dependent trend for both colon and rectal cancers. It was also noted that
decaffeinated as well as boiled coffee showed an inverse association (OR, 0.82;
95% CI: 0.68-0.99; P=0.04) and (OR, 0.82; 95% CI: 0.71-0.94; P=0.004),
respectively [14]. In addition to coffee, it has also been shown that regular green
tea consumption (at least three times per week for a minimum of 6 months),
which is a rich source of antioxidant tea polyphenols, reduces the risk of CRC
(HR=0.54, 95% CI: 0.34-0.86). Furthermore, it was noted that as green tea
consumption was increased risk of CRC decreased (Ptrend=0.01) [15].
In addition to dietary influences, another important factor that must be considered
is the long term use of medications such as statins, aspirin and non-aspirin
nonsteroidal anti-inflammatory drugs which are also believed to lower the risk of
developing CRC. For example statins which are believed to inhibit 3-hydroxy3methylglutaryl coenzyme A (HMG-CoA) reductase which is overexpressed in
colorectal cancer cells were associated with a 47% relative reduction in risk of
CRC [16]. Whereas, NSAIDS, which are believed to act by inhibiting
cyclooxygenase-2, which has been shown to be upregulated in CRC, was shown
to yield an adjusted relative risk of 0.5 (95% confidence interval of 0.4-0.7) [17].
Boundless insight into the complex exchange between the individual and their
environment and their associated risk of developing CRC has been gained by the
sheer depth of epidemiological studies conducted to date [18-22]. However, the
above findings should be interpreted with caution due to the dangers of inferring
causation from association. Nevertheless, the above studies provide a promising
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foundation from which the topic of my dissertation, i.e. the use of Anthos as both
a chemopreventive and chemotherapeutic agent, has been constructed.
Role of carcinogens
A variety of environmental carcinogens such as PAHs, PCBs and PCDDs [18]
have been linked to the development of CRC. One specific class of carcinogens
that are particularly ubiquitous and relevant though are polycyclic aromatic
hydrocarbons (PAHs). The PAH, B[a]P, is a byproduct of incomplete combustion
of organic materials and is commonly found in charbroiled meat, vehicle exhaust,
coal tar, and tobacco smoke. In addition to these more well-known sources of
exposure, B[a]P has been found to contaminate a wide array of foods including
cooked meat (4 ng B[a]P/g, i.e., 4 ppb of cooked meat), as well as kale and
collard greens (0.5 ng B[a]P/g) [19], with the daily estimated oral intake of B[a]P
of 40.1 to 60 ng for most individuals in a study comprised of residents of the
metropolitan area of Washington, DC, USA [19]. It should be noted that the range
of estimated B[a]P intake for this study went up to 140-160 ng/day [19]. The
classical mechanism by which B[a]P causes carcinogenesis is by intercalating
into DNA and ultimately covalently binding of its electrophilic metabolites with
guanine bases. The most active metabolite of B[a]P, benzo[a]pyrene-7,8diolepoxide (BPDE) is classified as a group 1 carcinogen by the International
Agency for Research on Cancer (IARC) and is the result of the bioactivation of
B[a]P by enzymes including the cytochrome P450 (CYP) 1A1 and/or 1B1 and
microsomal epoxide hydrolase (mEH) (1 , 4 , 5 ). It should be noted that various
enzymes including members of the glutathione s-transferase (GST), uridine 5'7

diphospho-glucuronosyltransferase (UGT) and sulfotransferase (SULT) families
are involved in the detoxification of the intermediates along this bioactivation
pathway. Intercalation of DNA acts to distort the structure of DNA disrupting the
copying of DNA, which in turn causes mutations. BPDE has also been found to
target p53 thereby altering the tumor suppression of cells which may ultimately
lead to cancer [23].
Role of bacterial dysbiosis
Although bacteria have long been associated with a variety of diseases such as
diphtheria, tetanus, tuberculosis, typhoid fever and botulism, to name a few, only
recently has the role of bacteria in carcinogenesis been elucidated. In fact,
bacteria such as Heliobacter pylori and Enterotoxigenic Bacteroides fragilis
(ETBF) have been linked to a variety of cancers including gastric and colon
cancer, respectively. One particular toxin producing bacteria, ETBF has recently
come to the forefront in its role in colon cancer. Although the gram negative B.
fragilis bacteria make up a minority when compared to the prevalence of other
bacterial community members, they cause the majority of anaerobe-associated
invasive disease cases [24]. A particularly toxic member of the B. fragilis family is
ETBF. This bacteria secretes the enterotoxin b. fragilis toxin (BFT) which is a 20
kDa zinc-dependent metalloprotease toxin which indirectly stimulates the
cleavage of E-cadherin thus leading to increased colonic permeability [25].
Additionally, it leads to activation of β-catenin, which further leads to enhanced
proliferation of cancerous CECs [26]. ETBF induces Stat3/Th17 inflammation
which further fuels colon tumorigenesis [27]. Interestingly, the BFT toxin, of which
8

three similarly acting isotypes, BFT-1, BFT-2, and BFT-3, have been identified, is
structurally similar to other bacterial toxins including the tetanus and diphtheria
toxins [24]. Recent work from the Sears lab shows that patients with the inherited
disease, familial adenomatous polyposis (FAP), which is caused by as APC
mutation, are more prone to having patchy bacterial biofilms that were composed
primarily of Escherichia coli (colibactin producing) and ETBF [28]. Thus, given
the clinical relevance and pathogenicity, ETBF bacteria is an ideal candidate for
further research.
Outline of mutations linked with development of CRC
In addition to the extrinsic influences discussed above, another key participant in
the dialogue of colorectal carcinogenesis is genetics. Some of the key genes that
have been found to influence the development of CRC include TP53,
KRAS/BRAF [29, 30], EGFR/PTEN [31-33], SMAD7 [34], MLH1 [35], MUTYH
[36] and the adenomatous polyposis coli (APC) gene [37-40].
Both sporadic and hereditary cases of CRC have been attributed to mutations in
the adenomatous polyposis coli (APC) gene. It has been noted that 34-70% of
sporadic colon cancer cases feature inactivating mutations in APC particularly in
the mutation cluster region, with genetic aberrations such as deletions,
insertions, point and missense mutations detected in the mutation cluster region
in 72% of the patients studied [37]. It has also been shown that individuals with
APC gene mutations possess a significantly increased risk for CRC (pooled OR
of 1.42 and 95% CI of 1.16-1.74 with a P value of 0.00085) [38]. Furthermore, it
should be noted that APC mutations appear to be more likely to occur with TP53
9

mutations (OR 3.513, 95% CI of 1.212-10.184) and KRAS mutations (OR 1.995,
95% CI of 0.607-6.554) [40].
The important role that the above mutations, especially APC, play in the
development of CRC has been historically well documented. Moving forward, the
characterization or “fingerprinting” of an individual’s specific mutations will be key
in developing personalized therapeutic regimens for each patient.
Pathways of genomic instability that can lead to CRC
It is commonly accepted knowledge that three main molecular pathways of
genomic instability are involved in the development of CRC and include: the
chromosomal instability pathway (CIN), the mismatch repair-deficient or
microsatellite instability pathway (MSI), and the CpG island methylator phenotype
(CIMP) pathway.
The CIN pathway, which was originally elucidated by Fearon and Vogelstein in
1990, is believed to be responsible for most cases of CRC and is observed in 6570% of sporadic CRC’s [41]. These cases feature characteristic loss of
heterozygosity (LOH), sub-chromosomal genomic amplifications and widespread
aneuploidy. In Fearon and Vogelstein’s seminal 1990 article, they proposed a
multi-step model for colorectal carcinogenesis [42] (Figure 2). The initiating event
in adenoma formation is the inactivation of the Adenomatous Polyposis Coli
(APC) tumor suppressor gene which is followed by activating mutations of KRAS.
Additional mutations in TGF-β [43], PIK3CA [44], and TP53 [45] pathways then
drive the subsequent malignant transformation. It should be noted that although

10

APC mutations serve as the initiating event in human and mouse models,
mutational activation of KRAS is unable to initiate cancer in vivo and only when
combined with mutant APC will mutant KRAS promote tumor progression, thus
supporting Fearon’s multi-step model [46].
The MSI pathway accounts for approximately 10-20% of all CRCs [47]. Although
the MSI pathway was originally elucidated for individuals with familial Lynch
syndrome, most CRCs with MSI are sporadic. In fact, only 3% of all CRCs come
from Lynch syndrome families [48]. MSI tumors caused by Lynch syndrome are
associated with germline mutations in DNA mismatch repair (MMR) genes and
often have KRAS mutations, but never have BRAF mutations.
Lynch syndrome tumors also typically occur in younger individuals and typically
have a better prognosis than non-MSI tumors [49]. Approximately 50% of
sporadic cases of MSI have BRAF mutations and are associated with CIMP,
unlike Lynch syndrome tumors. As can be expected, sporadic cases of MSIassociated CRCs typically occur in older individuals[48].
The CpG island methylator (CIMP) is observed in approximately 30% of CRC
cases [50]. As its name implies, the CIMP pathway promotes epigenetic
instability and enables sporadic cancers to methylate the promoter regions of key
tumor suppressor genes thereby effectively inactivating their expression [51]. In
fact it is present in all tumors with MLH1 aberrant methylation [52]. CIMP positive
tumors typically exhibit specific clinicopathological features such as proximal
location and tend to be more common in older women, are often MSI and poorly
differentiated. They also tend to have a distinct molecular profile which features
11

low TP53 and high BRAF mutation rates [53]. Furthermore, cases of colorectal
cancer that develop via the CIMP pathway tend to develop from sessile serrated
adenomas rather than adenomatous polyps [54].
Current standard of care
As with most cancers current treatment options for individuals diagnosed with
CRC include one or more of the following options: surgery, radiation therapy,
non-targeted chemotherapy, or targeted therapy.
According to the American Cancer Society, drugs currently approved by the U.S.
FDA for the treatment of CRC include: capecitabine, fluorouracil (5-FU),
irinotecan,

oxaliplatin,

and

trifluridine/tipiracil.

One

or

more

of

these

chemotherapeutic drugs are most often given over the course of treatment with
more common treatment regimens with these drugs including: 5-FU, 5-FU with a
vitamin called leucovorin which improves the efficacy of 5-FU [55], capecitabine,
5-FU with leucovorin and oxaliplatin (FOLFOX), 5-FU with leucovorin and
irinotecan (FOLFIRI), capecitabine with either irinotecan (XELIRI or CAPIRI) or
oxaliplatin (XELOX or CAPEOX), and irinotecan alone.
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Figure 2: Adenoma-carcinoma sequence in the development of colorectal
cancer
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A

variety

of

side

chemotherapeutic

effects

drugs

are

including:

associated
nausea,

with

taking

vomiting,

the

standard

fatigue,

diarrhea,

suppression of bone marrow, immunosuppression, and liver damage [56, 57].
Given the current limitations and these side effects associated with the current
standard of care, additional treatment options are warranted.
In addition to non-targeted chemotherapeutic treatment options, targeted
therapies are also common, including: bevacizumab, regorafenib, ramucirumab
and ziv-aflibercept, which are antiangiogenesis therapies, and cetuximab and
panitumumab which are anti- EGFR therapies [58]. Although, one of the key
benefits of targeted therapy is the reduction in off-target side-effects, they are
also accompanied with side-effects including gastrointestinal perforation, arterial
thromboses which include strokes and myocardial infractions [59].
In addition to the above therapies, within the past year the FDA has approved
use of the immune checkpoint, PD-1, inhibitor, pembrolizumab for the treatment
of CRC cases that have mismatch repair deficient (dMMR) and microsatellite
instability high (MSI-H) abnormalities. However, like the previously mentioned
therapies, pembrolizumab treatment has been associated with immune related
adverse effects such as inflammation of the lungs, colon, kidney, thyroid and
pituitary gland [60]. Therefore, there remains significant room for the
development of cost-effective, non-toxic prevention and treatment options.
Treatment options for individuals diagnosed with colon cancer are typically
dependent upon their specific stage. Additional factors such as age and other
health problems are also considered for the optimal treatment plan [61]. In most
14

cases, when the cancer has not spread to distant sites, surgery is typically the
first

main

treatment.

For

more

advanced-stage

cancers,

an

adjuvant

chemotherapy may also be recommended. Adjuvant chemotherapy may be
recommended as early as stage II, but is more typically recommended beginning
in stage III [61]. For the more advanced stage IV cases of colon cancer where
the disease has spread to distant organs and tissues, a key component of the
treatment is chemotherapy since in most cases surgery will not cure these
individuals. Since the early 2000’s, 5 new drugs have been approved for the
treatment of stage IV colon cancer. These drugs fall into one of the three
following classes: multi-kinase inhibitors, anti-angiogenic (Bevacizumab, Zivaflibercept), or EGFR blockers (Cetuximab, panitumumab) [62].
Key limitations in the current standard of care include, but are not limited to the
following areas: off-target side effects, the current gap that exists in adjuvant
therapy for stage I and especially stage II cancers of the colon, and limitations in
treatment options for older individuals. Given these limitations, research
investigating alternative preventative treatment options is of great importance.
Familial Adenomatous Polyposis (FAP)
The majority of CRC cases originate from previously benign adenomatous
polyps. This process of transformation from benign polyp to malignancy typically
takes decades to occur, with approximately 85% of colorectal cases occurring
after the age of 55 years, according to data acquired by the U.S. preventive
services task force. A small subset of CRC cases stem from familial syndromes
such as Lynch syndrome, FAP, attenuated FAP (AFAP), MUTYH-associated
15

polyposis (MAP) and rare syndromes such as hyperplastic polyposis, PeutzJeghers syndrome (PJS) and juvenile polyposis syndrome [63, 64].
FAP is an autosomal dominant pre-cancerous colorectal condition with an
incidence at birth of around 1/8,300 [65]. FAP occurs with equal frequency in
both males and females and accounts for less than 1% of colorectal cases [65].
The disease may begin as early as the teenage years, with colon cancer
developing on average by the age of 39 years old. Furthermore, approximately
7% of individuals with FAP will develop CRC by the time they reach 21 years old
and 95% of FAP sufferers will develop CRC by the time they reach the age of 50
[66]. FAP is caused by mutation(s) in the APC gene. The APC gene, which is
located on chromosome 5q21 is a tumor suppressor gene that encodes for a 312
kDa protein with 2843 amino acids. It is expressed in a variety of fetal and adult
tissues including colorectal epithelium as well as mammary [67].
Mutation(s) in the APC gene, 60% of which are nonsense mutations, have been
shown to accelerate the initiation of the adenoma-carcinoma sequence since the
inactivation of APC serves as the initial step in the development of CRC in FAP
[65]. The APC protein serves as a scaffolding protein which affects cell adhesion
and migration. The mammalian form of APC contains multiple binding domains
including an oligomerization domain, an armadillo repeat domain, a repeat
domain consisting of between 15-20 residues which is important for binding to βcatenin, SAMP repeats which are important for axin binding, a basic domain that
is responsible for microtubule binding, and finally C-terminal domains, which bind
the proteins, EB1 and HDLG [68].
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APC interacts with a variety of other key proteins such as the Wnt/Wg pathway
members, β-catenin and axin, the Rac guanine-nucleotide-exchange factor
(GEF) Asef1, the cytoskeletal regulators EB1 and IQGAP1, as well as
microtubules [69]. Mutations in APC lead to the accumulation of β-catenin in the
cytoplasm where it binds and activates the T-cell factor (TCF) and lymphoid
enhancer factor (LEF) families of transcription factors altering the expression of
genes that encode for the metalloprotease matrilysin, ephrins, cyclin D1 and the
proto-oncogene c-myc which in turn lead to changes in cellular proliferation,
differentiation and migration [70].
If left untreated, individuals with FAP will develop CRC by their forties [71]. As
discussed above, APC plays a key role in the multi-step model of colorectal
cancer proposed by Fearon and Vogelstein (Figure 1). The disease is
characterized by the development of hundreds to thousands of adenomatous
colon polyps. Currently, the only approved primary modality of treatment for FAP
is prophylactic cancer-preventive colorectal surgery. Given the lack of noninvasive treatment options and the role of FAP in CRC development, additional
treatment options are of great need.
Anthos: a promising treatment for FAP and colorectal cancer
Several plant-derived compounds such as quinine, codeine, paclitaxel,
apomorphine, have been an invaluable source of medicines for humans
throughout history. One particular family of compounds that has sparked recent
interest is flavonoids and members such as anthocyanins.
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Flavonoids
One particular class of relevance is the flavonoids which is one of the largest
groups of secondary metabolites with well over 6000 molecules [72]. Compounds
classified as flavonoids, which all share a common core 15-carbon skeleton, can
be divided into 6 major classes: flavanols, flavonols, flavonones, flavones,
isoflavones and anthocyanins. Flavonoids are commonly synthesized by plants in
order to fulfil a variety of protective functions ranging from chromatic attractants
for pollinators, deterrents for pests, protectants against UV-B, as well as
antimicrobial agents [73].
Anthocyanins and anthocyanidins
Found in dark-colored vegetables, fruits, grains and flowers, anthocyanins, which
comes from the Greek words Anthos for flower and kyanos for blue, provide the
characteristic red, purple and blue hues to eggplant, blueberry, black rice and
black sesame seeds. Over 600 structurally distinct anthocyanins have been
identified in nature [74, 75]. It should be noted that anthocyanins are known as
anthocyanidins when non-glycosylated. Of the seventeen anthocyanidins found
in nature, only six, including the glycosylated forms of cyanidin (Cy), delphinidin
(Dp), petunidin (Pt), peonidin (Pn), pelargonidin (Pg) and malvidin (Mv), are
widely distributed [76]. The above anthocyanidins are typically bonded to
glucose, galactose, arabinose, rhamnose, and xylose in either a mono-, di- or trisaccharide form. An additional layer of complexity is provided by the fact that the
sugar moieties can also be acylated by various aromatic or aliphatic acids. The
various combinations/permutations of anthocyanidins and their pendant sugars
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vary from plant to plant. Importantly, it should be highlighted that the active
component of the compounds is the central anthocyanidin moiety.
The core structure of anthocyanidins (Figure 3) is composed of an aromatic ring
A that is bonded to a heterocyclic ring C containing oxygen that is bound via
carbon to a third aromatic ring B. The substituted flavonoids contain a flavylium
cation, which due to its conjugated double bonds, absorbs light with a
characteristic peak range between 500 – 550 nm. The specific hue(s) associated
with each anthocyanin depend upon the degree of hydroxylation and
type/number of substitutions. A total of 17 anthocyanidins have been isolated to
date [77].
The specific anthocyanin fingerprint varies between each type of fruit, vegetable,
grain or flower. For example, fruits such as red currants and elderberry contain
primarily cyanidin, whereas blueberry, bilberry and jamun (Indian black plum)
contain 5 anthocyanidins - cyanidin, delphinidin, petunidin, peonidin and
malvidin, all in their glycosylated forms. Bilberry in particular contains a native
mixture of delphinidin, cyanidin, malvidin, peonidin, and petunidin in a relative
ratio of 33:28:16:16:7 [78]. As noted above, in addition to variations in the core
anthocyanidin structure, variations in the pendant sugar moieties also varies from
plant to plant. For example, even though red currant and blackcurrant are closely
related, red currant contains mainly mono- and diglycosides, whereas black
currant contains primarily rutinosides and only a minor glycoside component [79].
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Role of anthocyanins within plants
Within plants, anthocyanins accumulate in vacuoles of a variety of cells in both
vegetative as well as reproductive organs. Most of the 17 anthocyanidins isolated
to date are found only in the reproductive structures of the plants whereas only
six anthocyanidins (cyanidin, peonidin, delphinidin, petunidin, malvidin and
pelargonidin) have been found in the vegetative organs [80].
Furthermore, anthocyanins are synthesized in the branch of the flavonoid
biosynthetic pathway that is involved in the synthesis of isoflavonoids and
flavonols [77]. Anthocyanins are thought to play a variety of different functions
within plants ranging from as antioxidants, sunscreens, and even as metalchelating agents and in delaying foliar senescence under conditions of mineral
imbalance or macronutrient deficiency [77]. Given their beneficial roles in plants,
one can easily hypothesize that benefits may be gained from their consumption
by humans.
Anthocyanin absorption, stability, and digestion
Absorption of anthocyanidins and anthocyanins by gut epithelial cells occurs via
different mechanisms due to the structural differences. Due to the hydrophilicity
added by the sugar residues on anthocyanins they must utilize facilitated
transport mechanisms whereas (the sugar-free) anthocyanidins are more
hydrophobic and are able to be passively absorbed by gut epithelial cells [81]. In
fact, the hydrophobicity of a compound, expressed in terms of its partition
coefficient (log octanol/water) is often used as a predictive means to determine
the ability of a compound to passively diffuse across a biological membrane.
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Interestingly, it has been found that nonenzymatic deglycosylation does not occur
in the human body for polyphenols such as quercetin [82]. Additionally, only
polyphenols with attached glucose, arabinose or xylose and not rhamnose
moieties can serve as potential substrates for human β-glucosidases. Therefore,
rhamnose moieties can only be cleaved once they reach the colon where they
can serve as a substrate for bacterial α-rhamosidases [81]. This limitation may
have important ramifications for the activity of rhamnose-containing anthocyanins
in diseases of the small intestine or in diseases where digestive transport time is
expedited such as inflammatory bowel disease (IBD).
Another important topic that must be addressed in the discussion of anthocyanin
metabolism is the role of deconjugation and reconjugation reactions. Although
anthocyanins do not appear to undergo as extensive of metabolism as other
flavonoids, it will be discussed for completion since it occurs and is a variable
that must be considered [83]. Following hydrolysis, the free aglycones undergo
metabolic processing in the form of methylation, sulfation, glucuronidation or a
combination of the above reactions [84, 85]. Based on the structural differences
between anthocyanins versus anthocyanidins, the impact that conjugation has on
the biological properties of the circulating metabolites is evident.
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Figure 3: Structures for the five anthocyanidins (the active moiety of
anthocyanins) contained in blueberry and bilberry
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Overall, one should understand that a competition between the uptake of
anthocyanidins and the excretion of more hydrophilic anthocyanins as well as
their conjugated counterparts exists. Therefore, one could posit that by
administering anthocyanidins either in their pure form or by nano-delivery
systems to enhance oral bioavailability, one would enhance their therapeutic
potential in the clinical setting.
Data from In vitro work
A variety of in vitro studies have been conducted in order to investigate the
impact that anthocyanins derived from various sources have on colon cancer cell
lines. Berry extracts containing anthocyanins isolated from cowberry, strawberry,
bilberry, and blueberry have been shown to inhibit the proliferation of the colon
cancer cell line HCT116 [86]. Furthermore, anthocyanin rich extracts derived
from fruits including bilberry (Vaccinium myrtillus L.), grape (Vitis vinifera), and
chokeberry (Aronia meloncarpa E.) have been shown to inhibit the growth of the
colon cancer cell line HT-29 cells but not the non-tumorigenic NCM460 colon
cells [87].
A variety of potential mechanisms have been suggested in the literature. For
instance, anthocyanins isolated from the grape, Vitis coignetiae Pulliat were
shown to induce caspase-dependent apoptotic cell death, activate p38-MAPK
and suppress Akt in HCT-116 colon cancer cells [88]. Moreover, pelargonidin,
found in a variety of berries such as strawberry and raspberry, was shown to
inhibit proliferation of the colon cancer cell line HT-29 and induce apoptosis and
G2/M cell cycle arrest by the intrinsic apoptotic pathway [89]. Additionally,
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delphinidin, found in fruits like blueberry, has also been shown to induce
apoptosis and G2/M cell cycle arrest in HCT116 colon cancer cells [90]. The
mechanism by which delphinidin led to G2/M arrest and apoptosis in HCT116
cells is believed to be due to suppression of the NF-κB pathway [90].
Anthocyanins and anthocyanidins have also been shown to induce significant
oxidative DNA-strand cleavage in the presence of dithiotheritol (DTT), but not
DMSO, which serves as a free radical scavenger, at physiological pH. It was
further hypothesized that at pH 7.5, the quinones formed from anthocyanins and
anthocyanidins autoxidize to yield hydrogen peroxide [91]. Fe

3+

is believed to

increase anthocyanin-induced cleavage since when it is reduced it is able to
stimulate the production of hydroxyl radicals from hydrogen peroxide. The
resulting hydroxyl radical, rather than hydrogen peroxide, is believed to induce
the cleavage of DNA [91]. Only at high concentrations were anthocyanins also
shown to inhibit topoisomerase relaxation [91].
Data from in vivo studies
The beneficial effects of anthocyanins shown in vitro have also been shown to
exist in vivo. For instance, the anthocyanin-rich soybean fraction containing
cyanidin-3-glucoside, delphinidin-3-glucoside and petunidin-3-glucoside, was
shown to significantly decrease the number of intestinal tumors in ApcMin/+ mice
fed a 0.5% anthocyanin-rich extract compared to control animals [92].
Furthermore,

mucosal

expression

of

cytosolic

phospholipase

A2

and

cyclooxygenase-2, which are both involved in inflammatory response, were
significantly decreased in mice treated with 0.5% anthocyanin-rich extract [92].
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Additionally, an in vivo study in ApcMin/+ mice using 0.3% oenocyanin, which
contains the 3-glucosides of delphinidin, cyanidin, petunidin, peonidin, and
malvidin extracted from grape pomace, showed a reduction in adenoma burden
and reduction in proliferation index in colonic adenomatous crypts [93]. A
reduction in the expression of Akt, which is involved in a variety of cellular
processes including glucose metabolism, apoptosis, cellular proliferation,
transcription and migration, was also observed in 0.3% oenocyanin-treated mice
[93]. Interestingly, oenocyanin anthocyanins and their metabolites were not found
in the plasma but rather only in the urine and intestine [93]. Moreover, in a mouse
model of colitis, dextran sulfate sodium (DSS) induced histological damage and
weight loss were significantly improved in mice administered a red raspberry
anthocyanin-rich fraction [94]. In the same study, anti-inflammatory properties
were shown in vivo with overall reductions in the expression of cyclooxygenase-2
(COX-2), interleukin-1 beta (IL-1β), IL-6 and inducible nitric oxide (iNOS) in red
raspberry anthocyanin-rich fraction treated RAW264.7 cells [94].
A study assessing the impact of dietary cyanidin-3-glucoside and an anthocyanin
mixture from bilberry on the development of adenomas in an ApcMin/+ mouse
model for FAP [95] showed that ingestion of cyanidin-3-glucoside or a bilberry
derived anthocyanin mixture led to a reduction in adenoma load in a dosedependent fashion. It should be noted that although significant reductions in
adenoma numbers were seen for cyanidin-3-glucoside (p< 0.001) and
Mirtoselect® bilberry anthocyanins (p<0.05), the doses that were used were 0.3%
of the diet which is equivalent to 450 mg/kg/day or 2.6 g/80 kg human dosage,

25

when the authors extrapolated using the dose/surface area comparison between
species [96]. When the Mirtoselect

®

native bilberry mixture was extrapolated

back to the amount of fresh berries that would need to be consumed, it was
concluded that an individual would need to consume ~740 g of fresh bilberry a
day [95]. Given the large nature of the dose used in the study, which is further
complicated due to the presence of high sugar content (about 60% in blueberry),
it is clear that one would need to lower the dose by identifying the active
principles as well as eliminate large sugar content in order to be a clinically-viable
option.
Data from clinical trials
A limited number of clinical trials have been undertaken to assess the impact that
anthocyanins, taken in the form of either berry powder or as an anthocyanin-rich
standardized bilberry extract, has on CRC. The first study was a clinical trial
assessing whether an anthocyanin-rich standardized bilberry extract (Mirtocyan®)
administered to patients (1.3, 2.8 or 5.6 g, containing 0.5-2.0 g anthocyanins)
daily for 7 days before surgery would induce pharmacodynamics changes that
would be in agreement with chemopreventive efficacy [97]. Results from the
study showed that a 7% decrease in proliferation was observed in tumor tissues
taken from patients when compared to their pre-intervention values. Another
clinical trial investigating the impact of freeze-dried blackberry powder (60 g/day,
for 1 to 9 weeks) in colorectal cancer patients showed beneficial changes in GMCSF and IL-8, markers for proliferation and apoptosis respectively [98].
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A clinical trial assessing the impact of black raspberry powder on biomarkers of
colorectal tumor development showed that the methylation patterns of three Wnt
inhibitors including WIF1, SFRP2, SFRP5 and the developmental regulator
PAX6a were protectively modulated in normal and in colorectal tumor tissues in
patients receiving the black raspberry powder (60 g/d) for an average of 4 weeks.
Furthermore, the protective modulation of methylation was associated with
decreased expression of the enzyme that transfers methyl groups to the cytosine
nucleotides in genomic DNA, DNA (Cytosine-5-)-Methyltransferase 1 (DNMT1)
[99]. Interestingly, the authors also noted that black raspberry powder decreased
β-catenin as well as protectively modified Ki-67, TUNEL, CD105, as well as
DNMT1 in colorectal tissues from the 20 patients. CD105 and DNMT1 were also
found to be modulated in adjacent normal tissues. The impact on β-catenin and
E-cadherin expression was also shown to be dose dependent, with the high dose
(~ 4 weeks) black raspberry powder treatment yielding greater impact than the
low dose (~ 2 weeks) black raspberry powder treatment [99].
In addition to studies on CRC, anthocyanin-rich bilberry extract has also been
shown to reduce the amount of pro-inflammatory cytokines including TNF-α and
IFN-γ in colon biopsies from patients with ulcerative colitis (UC). Furthermore,
serum levels from UC patients that were successfully treated with anthocyaninrich bilberry extract had enhanced levels of immunoregulatory IL-10 and the Th17 cell specific cytokine IL-22 and reduced levels of TNF-α and IFN-γ [100]. In
another clinical trial testing the impact of a standardized anthocyanin-rich bilberry
extract on UC disease activity showed that after 6 weeks of treatment, 63.4% of
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patients achieved remission and 90.9% of patients showed a response. It was
also noted that fecal calprotectin levels were also decreased during the
treatment, which further suggests that intestinal inflammation was reduced [101].
It should be noted that all of the anthocyanin-mediated colorectal cancer clinical
trials published to date have been conducted using anthocyanins rather than
anthocyanidins. Although the bioavailability of anthocyanins is very low in the
plasma (<1%), greater bioavailability has been found in colonic tissues [102].
This suggests that they may have greater potential since they can directly
interact with the colon tissue. Additionally, one can posit that additional benefits
in uptake, if administered in the aglycone form (i.e., as anthocyanidins) or by
utilizing a nano drug delivery vehicle such as bovine milk-derived exosomes (i.e.
ExoAnthos).
Exosomes
Size, history, sources
Exosomes are defined as membrane-bound vesicles that range in size from 30100 nm, in diameter, feature a density in sucrose gradients of 1.13-1.19 g/ml, are
highly enriched with tetraspanin molecules and are of endocytic origin [103].
Exosomes were discovered in 1983 by Pan and Johnstone. In 1989, Pan and
Johnstone named the vesicles exosomes [104]. Since their identification,
exosomes have been isolated from essentially all biological fluids such as saliva,
peripheral blood, cerebrospinal fluid (CSF), urine, sweat, malignant effusions and
milk [105].
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Exosome formation
Exosomes are initially formed via a process of endocytosis, with the
internalization of the cell membrane to yield endosomes (Figure 4). Following the
formation of endosomes, many small vesicles are formed inside the endosome
by invagination of parts of the endosomal, multi-vesicular body (MVB),
membrane. The MVBs then fuse with the cell membrane thereby releasing the
intraluminal vesicles into the extracellular space. Following their release, these
vesicles are referred to as exosomes.
Exosome composition
Exosomal membranes are primarily composed of lipids and proteins and are
enriched with lipid rafts [106]. The lipid composition of exosomes is distinctively
rich in cholesterol, ceramide, sphingomyelin, and phosphatidylserine [107].
However, exosomes contain minimal to no lysobisphospatidic acid (LBPA), which
distinguishes them from MVBs’ intraluminal vesicles (ILVs) [107]. Furthermore,
the fatty acids in exosomes tend to be saturated or monounsaturated, which in
addition to the high concentration of cholesterol is believed to lead to the lateral
segregation of these lipids into exosomes during their formation [108]. Results
from proteomic studies suggest that exosomes contain specific proteins from
endosomes, plasma membrane, and cytosol [109]. Examples of proteins from the
endosome include Alix, Tsg101, Rab GTPase, SNAREs Annexin and Flotillin.
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Figure 4: Classic pathway of exosome formation. After endocytosis, endosomes
are formed via the internalization of the cell membrane (sidedness noted in the
diagram as blue for the initial internal face and black for the initial external face).
A process of invagination of the endosome yields smaller bodies inside the MVB,
which can proceed to processing via the golgi apparatus, be released via
exocytosis yielding exosomes or be degraded by the lysosome.
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Proteins originally associated with the plasma membrane include tetraspanins,
such as CD63, CD81 and CD37. It should be noted that exosomes contain very
few proteins from other intracellular organelles such as the nucleus, mitochondria
and Golgi [107].
Exosome cargo
In addition to proteins, exosomes have been found to carry as cargo within their
lumen, that include mRNA, miRNA, small noncoding RNA species such as
structural RNAs, tRNA fragments, vault RNA, small interfering RNAs, RNA
transcripts that overlap with protein coding regions and repeat sequences [108].
More recent data indicate the presence of some DNA as well [110]. The RNA
cargo contained within exosomes can either be taken up by neighboring cells or
transported by the circulating exosomes and taken up by distant cells. Ultimately,
the RNA cargo in exosomes is believed to function as a form of genetic
exchange between cells [106].
Exosome role in cell to cell communication
Once called the “garbage bag” of cells, exosomes have been found to play an
important role in cell to cell communication.

After finding that mRNAs and

miRNAs were present in exosomes derived from mast cells, it was also found
that the mRNA in these exosomes were transported to recipient cells and
following uptake were translated into proteins thus providing evidence for the
ability of exosomes to transfer of genetic material [111]. It was noted that not all
mRNAs that were abundant in the secreting cells were packaged into exosomes
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thereby suggesting that specific targeting machinery for mRNAs may exist [111].
It has also been shown that tumor-derived exosomes can both suppress the
function of immune cells by promoting the differentiation of regulatory T
lymphocytes or by inducing apoptosis of activated cytotoxic T cells [112].
Exosomes can also induce immune responses by transferring tumor antigens to
dendritic cells and to present tumor antigens [113]. Interestingly, it has been
found that exosomes can fuse especially well with the plasma membranes under
acidic conditions mimicking those of the cancer cell microenvironment [114].
Exosomes as therapeutics
Special interest in the application of exosomes for diagnostic as well as drug
delivery purposes has recently taken root within the scientific community. A key
area of research within our laboratory is in utilizing exosomes as a drug delivery
vehicle. Prior to the work conducted in this laboratory the primary source of
exosomes for drug delivery purposes was from cell culture media and serum. In
order to overcome the obvious limitations posed by these sources such as
quantity, safety, cost and translatability, our laboratory pioneered the use of
exosomes derived from bovine milk [115, 116]. Not only does bovine milk provide
a scalable source of exosomes, it also exhibits cross-species tolerance.
Furthermore, no adverse immune or inflammatory responses have been found
[117].
Exosomes derived from raw bovine milk can effectively deliver a variety of both
hydrophilic as well as lipophilic compounds such as curcumin, withaferin A
(WFA), paclitaxel, celastrol and doxorubicin. Moreover, tumor targeting of the
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exosomes with folic acid was shown to increase biological efficacy. Exosomal
formulations containing WFA, celastrol, or curcumin have shown increased
efficacy over drug alone in both in vitro and in vivo against lung and breast
cancer [115, 116]. Prior to the body of studies contained within this dissertation
no experiments were undertaken with colon cancer. In addition to the role of the
exosomes as a drug delivery vehicle, they are also believed to deliver an
additional “payload” of their own. For instance, our laboratory has identified the
presence of immune-related miRNAs such as miR-146a, -155, -181a and -223 in
bovine milk derived exosomes [115].

Overall Goals of Doctoral Research Project
The overarching goal of my doctoral work has been to investigate the use of
bilberry- derived Anthos as both a chemopreventive and chemotherapeutic agent
in bacterially-induced CRC and to study how Anthos modulate the influence of
the environmental carcinogen B[a]P on the balance between phase I and II
enzymes. In order to accomplish this goal, my research project was divided into
three specific aims, the interwoven nature of which is highlighted in each of the
subsequent chapters:
Aim 1: Determine anti-proliferative efficacy of optimal mixture of Anthos against
colon cancer and normal cells in vitro.
Aim 2: Determine efficacy of Anthos against colorectal cancer using a bacteriadriven ApcMin/+ ETBF mouse model.
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Aim 3: Determine the mechanistic influence of Anthos on ETBF and B[a]P in
CRC.
This dissertation has been written with the goal of submitting the findings for
publication in peer reviewed journals. Thus, chapters two to four are intended to
be able to exist independently, with the introductory and summary chapters
aiming at forming the foundation for the subsequent chapters with the summary
chapter tying together all of the mechanistic findings.
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CHAPTER 2:
NOVEL INSIGHT INTO THE PREVENTION AND TREATMENT OF COLORECTAL CANCER AND
FAMILIAL ADENOMATOUS POLYPOSIS BY ANTHOCYANIDINS

Introduction
CRC
Colorectal cancer (CRC) is the third leading type of cancer diagnosed and third
leading cause of cancer-related deaths within the United States each year.
According to the American Cancer Society, an estimated 140,250 individuals will
be diagnosed and 50,630 will die from CRC in the U.S. in 2018 alone. Although
the overall incidence of developing CRC has been decreasing since the mid to
late 1980s for individuals over 55 years old, a recent study has uncovered a
disquieting increase in the CRC incidence for individuals below 55 years old [12].
Although much progress has been made in combating the disease due to
advancements

made

in

early

detection

of

CRC,

clinically-effective

chemopreventive measures are still of great need.
Familial adenomatous polyposis (FAP)
The majority of CRC cases originate from previously benign adenomatous
polyps. This process of transformation from benign polyp to malignancy typically
35

takes decades to occur, with approximately 85% of CRC cases occurring after
the age of 55 years, according to data acquired by the U.S. preventive services
task force. A small subset of CRC cases stem from familial syndromes. One such
precondition for colorectal cancer is FAP. FAP is an autosomal dominant precancerous colorectal condition with an incidence at birth of around 1/8,300 [65]
that is caused by mutation(s) in the adenomatous polyposis coli (APC) gene.
FAP occurs with equal frequency in both males and females [65]. The disease
may begin as early as the teenage years, with colon cancer developing on
average by the age of 39 years. Furthermore, approximately 7% of individuals
with FAP will develop CRC by the time they reach 21 years and 95% of FAP
sufferers will develop CRC by the time they reach the age of 50 [66]. The only
currently approved standard of care for the treatment of FAP is surgical resection
of the colon [118]. Even after removal of the colon, individuals with FAP are still
at risk for developing adenomas at other sites [118]. Given the limited treatment
options for FAP and need for clinically- effective chemopreventive measures for
CRC, there is a need for additional research for better treatment and prevention
methods.
Previous work in chemoprevention of FAP and CRC
A wide variety of compounds have been considered in both pre-clinical and
clinical populations for the prevention of CRC and/or FAP. Clinical trials
conducted with chemopreventive agents for CRC include non-steroidal antiinflammatory drugs such as aspirin [119] and cyclo-oxygenase-2 (COX-2)
inhibitors, calcium [120], vitamin D [121], folic acid [122], and dietary phenolics
36

such as resveratrol [123], curcumin [124], green tea extract [125], soy
isoflavones [126] , black raspberry powder [99], pomegranate extract [127] and
bilberry extract [97]. However, the application of these interventions either were
deemed ineffective or required large dosages [128, 129]. Therefore, identification
of plant bioactives present in the human environment for improved clinical
translation is of utmost importance.

Anthocyanins/Anthocyanidins
Throughout history, plants have served as an invaluable source of medicines
including but not limited to paclitaxel, quinine, and digoxin to name a few. One
particular class of compounds, the anthocyanins, have recently been of great
interest in the scientific and medical community due to their reported therapeutic
activities

including

anti-inflammatory

[94],

chemopreventive

and

chemotherapeutic [86, 130], obesity control, cardiovascular disease prevention,
and alleviation of the symptoms of diabetes [131]. Anthocyanins, which come
from the Greek words Anthos for flower and kyanos for blue, are ubiquitous plant
pigments that provide the characteristic red, purple and blue hues to vegetables
(eggplant, purple cabbage), fruits (berries), grains (black rice, purple corn) and
flowers (hibiscus). In fact, over 600 anthocyanins have been identified at the
current time. Anthocyanins feature an aryl-substituted chroman ring system.
Differences

between

each

specific

anthocyanin

is

dependent

upon

functionalization group(s) at the 3 and 5 prime locations and the composition of
the pendant sugars.

Furthermore, the active moiety of anthocyanins,
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anthocyanidins are devoid of the sugar residues but feature the same key central
ring structure and various permutations of hydroxyl, hydrogen and methoxy
functional groups (Chapter 1, Figure 3).
Studies from our own laboratory as well as others have shown therapeutic
activity of anthocyanins against a variety of cancers including but not limited to
breast, lung, esophageal, skin and CRC [130, 132]. One such study by Cooke et
al. [95] showed that ingestion of cyanidin-3-glucoside or a bilberry-derived
anthocyanin mixture showed a modest reduction in adenoma in CRC in a dosedependent fashion. This, however, required large doses (450 mg/kg/day) which
would translate to 2.6 g/80 kg person. When the native bilberry extract
(Mirtoselect) was extrapolated to the amount of fresh berries that would need to
be consumed, it was concluded that an individual would need to consume ~740 g
of fresh bilberry a day. Given the large nature of the dose used in the study,
which is further complicated by the presence of high sugar content (about 60%),
it is clear that one would need to lower the dose by identifying the active
principles for clinical translatability. Use of berry extracts can reduce doses and
elimination of the sugars would overcome these concerns. Previous work from
our group has shown that anthocyanidins yield greater potency in vitro and in
vivo against lung cancer [78, 133]. The goal of the series of experiments
contained within this chapter was to elucidate whether Anthos would be an
efficacious treatment in preventing and treating FAP and a bacterially-induced
model of CRC.
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Materials and methods
Anthocyanins and anthocyanidins
The anthocyanin, delphinidin 3,5-diglucoside was a kind gift from Dr. Inder P.
Singh of the National Institute of Pharmaceutical Education and Research (S. A.
S. Nagar, India). The individual anthocyanidins, cyanidin, delphindin, petunidin
and malvidin were purchased from Chromadex (Irvine, CA). The native mixture of
anthocyanidins (or Anthos) isolated from standardized bilberry extract, with purity
of >80% was generously provided by 3P Biotechnologies, Inc. (Louisville, KY).

Isolation of bilberry-derived Anthos
The native bilberry Anthos was further enriched using C18 Sep-Pak cartridges
(Waters, Milford, MA). Anthos were eluted in acidified (0.1% HCl) ethanol. The
enriched extract was then dried using a Savant SC210A Speed-Vac
(ThermoFisher Scientific, Waltham, MA) and stored under argon at -20 °C. Purity
was verified using HPLC-PDA-UV. Briefly, 15 µl samples were analyzed using a
Shimadzu Premier C18 reverse-phase column (250x4.6 mm i.d., 5 µm). Mobile
phase A was composed of water: formic acid: acetonitrile (87:10:3) and mobile
phase B was composed of water: formic acid: acetonitrile (40:10:50). The flow
rate was 0.6 ml/min and the gradient condition was 0-5 min 5% B; 5-15 min 15%
B; 15-20 min 25% B; 20-30 min 35% B; 30-40 min 45% B; 40-45 min 100% B;
45-50 min 5% B. Detection of Anthos was at 520 nm by PDA-UV and total
Anthos concentration was calculated using a standard curve. The reference
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compounds were purchased from Chromadex (Irvine, CA) and Cayman
Chemical Company (Ann Arbor, MI).

Cells, culture conditions and treatments
The APC wild-type HCT 116 (ATCC® CCL-247™) colon cancer cell line and
CCD-18Co colon (ATCC® CRL-1459™) normal cells were acquired from
American Type Culture Collection (Manassas, VA). The APC mutant colon
cancer cell line HT-29 (ATCC® HTB-38D™) was a kind gift from Dr. Nobuyuki
Matoba (University of Louisville). HCT-116 and HT-29 cells were maintained in
McCoy’s 5A medium (Gibco, Grand Island, NY) supplemented with 10% FBS,
100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere
containing 5% CO2 at 37°C. CCD-18Co cells were maintained in MeMα (Gibco,
Grand Island, NY) supplemented with 20% FBS, 100 U/ml penicillin and 100
µg/ml streptomycin in a humidified atmosphere containing 5% CO2 at 37 °C.

Measurement of cell viability
The cytotoxicity of individual anthocyanins and anthocyanidins and the Anthos in
colon cancer and normal cell lines was assessed by enzymatic reduction of the
tetrazolium dye MTT. Briefly, 3.0 x103 cells/well were grown in a 96-well tissue
culture plates and were then exposed to varying concentrations of test agents or
vehicle for 24 h after seeding. After 72 h treatment, cells were incubated with 5
mg/ml MTT reagent for 2 h. The resulting formazan crystals were then solubilized
in dimethyl sulfoxide and spectrophotometrically measured at 570 nm (Bio-rad,
40

Philadelphia, PA). IC50 values were then determined using Calcysyn software
version 2.1 (Biosoft, Cambridge, England).

Western-blot analysis
For western-blot analysis, 50 µg of protein from in vitro and in vivo tissue lysates
was resolved using gel electrophoresis and electrotransferred to polyvinylidene
difluoride membranes by semi-dry transfer (Biorad Trans-blot SD, Hercules, CA).
Blots were blocked with 4% dry powder milk or BSA for 1 h and then incubated
with primary antibodies for p-EGFR (Y845), p-EGFR (Y1068), p-EGFR (Y1173),
total EGFR, p-Src (Y418), total Src, pSTAT3 (Y705), total STAT3, pSTAT5
(Y694/Y699), total STAT5, COX-2, Cyclin D1, and Cyclin D2 which were all
acquired

from Santa Cruz Biotech (Santa Cruz, CA) at 4ºC overnight and

secondary antibodies (Santa Cruz Biotech, Santa Cruz, CA). conjugated to
peroxidase for 1 h at room temperature. Blots were then developed with an ECL
detection system. Densitometric analysis was then performed using ImageJ 1.x
software [134].

Animal model for FAP and CRC
ApcMin/+ mice are a well-established and accepted model for studying FAP and
CRC. The mice characteristically exhibit a germline nonsense mutation at codon
850 of the APC gene that causes the spontaneous development of polyps, which
predominantly occur in the small intestine by the age of 10-12 weeks.
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ETBF
Enterotoxigenic Bacteriodes fragilis (ETBF) exists asymptomatically in 12.4% of
individuals overall and in 27% of individuals with diarrhea symptoms [135].
Furthermore, presence of ETBF in the gut is a well-known global cause of
diarrheal disease that is accompanied by colitis in both humans and animals. The
pathogenicity associated with ETBF is due to the secretion of a 20 kDa zincdependent metalloprotease toxin, B. fragilis toxin (BFT), which binds to colonic
epithelial cells and leads to the cleavage of the tumor suppressor protein, Ecadherin, and the secretion of interleukin-8 [136]. Overall, this process leads to
the stimulation of proliferation and migration of human colon cancer cells [137].
BFT has also been shown to induce pro-inflammatory cytokine secretion by
further activating the NFƘB pathway [137].

In vivo FAP and CRC studies
Animal experiments were performed in agreement with an approved protocol by
the Institutional Animal Care and Use Committee at the University of Louisville.
Breeding colonies were established by Dr. Nejat K. Egilmez’s lab [138] at the
University of Louisville using C57BL/6J Min/+ (ApcMin/+) mice that were originally
attained from Jackson Laboratories (Bar Harbour, ME). Mice were genotyped for
the APC mutation using PCR according to the protocol established by Jackson
Laboratories. Mice were fed a standard chow diet. Animals received diet and
water ad libitum and were maintained on a standard light/dark cycle for the
duration of the study. For the FAP study, treatments began when animals were
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8-9 weeks old. Male (n=4) and female (n=4) ApcMin/+ mice were administered by
oral gavage 40 mg/kg Anthos or vehicle control. Animals were treated 3 times
per week for 5 weeks. Animals were euthanized at 13-14 weeks. Following
fixation of intestines using formalin, intestinal polyps were counted using a
microscope (Leica EZ4, Wetzlar, Germany) by four different experienced
individuals after blinding the samples.

Two CRC studies were performed to test the impact of the Anthos on tumor
number. At 5-6 weeks of age, animals were administered antibiotic. Four days
later the animals were administered ETBF to promote tumorigenesis and one
week following ETBF inoculation, animals began their respective treatment
regimen. In the first study male ApcMin/+ mice were administered by gavage 20
mg/kg Anthos or vehicle control. Animals were treated 5 times a week for 4
weeks. Animals were culled in the fed state at 12 weeks and colon tumors were
counted. For the second study female ApcMin/+ mice were administered by
gavage 40 mg/kg Anthos or vehicle control. Animals were treated 3 times a week
for 4 weeks. Animals were culled in the fed state at 11-12 weeks and colon
tumors were counted.

Data analysis
Statistical analysis was performed using Graph Pad Prism statistical software
version 4.03 (La Jolla, CA) and RStudio software version 1.0.153 (Boston, MA)
Lattice package [139, 140]. Test for normality, F-test for equal variance, and
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appropriate t-test were used for both animal studies and for analysis of western
blot results. IC50 values were determined using CalcuSyn software version 2.1
(Biosoft, Cambridge, England). Heat maps were constructed using RStudio
software version 1.0.153 (Boston, MA) gplot package [140, 141].

Results

Anti-proliferative effects of Anthos on colon cancer cells but not normal
colon cells
Previous work within our laboratory has shown that anthocyanidins are more
potent than their respective anthocyanins [133]. However, prior to pursuing work
with Anthos, we first compared antiproliferative activity of anthocyanidins and
anthocyanins by using two individual anthocyanins (anthocyanins delphinidin 3,5diglucoside, cyanidin 3,5-diglucoside and cyanidin 3-glucoside) with their
respective anthocyanidins (delphinidin and cyanidin) in HCT-116 colon cancer
cells. As shown in Figure 6, a clear benefit is derived for antiproliferative activity
from the cleavage of the sugar moiety from the anthocyanin parent compound.
This is best demonstrated by the reduction in the IC50 shown for delphinidin
which yielded >6-fold reduction when the sugar moiety was absent. A reduction
was also observed when comparing cyanidin versus cyanidin 3-glucoside, and
cyanidin 3,5-diglucoside, with 2- and nearly 5-fold reductions, respectively
(Figure 6).
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99% pure

Dp
40.1 %
Cy
25.3 %

Pt
15.4 %
Mv
12.8 %
Pe
5.4 %

Figure 5. Representative chromatogram of C18-enriched bilberry-derived
Anthos: HPLC profile of bilberry-derived anthocyanidin native mixture including
delphinidin (Dp), cyanidin (Cy), petunidin (Pt), peonidin (Pe), and malvidin (Mv).
Purity was verified to be > 96% for Anthos based on HPLC analysis.
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Figure 1: Antiproliferative action of
delphinidin (Dp) vs. delphinidin-3diglucoside
(D3DG)
Figure
6. Antiproliferative
activity of select

anthocyanidins and their

anthocyanin counterparts against colon cancer cell line HCT-116: Colon
cancer HCT 116 cells were treated with various concentrations of the individual
anthocyanidins, cyanidin (Cy) or delphinidin (Dp) and their anthocyanin
counterparts cyanidin 3-glucoside (C3G), cyanidin 3,5-diglucoside (C3DG) or
delphinidin 3,5-diglucoside (D3DG), respectively for 72 h and the effect on cell
growth inhibition was assessed using an MTT assay. Data represent average ±
SD (n=3).
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Figure 7. Antiproliferative activity of Anthos against colon normal and
cancer cells in vitro: Colon normal cells, CCD-18Co and colon cancer cells,
HCT-116 and HT-29 were treated with various concentrations of Anthos for 72 h
and the effect on cell growth inhibition was assessed using an MTT assay. Data
represent average ± SEM (n=4).
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Once anthocyanidins were confirmed to yield greater antiproliferative properties
than their parent anthocyanins, we assessed the antiproliferative properties of a
native mixture of Anthos found in bilberries and whether this native mixture
showed any in vitro toxicity toward normal colon CCD-18Co cells (Figure 7).
Tabulated selectivity index (SI) values (Table 1) of 14 and 9 clearly show that
Anthos selectively targets colon cancer cells (HCT-116 and HT-29) over the
normal cells (CCD-18Co). It should also be highlighted that these values are well
above the recommended minimal SI value of 3 that is commonly used to
determine whether a drug selectively targets cancer cells over normal cells.

Impact of Anthos on polyp development in ApcMin/+ mice FAP model
A wide variety of plant-derived compounds, including but not limited to
compounds such as curcumin, epigallocatechin gallate and anthocyanins have
been shown to have chemopreventive properties [129]. However, large doses
have been a hallmark prerequisite for their efficacy in vivo [129]. Therefore, in
order to test whether Anthos is both efficacious and translatable for the required
dose to elicit such properties, we investigated the effect of the Anthos on
intestinal polyp number utilizing ApcMin/+ mice. Both male and female mice (n=4
per group) were treated with 40 mg/kg Anthos three times per week
(approximating 17 mg/kg/day) for four weeks by oral gavage. Results from the
study (Figure 8a) showed a greater than 2-fold overall reduction in intestinal
polyps in Anthos versus vehicle control. The overall results in both male and
female mice treated with the Anthos elicited polyp reductions that were
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Figure 4: A) Effect of bilberry-derived anthos on tumor formation in ETBF
treated female and male APCmin/+ mice. Animals received anthos orally 3x
week for 5 weeks. B) Image highlighting the differences in tumor size
between control and Anthos treated animals in the same study

Figure 8. Anti-polyp and anti-tumor activities of Anthos against intestinal
polyps and colon tumors: a) ApcMin/+ mice were treated via oral gavage with
Anthos three times a week (40 mg/kg bw) or vehicle control. Data represent the
distribution of animal polyp counts by gender, with the average noted. Male
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Anthos versus control P=0.02 and female Anthos versus control P=0.004. b)
ApcMin/+ mice inoculated with ETBF were treated via oral gavage with Anthos
three times per week (40 mg/kg bw), five times per week (20 mg/kg bw), or
vehicle control. Data represent the distribution of animal tumor counts by gender,
with the average noted. Male and female Anthos versus control P<0.001. c)
Representative images of colons taken from control versus Anthos-treated
animals, with arrows highlighting some of the tumors.
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statistically significant (P=0.02 and P=0.004, respectively). Interestingly, when
the data was stratified by sex, it was noted that the effect of Anthos treatments
was somewhat enhanced in female mice which showed 3.1 fold reductions in
polyp numbers (P=0.004) as compared to the 1.8 fold reduction (P=0.02) found
within males.

Impact of Anthos on colon tumor development in ETBF ApcMin/+ mice CRC
model
Previous work within our group has shown that Anthos decreases tumor burden
in lung and ovarian cancer models [142] [78] . However, no work has been
reported to assess the impact of bilberry-derived Anthos against either FAP,
colorectal cancer or bacterially-induced cancers. Therefore, following the
completion of in vitro testing of Anthos in both APC wild-type and APC mutant
cell lines, we investigated whether Anthos treatment would impact colon tumor in
a bacterially-driven ApcMin/+ colorectal cancer mouse model. In these studies,
mice which were treated with Anthos at either 20 mg/kg Anthos 5 times per week
(i.e. 14 mg/kg/day) or 40 mg/kg 3 times per week (i.e. 17 mg/kg/day) for 4 weeks
by oral gavage. Results show an average reduction of 2.6 fold in the number of
colorectal tumors in Anthos-treated mice compared with control (Figure 8b and
8c). This reduction was highly statistically significant (P < 0.001).
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Figure 9. Changes in Src and EGFR phosphorylation after treatment with
Anthos: Colon cancer cell line HT-29 was treated with various concentrations of
Anthos overnight and the effect on phosphorylation of Src (Y418) and EGFR
(Y1068) was assessed using western blot analysis and compared to total EGFR
and β-actin loading control. Densitometry values listed are the ratio of each dose
to the vehicle control for the phospho-protein/total protein, both corrected for βactin loading control.
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Insights into Anthos mechanism of action
To understand Anthos mechanism of action we focused on the Src and EGFRrelated pathways. Our preliminary in vitro work with lysates prepared from
Anthos-treated APC mutant HT-29 cells showed that Anthos treatment led to a
dose-dependent decrease in the phosphorylation status of EGFR (Y1068) and
Src (Y418) (Figure 9). With these promising in vitro findings we next sought to
determine the influence of Anthos treatment on the Src and EGFR-related
pathways in an ETBF-treated ApcMin/+ mouse model which has been reported to
have increased

EGFR activity and c-Src expression in the adenoma and

intestinal enterocyte tissue. Results from our analysis (Figure 9) of the
phosphorylation status of the tyrosine kinase, Src at position Y418 showed a
significant decrease in phosphorylation in Anthos-treated animals compared to
control animals. The phosphorylation status of transphosphorylation site Y845 of
the receptor tyrosine kinase (RTK), EGFR, a site noted for its activation by Src
was also significantly decreased in adjacent normal and colon tumor samples
taken from Anthos–treated animals over control animals. The transcription factor,
STAT5a/b, which is immediately downstream of EGFR Y845, also showed a
significant decrease in phosphorylation at tyrosine positions 694 and 699 in both
adjacent normal and tumor tissue samples from Anthos treated animals. The
ultimate expression of the downstream targets cyclin D1, cyclin D2 and COX-2
were also significantly downregulated in the Anthos group for both adjacent
normal and tumor tissue samples (Figures 10-12). Interestingly, significant
differences in the phosphorylation status of the autophosphorylation sites of
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Figure 10. In vivo changes in Src and EGFR pathways following treatment
with Anthos: changes in the phosphorylation and expression of Src and EGFR
along with corresponding downstream pathway targets including STAT3, STAT5,
cyclin D1, cyclin D2, and COX-2 in a) adjacent normal and b) tumor colon tissue
taken from ETBF-inoculated ApcMin/+ mice after treatment with Anthos or vehicle
control as assessed using western blot analysis with β-actin loading control.
Quantitative data summarized in Table 1.
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Figure 11. Representative heatmap for in vivo changes in Src and EGFR
pathways following treatment with Anthos: representative heat map legend
depicts the average fold change and significance level in either phosphorylation
status or expression levels between Anthos treated and vehicle control animals
within either adjacent normal (n=3) or tumor colon tissue (n=3).
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Table 1. Raw densitometry values calculated for Src/EGFR pathway
western blot analysis

Target
Src
Src (Y418)
EGFR
pEGFR (Y845)
pEGFR (Y1068)
pEGFR (Y1173)
pSTAT3
STAT3
pSTAT5
Cyclin D1
Cyclin D2
COX-2

Adjacent Normal
Control Anthos Fold change
6883
7922
1
20688
4816
-4
18661 20531
1
18141
5950
-3
19771 17469
-1
21496 20029
-1
15938 11067
-1
5088
7000
1
19969
3436
-6
22846
7075
-3
21036
6480
-3
19808
2687
-7
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Tumor
Control Anthos Fold change
9558
8474
-1
20516
6259
-3
18388 20599
1
17230
8659
-2
25990 12493
-2
16854 10731
-2
25354
5274
-5
10291
8208
-1
25057
6779
-4
27696 14658
-2
15580
3503
-4
18224
4358
-4
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Figure 12. Pathway involving modulation of Src and EGFR phosphorylation
status and downstream targets: the pathway deduced is based upon results
from western blot analysis for adjacent normal and tumor tissue samples and is a
modified version of the Qiagen EGFR signaling pathway.
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EGFR Y1068 and Y1173 were noted in the tumor but not the adjacent normal
colon tissue of Anthos treated compared to control animals. This difference
between adjacent normal and tumor tissue was also noted in the phosphorylation
status of the immediate downstream protein STAT3, with a significant decrease
in the phosphorylation at Y705 observed only in the tumor tissue and not the
adjacent normal tissue in Anthos treated animals. A significant decrease in the
levels of total EGFR, which was factored into the determination of
phosphorylation status, was also seen in only the tumor samples of Anthos
treated mice.

Discussion
Although much progress has been achieved in the treatment of CRC, it remains
the third leading cause of cancer-related death in the U.S. Furthermore, FAP
remains an orphan disease with the only viable treatment option being surgical
resection of the colon. Even after this drastic procedure, individuals with FAP are
still at a greater risk for developing cancers of the small intestine. With the above
factors in mind, the development of alternative prevention and treatment
strategies for combating both FAP and CRC are of great importance and
represent an unmet need.
One particular class of plant bioactive compounds that have been studied for
their health-promoting properties is that of the anthocyanins. This family of
colored pigments is particularly promising given its long history as a dietary
constituent for many humans. However, anthocyanins, when taken in their native
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form are often plagued by issues with their limited bioavailability and stability,
which effectively limit their translation into a clinically-viable option due to the
large doses that would need to be consumed in order to elicit therapeutic
efficacy. With this in mind, the focus of this study has been to utilize the Anthos,
which we have previously shown to be more active than the native anthocyanin
counterpart in A549 lung cancer cells [133]. This relationship is also valid in colon
cancer with delphinidin, and cyanidin yielding greater potency than their 3monoglucoside and 3,5-diglucoside anthocyanin counterparts. These results are
not surprising considering that anthocyanidins are somewhat more lipophilic due
to their higher partition coefficients than their anthocyanin counterparts. For
example, the anthocyanin, cyanidin 3,5-O-diglucoside has an octanol to water
(KOW) partition coefficient of 0.21 as opposed to its anthocyanidin counterpart,
cyanidin which has a partition coefficient of 10.07 [143]. These higher partition
coefficients enable anthocyanidins to be taken up passively by cells whereas
anthocyanins are known to require active transport and thus may be limited in
their transport efficiency/limitation [81].

Anthos were not only more potent than their anthocyanin counterparts, but
exhibited selectively toxicity towards colon cancer cells over the normal colon
cells with SI values that were well above the recommended cutoff for lack of
toxicity. We had previously shown that Anthos were non-toxic in wild-type mice
[144]. Furthermore, work with anthocyanins derived from blueberry, black currant
as well as elderberry showed no toxicity when administered to rats (20
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mg/kg/day), mice (25 mg/kg/day), or guinea pigs or rats (>3 g/day for 15 days or
90 days) [145].

Given the lack of more favorable/less invasive treatment options for FAP and the
severity and ultimate lethality of the disease at early ages, there is a great need
for developing alternative preventative treatment options. With this unmet need,
the potential application of Anthos to the prevention of FAP is a key possibility
based on our in vivo findings indicating significant decreases in intestinal polyp
number with Anthos intervention in ApcMin/+ mouse model.

In addition to the

promising results attained with the chemoprevention in the FAP study, Anthos
exhibited significant anti-tumor activity against ETBF induced colorectal tumors in
the ApcMin/+ mouse model.

ETBF, a subtype of B. fragilis that secrets the metalloprotease enterotoxin B.
Fragilis toxin (BFT), is associated with diarrheal disease in both humans and
animals as well as active inflammatory bowel disease. A study looking at the
prevalence of ETBF found that 26.8% of individuals with diarrhea and 12.4% of
individuals without diarrhea had stool samples that were positive for the presence
of ETBF [135]. Furthermore, a recent study looking at the bacterial composition
in individuals with FAP compared to normal controls found that the colonic
mucosa of individuals with FAP were highly enriched with genes for the toxin,
BFT, that is secreted by the ETBF bacteria [28]. In view of our encouraging
findings, it is presumable that use of Anthos in human inflammatory bowel
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conditions and colorectal tumors associated with ETBF and FAP could be of
great benefit.

We have previously shown that Anthos favorably modulate targets such as βcatenin, cyclin D1, cyclin B1, pERK, VEGF proteins, c-myc and MMP9 in lung
cancer H1299 cells [25]. Furthermore, anthocyanin substitution patterns were
found to lead to different cellular signaling cascades effects [36]. For instance,
only malvidin which features methoxy groups at the 3’ and 5’ positions of the Bring lead to inhibition of cAMP-specific phosphodiesterases (PDEs) whereas,
cyanidin and delphinidin were shown to inhibit EGFR in human vulva carcinoma
A431 cells [36]. In this report, we deduced mechanistic work utilizing APC mutant
colon cancer cells and adjacent normal and colon tumor tissue samples from
ETBF ApcMin/+ mouse model treated with Anthos. It was previously shown that
APC deficiency was associated with an increase in EGFR activity and c-Src
expression in ApcMin/+ mouse adenomas and intestinal enterocytes [146].
Furthermore, In addition to increasing the secretion of chloride and permeability
of intestinal epithelial cells, BFT also activates STAT3 and TH17 responses and
leads to increased COX-2 [147]. However, no work had been conducted to
assess the impact of Anthos or anthocyanins on Src in any cancer model or
Anthos on EGFR in a colorectal cancer model. In vitro work using the APC
mutant HT-29 colon cancer cells showed a clear dose-dependent decrease in
the phosphorylation status of Src (Y418) and EGFR (Y1068). Results from our
survey of the Src and EGFR-related pathways show a significant decrease in Src
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phosphorylation (Y418), EGFR phosphorylation (Y845) and the downstream
mediator STAT5a/b (Y694 and Y699), both in adjacent normal and colon tumor
tissue taken from ETBF treated ApcMin/+ mice that received Anthos treatment.
Furthermore, phosphorylation status of EGFR at Y1068 and Y1173 along with
the downstream mediator STAT3 (Y705) was shown to decrease in tumor tissue
in Anthos treated mice. Key regulators of cell cycle progression and
inflammation, including Cyclin D1, Cyclin D2 and COX-2, were shown to be
favorably modulated by Anthos, with the most dramatic reductions in expression
observed in tumor tissue samples. Overexpression of COX-2 has been noted in
colon tumor tissue and plays a role in the pathogenesis of FAP, ETBF and
ultimately colon cancer [148, 149]. Overall, these findings provide novel
mechanistic

insight

into

the

method

by

which

Anthos

achieve

both

chemopreventive and therapeutic effects against a highly relevant bacteriallydriven colon cancer model.

In summary, our data provide compelling evidence for the use of a bilberry
Anthos against FAP and CRC. Anthos were shown to yield greater potency and
efficacy than their counterpart anthocyanins and no toxicity toward normal colon
cells in vitro. Furthermore, in vivo anti-polyp and anti-tumor efficacy along with
corresponding mechanistic insight suggest that Anthos lead to a potent decrease
in the phosphorylation status of Src, EGFR, STAT5, STAT3 and expression of
key markers for proliferation and inflammation including cyclin D1, cyclin D2, and
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COX-2. Overall, results from this study offer an exciting possibility for potential
treatments with berry Anthos for FAP and CRC in the future.

Abbreviations
CRC: colorectal cancer, Anthos: native anthocyanidins mixture from billberry,
FAP: familial adenomatous polyposis, APC: adenomatous polyposis coli, COX-2:
cyclo-oxygenase-2, Cy: cyanidin, Dp: delphinidin, Pt: petunidin, Mv: malvidin, Pe:
peonidin, HPLC: high performance liquid chromatography, PDA: photodiode
array detector, UV: ultraviolet, ETBF: enterotoxigenic Bacteriodes fragilis, BFT:
B. fragilis toxin.
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CHAPTER 3:
THE ROLE OF ANTHOCYANIDINS IN RE-EQUILIBRATING METABOLIC SHIFTS INDUCED BY
DYSBIOSIS OF THE GUT MICROBIOME AND THE UBIQUITOUS ENVIRONMENTAL
CARCINOGEN, BENZO[a]PYRENE

Colorectal cancer (CRC)
Although much progress has been made in the diagnosis and treatment of
cancer over the last thirty years, CRC remains as a looming threat on the
horizon. For instance, although the incidence of CRC

has been trending

downward since the mid to late 1980s for individuals 55 years or older, a recent
study has found a rather disconcerting uptick in the CRC incidence for individuals
below 55 years old [12]. According to the CDC, the third most common form of
cancer in the US is CRC. Furthermore, CRC is the third leading form attributed to
cancer-related deaths each year. In fact, according to the American Cancer
Society, it is estimated that 140,250 individuals will be diagnosed and 50,630 will
die from CRC in the US in 2018 alone. Epidemiological studies suggest that
lifestyles with diets rich in fat, smoking, and alcohol consumption as well as
exposure to environmental pollutants and dysbiosis of gut microbiota increase
the risk of developing CRC [3, 150]. Much progress has been made in combating
the disease due to advancements made in early detection of CRC. However,
options for chemoprevention from environmental insult and an understanding of

64

how such treatments could alter the dialogue between one’s microbiome and
environmental toxins have yet to be achieved.
Factors in the development of CRC
Environmental factors in CRC
Environmental factors such as air pollution, cigarette smoke, and dietary
contamination have been epidemiologically and mechanistically linked to an
increased risk of CRC [151-153]. One particular class of environmental pollutants
that is especially pervasive is polycyclic aromatic hydrocarbons (PAHs). One of
the most ubiquitous members of this family is benzo[a]pyrene (B[a]P) which is
found in cigarette smoke, as a contaminant in many foods, car exhaust fumes,
wood burning and coal tar. In order initiate the carcinogenic process, B[a]P
undergoes bioactivation by enzymes, such as the cytochrome P450 (CYP) 1A1
and/or 1B1 and microsomal epoxide hydrolase (mEH) (1 , 4 , 5 ), resulting in the
formation of the ultimate carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide
(BPDE). Various enzymes including members of the glutathione s-transferase
(GST), uridine 5'-diphospho-glucuronosyltransferase (UGT) and sulfotransferase
(SULT) families are involved in the detoxification of the intermediates along this
bioactivation pathway (Figure 13). The metabolites of B[a]P are classified as
group 1 carcinogens by the International Agency for Research on Cancer (IARC).
BPDE intercalates DNA and ultimately covalently binds with guanine bases. This
acts to distort the structure of DNA disrupting the copying of DNA, which in turn
causes
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Figure 13. Metabolism of benzo[a]pyrene to carcinogenic BPDE vs.
detoxification pathways
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mutations. BPDE has also been found to target p53 thereby altering the tumor
suppression of cells which may ultimately lead to cancer [23]. Interestingly,
research that measures all of the exposures of an individual in a lifetime and how
those exposures relate to health referred to as “exposome” has found that
exposure to B[a]P leads to the enhanced susceptibility of macrophage
membranes to bacterial infection and ultimately may lead to immunosuppression
[154]. Although one of the first carcinogens to be studied, B[a]P remains a
continued threat due to its widespread presence in the environment. Given the
continued relevance of B[a]P, work looking at how this and its metabolites
interact with endogenous factors such as the gut microbiome is of

high

importance in addressing the management of several diseases including colon
cancer.
Bacterial carcinogens
In addition to traditional carcinogens such as B[a]P, recent research has begun
to uncover the importance of the gut microbiome in the development of CRC.
Research has shown that imbalances in the intestinal microbiota lead to both an
increase in inflammatory conditions as well as an increased production of
carcinogenic metabolites, which may ultimately lead to neoplasia. Several
bacteria have been associated with increased risk of developing CRC including:
S. gallolyticus, H. pylori, virulent forms of Escherichia coli (E. coli),
Fusobacterium nucleatum (F. nucleatum), Salmonella enterica (S. enterica) and
enterotoxigenic B. fragilis [155]. Furthermore, a bidirectional dialogue has been
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found to exist between the gut microbiome and environmental chemicals, with
bacteria metabolizing the pollutants contributing to host toxicity and the
contaminants altering the composition of gut microbiota [150]. This dynamic
interaction between the host microbiome and environmental carcinogens is
becoming ever more prevalent and relevant in the modern era. Furthermore, little
is known regarding the impact that gut bacteria such as ETBF has on the
expression

of

phase

I/II

enzymes.

With

this

in

mind,

identifying

a

chemopreventive method to combat this omnipresent insult is of great
importance.
Anthos background
Anthos role in detoxification
Several plant bioactives have been an invaluable source of medicines for
humans. The family of plant pigments, known as the anthocyanins, have been
identified with a variety of health benefits including chemopreventive and
therapeutic effects due to their roles as anti-inflammatory, antioxidant agents and
modulators of cytochrome P450 enzymes, CYP1A1 and CYP1B1 in mammary
tissue [94, 131]. Found in dark-colored vegetables, fruits, grains and flowers,
anthocyanins provide the characteristic red, purple and blue hues. Anthocyanins
are, in part, converted to anthocyanidins (Anthos), the aglycone moieties, and, in
fact, have higher antiproliferative and anti-inflammatory activities than the
anthocyanins presumably due to higher cell uptake.
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The berry bioactive, Anthos present a promising chemopreventive option for
individuals to avoid developing CRC. Berries were shown to reduce the oral
dysplasia and carcinoma-in-situ by approximately 50% in animals previously
treated with a mixture of the cigarette smoke carcinogens, B[a]P and NNK [156].
Previous work from our laboratory against breast and lung cancer has shown that
Anthos possess chemopreventive as well as therapeutic effects due to their roles
as anti-inflammatory, antioxidant agents and modulators of CYP1A1 and
CYP1B1 [157]. We demonstrated that intervention with the anthocyanidin,
delphinidin favorably modulated the underlying mechanisms of potent PAHs
[158]. It should also be noted that work with both anthocyanins and Anthos
suggest that these compounds do not influence the expression or activity of key
enzymes involved in drug metabolism including CYP3A4, CYP2A6, CYP2B6, or
CYP2C9 [159]. Furthermore, although work has been conducted to research the
impact of anthocyanins on CRC [97, 160], no research had previously been
conducted to study the impact of Anthos or ETBF bacteria on alterations in phase
I and II enzyme expression.
With this in mind, the aim of this series of studies was to assess how treatment
with a native mixture of anthocyanidins derived from bilberry (Anthos) and an
exosomally-delivered preparation of Anthos (ExoAnthos) influences proliferation
and modulation of expression of key phase I and II enzymes both in vitro and in a
bacterially-induced in vivo model of colorectal cancer. Furthermore, the influence
of gut bacterial dysbiosis induced by ETBF on phase I/II enzyme expression was
also investigated.
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Materials and Methods
Chemicals
B[a]P was handled carefully with all safety procedures as it is a highly
carcinogenic and hazardous chemical. B[a]P (B-1760, St. Louis, MO) was
purchased from Sigma-Aldrich.
Isolation of bilberry-derived Anthos
The native bilberry Anthos mixture that was generously provided by 3P
Biotechnologies (Louisville, KY) was further enriched using C18 Sep-Pak
cartridges (Waters, Milford, MA) and eluted in acidified (0.1% HCl) ethanol. The
enriched extract was then dried using a Savant SC210A Speed-Vac
(ThermoFisher Scientific, Waltham, MA) and stored at -20 °C. Purity was verified
using HPLC-PDA-UV. Briefly, 15 µl samples were analyzed using a Shimadzu
Premier C18 reverse-phase column (250x4.6 mm i.d., 5 µm). Mobile phase A
was composed of water: formic acid: acetonitrile (87:10:3) and mobile phase B
was composed of water: formic acid: acetonitrile (40:10:50). The flow rate was
0.6 ml/min and the gradient condition was 0-5 min 5% B; 5-15 min 15% B; 15-20
min 25% B; 20-30 min 35% B; 30-40 min 45% B; 40-45 min 100% B; 45-50 min
5% B. Detection of Anthos was at 520 nm by PDA-UV and total Anthos
concentration was calculated using a standard curve. The reference compounds
were purchased from Cayman Chemical Company (Ann Arbor, MI). The HPLC
analysis of the Anthos was conducted by Mr. Jeyaprakash Jeyabalan, a
Research Scientist in our laboratory.
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Isolation of milk derived exosomes
Exosomes from cow colostrum were isolated using differential centrifugation as
described by Munagala et al., [115], and were generously provided by 3P
Biotechnologies (Louisville, KY).
Protein determination
Protein estimation for exosomal preparations was assessed using a bicinchoninic
acid (BCA) assay (Thermo Scientific, Rockford, IL). In order to determine protein
concentration, diluted exosomal preparations were compared, in triplicate, to a
serially diluted bovine serum albumin (BSA) standard curve.
ExoAnthos drug loading
Anthos was loaded onto exosomes by mixing Anthos (dissolved in ethanol and
water) with the exosomes suspension in a 1:5 (Anthos:Exosomal protein, w/w)
ratio at room temperature (22 ºC). Unbound Anthos and any co-agulated
exosomes were removed by low speed centrifugation (10,000×g for 10 min). The
exosomes

that

were

loaded

with

Anthos

were

then

collected

by

ultracentrifugation (135,000 xg for 1.5 h). The pellet was then suspended in PBS
and passed through a 0.22 µ filter and stored at -80 ºC. The percent loading was
determined using solvent extraction.
Analysis of drug loading
In order to determine the load of Anthos in the ExoAnthos formulation, the protein
and Anthos concentrations were measured. Briefly, a 50 µl aliquot of ExoAnthos
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formulation was mixed with 950 µl of acidified ethanol (0.1% HCl). The
precipitated proteins were separated by centrifugation (10,000 x g for 10
minutes). The drug contained in the supernatant was then analyzed using a
SpectraMax M2 spectrometer (Molecular Devices, Sunnyvale, CA). Anthos were
detected at 520 nm and total Anthos concentration was calculated using a
standard curve. Reference anthocyanidins were acquired from Chromadex
(Irvine, CA). Anthos concentrations were confirmed via HPLC-PDA. The pelleted
exosomal proteins were determined by the BCA method described above. The
percent drug load when then calculated by dividing the amount of Anthos by
exosomal proteins x 100 [115]. Equal loading of individual Anthos was confirmed
using HPLC-DAD.
Characterization of Exosomes and ExoAnthos
The size of colostrum-derived exosomes and ExoAnthos, which were diluted in
PBS to 1 mg/ml, were determined using a Zetasizer (Malvern Instruments Ltd,
Malvern, Worcestershire, UK). Colostrum exosome and ExoAnthos morphology
were determined by atomic force microscopy (AFM). Briefly, exosomes and
ExoAnthos were diluted with deionized water to 10 µg/ml. A 2 µl aliquot of each
sample was then placed on a silica wafer and air dried for 30 min. Images were
captured using an Asylum MF-3D AFM (Oxford Instruments, Goleta, CA)
tapping mode using aluminum-coated silicon probes.

in

The amplitude,

topographic height and phase retraces were imaged with a fixed force (<1nN) at
a scanning rate of 1 Hz. Images were processed using IGOR software. The AFM
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analysis was performed by Mr. Jeyaprakash Jeyabalan, a Research Scientist in
our laboratory.
Cells, culture conditions and treatments
The APC wild-type HCT 116 (ATCC® CCL-247™) colon cancer cell line and
CCD-18Co (ATCC® CRL-1459™) normal colon cells were acquired from
American Type Culture Collection (Manassas, VA). The APC mutant colon
cancer cell line HT-29 (ATCC® HTB-38D™) was a kind gift from Dr. Nobuyuki
Matoba (University of Louisville). HCT-116 and HT-29 cells were maintained in
McCoy’s 5A medium (Gibco, Grand Island, NY) supplemented with 10% FBS,
100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere
containing 5% CO2 at 37°C. Cells were pre-treated with Anthos (25, 50, 100, 200
µM) for 24 h and co-treated with Anthos (25, 50, 100, 200 µM) and B[a]P (20 µM)
for 24 h.

Measurement of cell viability
The cytotoxicity of bilberry Anthos in colon cancer cell lines was assessed by
enzymatic reduction of the tetrazolium dye MTT. Briefly, 3.0 x103 cells/well were
grown in a 96-well tissue culture plates and were then exposed to varying
concentrations of bilberry Anthos or vehicle control 24 hours after seeding. After
72 h treatment, cells were incubated with 5 mg/ml MTT reagent for 2 h. Resulting
formazan

crystals

were

subsequently

solubilized

in

DMSO

and

spectrophotometrically measured at 570 nm (Bio-rad, Philadelphia, PA). IC50
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values were then determined using Calcysyn software version 2.1 (Biosoft,
Cambridge, England).

Western-blot analysis
For western-blot analysis, 40 µg of protein from in vitro and in vivo tissue lysates
was

resolved

using

SDS-polyacrylamide

gel

electrophoresis

and

electrotransferred to polyvinylidene difluoride membranes by semi-dry transfer
(Biorad Trans-blot SD, Hercules, CA). Blots were blocked with 4% dry powder
milk or BSA for 1 h and then incubated with primary antibodies β-actin, UGT1A6,
SULT1, GSTM1, GSTM2, CYP1A1, CYP1B1, PXR, Nrf2, AhR, AhRR, and
ARNT1 which were all acquired from Santa Cruz Biotech (Santa Cruz, CA) at
4ºC overnight and secondary antibodies (Santa Cruz Biotech, Santa Cruz, CA).
conjugated to peroxidase for 1 h at room temperature. Blots were then developed
with an ECL detection system. Densitometric analysis was then performed using
ImageJ 1.x software [134].

Animal model for CRC
ApcMin/+ mice are a well established and accepted model for studying FAP and
CRC. The mice characteristically exhibit a germline nonsense mutation at codon
850 of the APC gene that causes the spontaneous development of polyps, which
predominantly occur in the small intestine by the age of 10-12 weeks.
Enterotoxigenic Bacteriodes fragilis (ETBF) is a highly relevant model for
development of CRC due to its contribution to both familial and sporadic forms of
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cancer [28, 135]. ETBF exists asymptomatically in 12.4% of individuals overall
and in 27% of individuals with diarrhea symptoms [135]. Furthermore, presence
of ETBF in the gut is a well known as a global cause of diarrheal disease that is
accompanied by colitis in both humans and animals. The pathogenicity
associated with ETBF is due to the secretion of a 20 kDa zinc-dependent
metalloprotease toxin, B. fragilis toxin (BFT), which binds to colonic epithelial
cells and leads to the cleavage of the tumor suppressor protein, E-cadherin, and
the secretion of interleukin-8 [136]. Overall, this process leads to the stimulation
of proliferation and migration of human colon cancer cells [137]. It should also be
noted that BFT has also been shown to induce pro-inflammatory cytokine
secretion by further activating the NFƘB pathway [137].

In vivo CRC studies
Animal experiments were performed in agreement with an approved protocol by
the Institutional Animal Care and Use Committee at the University of Louisville.
Breeding colonies were established in collaboration with Dr. Nejat K. Egilmez’s
lab [138] at the University of Louisville using C57BL/6J Min/+ (ApcMin/+) mice that
were originally attained from Jackson Laboratories (Bar Harbour, ME). Mice were
genotyped for the APC mutation using PCR according to the protocol established
by Jackson Laboratories. Mice were fed a standard chow diet and received water
ad libitum and were maintained on a standard light/dark cycle for the duration of
the study. At 5-6 weeks of age, animals were administered antibiotic. Four days
later the animals were administered ETBF to promote tumorigenesis and one
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week following ETBF inoculation, animals began their respective treatment
regimen. Male and female ApcMin/+ mice were orally administered (by gavage) an
average of 8 mg/kg/day Anthos, 8 mg/kg/day ExoAnthos or vehicle control for 4
weeks. Animals were culled in the fed state at 12 weeks, colon tumors were
counted and tissues were harvested.

Data analysis
Statistical analysis was performed using Graph Pad Prism statistical software
version 4.03 (La Jolla, CA) and RStudio software version 1.0.153 (Boston, MA)
Lattice package [139, 140]. Test for normality, F-test for equal variance, and
appropriate t-test were used for both animal studies and for analysis of western
blot results. One way ANOVA was used for assessing the significance of mean
differences across the various treatments for western data. IC50 values were
determined using CalcuSyn software version 2.1 (Biosoft, Cambridge, England).
Heat maps were constructed using RStudio software version 1.0.153 (Boston,
MA) gplot package [140, 141].

Results
Anti-proliferative effects of Anthos and ExoAnthos on colon cancer cells
but not normal colon cells
Previous work from our laboratory has shown that exosomal formulation yielded
enhanced

therapeutic potency and efficacy for drugs such as paclitaxel,

celastrol, curcumin and Anthos against lung cancer due to increased stability and
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bioavailability of these compounds [115-117, 142]. Prior to carrying out our in
vivo work, we first determined the impact of ExoAnthos, exosomal vehicle (Figure
14) and Anthos treatment on proliferation of HCT-116 and HT-29 colon cancer
cell lines and CCD-18Co normal colon cells (Figure 15). Results from these
studies showed a clear increase in the anti-proliferative properties of Anthos
against colon cancer cells, with 4-16-fold decreases in the IC50 values of
ExoAnthos as compared to the free Anthos (Figure 15). One can posit that the
improved anti-proliferative effects of the ExoAnthos formulation over Anthos
alone is most likely due to the increased cell uptake and stability in media of the
ExoAnthos over Anthos. Part of the higher efficacy of ExoAnthos may be
attributed to the intrinsic effect of the exosomes alone (Munagala et al. 2016,
2017).

In order to determine whether Anthos and ExoAnthos were selective toward
colon cancer over normal colon cells in vitro we determined the selectivity index
(SI) values for both HCT 116 and HT-29 colon cancer cells compared to normal
colon CCD-18Co cells. The results (Table 2) showed not only that both Anthos
and ExoAnthos were selective for colon cancer over normal colon cells, but that
ExoAnthos enhanced this selectivity, with the greatest increase yielded in HT-29
cells which went from an SI value of 9 for Anthos to 51 for ExoAnthos. Overall,
these results confirm that Anthos and ExoAnthos do not show in vitro toxicity for
the normal CCD-18Co colon cells and that the cytotoxicity is specific for colon
cancer cells.
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Figure 14. Antiproliferative activity of Exosomes against colon normal cells
and cancer cell lines: Colon normal cells CCD-18Co and colon cancer cell lines
HCT-116 and HT-29 were treated with various concentrations of milk derived
exosomes for 72 h and the effect on cell growth inhibition was assessed using an
MTT assay. Data represent average ±SEM (n=3).
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Figure 15. Antiproliferative activity of Anthos and ExoAnthos against colon
normal cells and cancer cells in vitro: Colon normal cells, CCD-18Co and
colon cancer cells, HCT-116 and HT-29 were treated with various concentrations
of bilberry-derived Anthos or ExoAnthos for 72 h and the effect on cell growth
inhibition was assessed using an MTT assay. Data represent average ± SEM
(n=4).

79

Table 2. Tabulated selectivity values for colon cancer and normal cells
treated with Anthos and ExoAnthos
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Impact of Anthos treatment on tumor number in vivo
As presented in chapter 2, Anthos led to a significant reduction in colon tumors in
an ETBF Apcmin/+ mouse model when given at an average dose of 16 mg/kg.
Given these promising results, we next sought to test our ExoAnthos formulation,
which makes use of an exosomal nano delivery method to see if greater
therapeutic effect could be achieved at lower doses due to enhanced stability
and bioavailability of the Anthos. We have previously found that Exosomal
delivery enabled us to achieve superior results for several drugs such as
curcumin, celastrol and paclitaxel when given alone in vivo for breast and lung
cancer [115-117, 144]. Results from the comparison of Anthos and ExoAnthos
treatment showed that ExoAnthos lead to a similar reduction in colon tumor
burden as Anthos alone, when given at the same dose (P=0.30). When
compared to control, a significant reduction in colon tumors was noted in the
ExoAnthos treated animals vs. exosome vehicle control (P=0.019) and Anthos
treated animals vs. vehicle control (P=0.0025) when given at 8 mg/kg (Figure
16). It should be noted that no significant difference was found between the
tumor numbers in control vs. exosome alone treated animals (P=0.728).

Impact of ETBF bacteria on phase I/II enzyme expression in colon/liver
Prior to this study, no work had been completed assessing the impact of ETBF
bacteria on the expression of phase I or II enzymes. However, there has been
growing interest in the scientific community regarding the impact of the gut
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Treatment:
-ExoAnthos
-Anthos
-Vehicle control
Antibiotic ETBF
Mice born

A.

5-6 wk

4 days

-Euthanasia
-Quantitation of
colon adenomas

4 wk

1 wk

B.

Figure 16. Anti-tumor activities of Anthos and ExoAnthos against colon
tumors. (A) Study overview, ApcMin/+ mice inoculated with ETBF were treated via
oral gavage with Anthos or ExoAnthos three times a week (20 mg/kg bw) or
vehicle controls. (B) Data represent the distribution of animal colon tumor counts,
with the average noted. Anthos versus control (P=0.0025), control versus
exosomes alone-treated animals (P=0.728), ExoAnthos treated animals versus
exosomes vehicle control (P=0.019), Anthos versus ExoAnthos (P=0.30). ***
signifies P<0.001, ** signifies P<0.01, and * signifies P<0.05.
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microbiome on the metabolism of drugs and environmental chemicals such as
polybrominated diphenyl ethers (PBDEs) [161]. Results from our investigation of
the influence of ETBF bacteria on the expression of phase I and II enzymes in
ApcMin/+ mice treated with the bacteria showed significant increases in the
expression of the phase I enzymes CYP1A1 and CYP1B1. Additionally, a
significant decrease in the expression of the phase II enzyme GSTM1 in normal
colon tissue was also noted. In order to assess how ETBF bacteria influences the
expression of these phase I and II enzymes we assessed the expression of AhR,
AhRR, ARNT1, Nrf2, VDR and PXR in ApcMin/+ mice with and without ETBF
treatment. Results from this survey (Figure 17) showed that mice treated with
bacteria had highly significant decreases in the expression of the AhR repressor,
AhRR. No significant changes in the expression of PXR, Nrf2, and VDR
expression were noted in colon tissue samples taken from the mice that received
bacteria. Liver samples taken from bacteria-treated mice also featured decreased
expression of the phase II enzymes UGT1A6 and GSTM1 and increased
expression of AhR when compared to ApcMin/+ mice that did not receive bacteria.

Impact of Anthos treatment on phase I/II enzyme expression in vivo:
colon/liver
In chapter 2, we showed that Anthos treatment led to decreases in the
phosphorylation status of both Src (Y418) and EGFR (Y845) in both tumor and
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ApcMin/+

Figure 17. In vivo changes in phase I and II enzyme expression and related
xenobiotic sensing nuclear receptors in normal colon tissue following
treatment with ETBF bacteria, bilberry-derived Anthos or ExoAnthos: changes
in the expression of key phase I and II enzymes along with key nuclear receptors
including CYP1A1, CYP1B1, GSTM1, SULT1, AhR, AhRR, ARNT1, Nrf2, PXR and
VDR in normal colon tissue

taken from ETBF-inoculated ApcMin/+

mice after

treatment with bilberry-derived Anthos, ExoAnthos or vehicle control as assessed
using western blot analysis compared to with ApcMin/+

bacteria and β-actin loading control.
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mice that received no

Fold change in expression

-10

0

10

P < 0.05 *
P < 0.01 **
P < 0.001 ***

Figure 18. Representative heatmaps for In vivo changes in phase I and II
enzyme expression and related xenobiotic sensing nuclear receptors.
Quantitative data summarized in Table 3.
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Table 3. Raw densitometry values calculated for western blot analysis of
phase I & II enzyme expression and related xenobiotic sensing nuclear
receptors in normal colon tissue
Normal Colon

AhR

58410

29526

Fold
change
(ETBF
vs. No
ETBF)
-2

17585

-2

14032

-2

AhRR

53603

13357

-4

27057

2

21555

2

ARNT 1

58885

40294

-1

34663

-1

15608

-3

CYP1A1

2726

9826

4

8187

-1

4482

-2

CYP1B1

3384

9273

3

9723

1

6887

-1

Nrf2

37037

59867

2

58756

-1

44028

-1

VDR

27347

32973

1

50719

2

45036

1

PXR

42009

69029

2

72372

1

60007

-1

GSTM1

6380

5734

-1

11143

2

7378

1

SULT1

7888

7061

-1

11076

2

10823

2

Target

ApcMin/+,
No ETBF

Control
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Anthos

Fold
change
(Control vs.
Anthos)

ExoAnthos

Fold change
(Control vs.
ExoAnthos)

adjacent normal tissue, and EGFR (Y1068 and Y1173) in colon tumor tissue.
However, no work had been conducted to assess whether Anthos modulated
phase I and II enzyme expression in colon or liver tissue in animals treated with
ETBF bacteria. Results from our survey of the impact of Anthos and ExoAnthos
on key phase I and II enzymes involved in the metabolism of the environmental
carcinogen B[a]P as well as other carcinogens, demonstrated significant
modulation of the phase I enzymes CYP1A1 and CYP1B1 and phase II enzymes
GSTM1 and SULT1 by Anthos and ExoAnthos (Figures 17-18) in normal colon
tissue. Our survey of nuclear transcription factors and associated proteins
including AhR, AhRR, ARNT1, Nrf2, VDR and PXR found that Anthos led to
increases in the expression of the AhR repressor AhRR when compared to ETBF
alone treated animals. Interestingly, ExoAnthos treatment was not shown to
increase expression of AhRR but rather it led to decreased expression of the aryl
hydrocarbon receptor nuclear translocator, ARNT1. No significant changes were
noted in the expression of PXR, Nrf2, or VDR in colon samples from Anthos or
ExoAnthos treated animals. Results from the enzyme expression analysis of liver
tissues taken from the same animals noted similar decreases in the expression
of CYP1A1 in Anthos treated mice and increases in the phase II enzymes
GSTM1 and UGT1A6 (Figures 19-20). No significant changes in expression of
mEH or SULT1 were noted in liver tissue. A significant decrease in AhR was
noted in ExoAnthos treated mice and a significant increase in AhRR expression
was noted in Anthos treated as compared to ETBF ApcMin/+ vehicle control mice.
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ApcMin/+

Figure 19. In vivo changes in phase I and II enzyme expression and related
xenobiotic sensing nuclear receptors in liver tissue following treatment
with ETBF bacteria, bilberry-derived Anthos or ExoAnthos: changes in the
expression of key phase I and II enzymes along with key nuclear receptors
including CYP1A1, mEH, GSTM1, SULT1, AhR, AhRR, in liver tissue taken from
ETBF-inoculated ApcMin/+

mice after treatment with bilberry-derived Anthos,

ExoAnthos or vehicle control. Assessed using western blot analysis compared to
with ApcMin/+ mice that received no bacteria and β-actin loading control.
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AhR
AhR
AhRR
AhRR
CYP1A1
CYP1A1
mEH
mEH
SULT1
SULT1
GSTM1
GSTM1
UGT1A6
UGT1A6

Fold change in expression
-10

0

10

P < 0.05 *
P < 0.01 **
P < 0.001 ***

Figure 20. Representative heatmaps for In vivo changes in phase I & II
enzyme expression and related xenobiotic sensing nuclear receptors in
liver tissue: heatmaps and significance levels produced from western blot data
and related statistical analysis. Quantitative data summarized in Table 4.
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Table 4. Raw densitometry values calculated for western blot analysis of
phase I & II enzyme expression and related xenobiotic sensing nuclear
receptors in liver tissue

Anthos

Fold
change
(Control
vs.
Anthos)

ExoAnth
os

Fold
change
(Contro
l vs.
ExoAnt
hos)

Target

ApcMin/+
, No
ETBF

Control

Fold
change
(ETBF
vs. No
ETBF)

AhR

943

34419

37

44576

1

38634

1

6464

-7

AhRR

51013

38000

-1

26864

-1

71099

2

42221

2

CYP1A1

40740

30904

-1

20889

-1

9504

-3

9614

-2

mEH

28247

30977

1

37739

1

30286

-1

36194

-1

Exo
Alone

Fold
change
(Control
vs. Exo)

SULT1

37873

55699

1

46368

-1

46320

-1

32923

-1

GSTM1

34244

11042

-3

29548

3

19038

2

26604

-1

UGT1A6

60110

26603

-2

21889

-1

13159

-2

42303

2
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Expression in tumor tissue
Alterations of phase I and II enzymes have been attributed to being one of the
causes for the development of chemo-resistance in cancer [162, 163]. Since
modulation of phase I and II enzymes were demonstrated in normal colon and
liver tissues, we sought to determine whether additional chemo-resistance could
arise for individuals undergoing chemotherapy if they were taking Anthos. In
order to do this, we assessed the expression of the phase II enzymes: GSTM1,
SULT1, and UGT1A6 in the tumor tissue taken from Anthos treated vs. ETBF
control mice. Results from this analysis (Figure 21) showed that Anthos
treatment led to no significant changes in the expression of the phase II
enzymes: UGT1A6, GSTM1, or SULT1 in the tumor tissue.
Impact of Anthos treatment on alterations induced by B[a]P treatment in
vitro
Alterations in the expression of phase I enzymes had been previously reported
by our laboratory in an ACI rat model for breast cancer [157].

Given this

background, we next sought to determine if Anthos and ExoAnthos treatment
would alter this shift in phase I/II enzyme expression induced by B[a]P treatment,
in vitro. Results (Figure 22) showed that cells treated overnight with B[a]P (20
µM) featured increased expression of CYP1A1 with decreased expression of
GSTM1. Furthermore, treatment with Anthos led to significant decreases in the
expression of CYP1A1 while significantly increasing the

phase II detoxifying

enzymes GSTM1 and SULT1. Anthos treatment, at the highest doses, led to
approximately
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Figure 21. Impact of in vivo Anthos treatment on phase II enzyme
expression in colon tumor tissue: changes in the expression of key phase II
enzymes including GSTM1 (P>0.2), SULT1 (P>0.2) and UGT1A6 (P>0.5) taken
from ETBF-inoculated ApcMin/+ mice after treatment with bilberry-derived Anthos
or vehicle control as assessed using western blot analysis compared to β-actin
loading control.
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3-fold reductions in the expression of a key transcription factor AhR, which is
involved in the expression of CYP1A1, in HCT-116 colon cancer cells.
Furthermore, Anthos treatment simultaneously led to a nearly 2-fold increase in
the expression of the AhR repressor, AhRR. Anthos treatment also led to 2- to
greater than 10-fold increases in the expression of a key nuclear receptor, PXR,
which regulates the detoxification process by upregulating enzymes UDPGT,
GSTs and SULTs when it identifies the presence of foreign potentially toxic
substrates [164]. It should be noted that the expression was enhanced, although
to a lesser extent than Anthos treatment, when in the presence of B[a]P alone.
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Figure 22.

Changes in expression of key phase I and II enzymes and

related nuclear receptors following treatment with B[a]P versus B[a]P and
Anthos. Colon cancer cell line HCT-116 was pre-treated with various
concentrations of Anthos for 24 h followed by co-treatment with B[a]P and Anthos
for 24 h and the effect on expression of AhR, AhRR, CYP1A1, SULT1, and
GSTM1 was assessed using western blot analysis and compared to β-actin
loading control. Densitometry values listed are the ratio of each dose to the
vehicle control (a) and B[a]P control (b), corrected for β-actin loading control.
Treatment and controls were run on the same gels.
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Discussion
Given the recent uptick in cases of CRC diagnosed in younger individuals [12],
CRC appears to be making a comeback and thus warrants research into
identifying potential chemopreventive methods to combat this disease. Although
much research has been conducted on the role of carcinogens such as B[a]P on
the development of colorectal cancer, little has been achieved in successful
prevention of this disease in populations who are exposed to such environmental
carcinogens on a daily basis. It should be noted that many studies have been
conducted on a variety of plant-derived chemopreventive agents but few agents
have successfully been translated, perhaps due to a generalized poor
understanding of how they function mechanistically and issues pertaining to
bioavailability. For instance, anthocyanins have been attributed with a variety of
health-promoting benefits including chemopreventive and therapeutic effects due
to their roles as anti-inflammatory and antioxidant agents [94, 131]. However, no
studies investigating the impact of Anthos on the balance of phase I/II enzymes
in the colon had been reported in the literature. Furthermore, the impact of
bacteria such as ETBF on this balance in the colon and liver has also yet to be
elucidated. Given the lack of understanding/knowledge in these areas, we sought
to uncover the impact of ETBF bacteria, Anthos and B[a]P on this crucial
enzymatic balance.
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Bacteria and role of ETBF in modulating phase I/II enzymes
Several recent studies have confirmed the link between dysbiosis of the gut
microbiome and colorectal cancer. Several bacteria in particular have been
associated with increased risk of developing CRC including: S. gallolyticus, H.
pylori, virulent forms of Escherichia coli (E. coli), Fusobacterium nucleatum (F.
nucleatum), Salmonella enterica (S. enterica) and enterotoxigenic B. fragilis
[155]. Although much research has been conducted on the role of bacteria on
inflammation and carcinogenesis [28, 147, 165],not much has been uncovered
on the role of ETBF on the expression of phase I and II enzymes. Results from
our assessment of the impact that ETBF has on the expression of phase I and II
enzymes in ApcMin/+ mice showed that treatment with the bacteria led to
significant increases in the expression of the phase I enzymes CYP1A1 and
CYP1B1 in normal colon tissue. Furthermore, highly significant increases in the
expression of AhR and significant decreases in the expression of the phase II
enzymes GSTM1 and UGT1A6 were noted in liver tissue samples taken from
ETBF mice when compared to mice that did not receive the bacteria. The results
gathered in this study provide an additional link between how “bad” bacteria such
as ETBF can ultimately lead to the development of cancer beyond the initially
elucidated inflammatory and gut barrier breakdown pathways [137, 147].
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Exo Anthos, Anthos modulate expression of phase I/II enzymes in normal
but not colon tumor tissue
After elucidating how ETBF bacteria increases the expression of phase I
enzymes while decreasing the expression of the phase II enzymes in normal
colon and liver tissue, we next wanted to determine if Anthos or ExoAnthos
treatment could alter this enzyme imbalance. We have previously reported that
Anthos treatment led to reductions in the phosphorylation status of Src, EGFR,
STAT3, STAT5 and expression of COX-2, Cyclin D1 and Cyclin D2 in this animal
model (Chapter 2). Furthermore, previous work from our laboratory has shown
that Anthos treatment led to decreased expression and activity of CYP1A1 and
CYP1A2 in a breast cancer model [157]. Results from this series of studies
showed that Anthos and ExoAnthos treatment significantly decreased the
expression of phase I enzymes CYP1A1 and CYP1B1, while increasing the
expression of the phase II enzymes GSTM1 and SULT1. Our survey of AhR,
ARNT1 and AhRR expression suggest that the modulation of phase I and II
enzymes could be attributable to the altered expression of AhRR and ARNT1
induced by Anthos and ExoAnthos treatment. It should be noted that AhRR is a
key protein in the AhR signaling cascade that acts as a repressor of AhRdependent gene expression. Structural work shows that AhRR acts by
competitively repressing AhR binding to ARNT and target DNA [166] .
Furthermore, AhRR levels have been shown to decline in a variety of disease
states ranging from rheumatoid arthritis [167] to lung cancer [168]. Interestingly,
DNA methylation at AHRR has also been shown to be a marker for smoking and
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was correlated with future smoking morbidity and mortality [169] .

As noted

above, ARNT1 is also a key component of the AhR signaling cascade and
functions by binding to the ligand bound form of AhR and aiding in the movement
of the AhR complex to the nucleus. ARNT has also been shown to be
upregulated under hypoxic conditions by a HIF-1α dependent mechanism in
Hep3B cells [170].
Importantly, no significant changes in the expression of the phase II enzymes
UGT1A6, SULT1 or GSTM1 were noted in colon tumor tissue taken from animals
treated with Anthos. Therefore, potential negative effects due to increased
breakdown of chemotherapeutic drugs that may result from increased phase II
enzyme expression, as evolves in many tumors, should not be a cause for
concern with Anthos treatment. With this in mind, the selective increase in phase
II enzyme expression in normal tissue over tumor tissue may actually be an
advantage in decreasing off target toxicity to healthy tissue for drugs such as
irinotecan [171]. However, additional studies would be needed to confirm this
hypothesis.

Influence of B[a]P and Anthos treatment on phase I and II enzyme
expression
Exposure to environmental pollutants is now considered to be one of the reasons
behind the increasing rates of individuals with disorders ranging from obesity and
type 2 diabetes to cancer [151, 153]. Up to 90% of CRC cases are of sporadic
origin and it is estimated that diet contributes to 80% of known cases of CRC.
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The role of chemicals that contaminate food and ultimately contribute to the
development of CRC has been of great interest [153]. A class of compounds that
is particularly relevant is PAHs. The PAH, B[a]P is of special interest due to its
presence in a variety of common sources of exposure ranging from charcoal
cooked food to cigarette smoke and several environmental sources and its
epidemiological correlation with increased risk of CRC. Similar to the alterations
in phase I and II metabolism found to exist in vivo following ETBF inoculation, we
found that cells treated overnight with B[a]P (20 µM) featured increased
expression of the phase I enzyme CYP1A1 with decreased expression of the
phase II enzyme GSTM1 as well as the AhR repressor, AhRR. These results
suggest that dysbiosis of the gut microbiome and exposure to the environmental
carcinogen B[a]P both lead to dysfunction of the balance between phase I and II
enzymes in colon tissue. Furthermore, treatment with Anthos effectively shifted
this balance in expression levels of AhRR, AhR, PXR, CYP1A1, and SULT1 to
greater favor a state of detoxification in B[a]P treated cells. It should be noted
that the beneficial effects attributed to consumption of Anthos in this study may
vary from person to person depending upon the presence of genetic
polymorphisms of these enzymes. However, since the expression of several
enzymes were shown to be modulated by these compounds, individuals may still
benefit overall by way of alternative enzymes.
Overarching results from this study stress the importance of integrating the gut
microbiome into the study of carcinogen metabolism and carcinogenesis. With
the ever omnipresent threat and buildup of carcinogens within the industrialized
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environment and the resulting inevitable daily exposure of the colon to these
compounds, a more integrated approach to the prevention of cancer is needed.
Future studies assessing potential synergy that may arise when dysbiosis of the
gut microbiome is combined with exposure to environmental carcinogens such as
B[a]P could lead to a better understanding and a potential explanation for the
current upward tick in colorectal cancer cases.
Abbreviations
B[a]P: Benzo[a]pyrene, CRC: colorectal cancer, PAHs: polycyclic aromatic
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CHAPTER 4:
MODULATION OF COLON INFLAMMATORY ENVIRONMENT BY BILBERRY-DERIVED
ANTHOCYANIDINS

Introduction
A recent report on the incidence of colorectal cancer (CRC) has uncovered an
alarming increase in the rate in individuals under the age of 40. Interestingly, this
increase was only observed for cases in the distal colon and rectum, which had
previously been declining [12]. Although the cause for this shift has yet to be
identified, one particularly compelling presumption would be to link an updated
version of Strachan’s hygiene hypothesis [172]. This hypothesis associates the
rise in atopic diseases such as food allergies, asthma, anaphylaxis, allergic
rhinitis and atopic dermatitis and disorders of the immune system e.g.,
inflammatory bowel disease (IBD) and type 1 diabetes (T1D) in the younger
generations to the increase in “hygienic” environments in the “developed” world
since the 1980’s. During this time, great strides have been made in the fight
against infectious diseases due to increased vaccination rates, use of antibiotics
and sanitation practices [173]. However, although the hygiene hypothesis makes
a compelling case, additional changes such as alterations in diet, environmental
carcinogens, exposure to parasites, increase in caesarean sections etc. have
occurred concurrently during this time period. The updated hypothesis which now
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targets promoting a healthy microbiome while maintaining stringent standards
for avoiding infectious diseases has taken on a variety of names such as
microbiome depletion hypothesis, old friends hypothesis, microbial diversity
hypothesis and targeted hygiene hypothesis [174].
Bacteria and evasion of immune response
Traditionally, the cause for the development of CRC has been attributed to the
presence of genetic mutations. However, the role of the gut microbiome in the
development of cancer, with a special emphasis on CRC, has been gaining everincreasing traction within the scientific community over the past 10 years.
Specifically, findings link the dysbiosis of the gut microbiome and the resulting
inflammation to genotoxicity and ultimately carcinogenesis. Various mechanisms
by which these “bad” bacteria take root and evade the immune system have
been hypothesized and include the ability of toxin-producing bacteria such as H.
pylori and B. fragilis to evade the normal host response. This was found to be in
part due to their ability to elicite a Th2 over Th1 response caused by their lipid A
structural differences which fail to activate toll like receptor 4 (TLR4), but activate
toll like receptor 2 (TLR2) [175]. Originally described by Mosmann et al., the T
helper (Th) cell balance between Th1 and Th2 cell subtypes, Th2 dominated
imbalances, which lead to increases in IL-4, IL-5 and IL-13, were found to lead to
allergen sensitization. In contrast, imbalances favoring Th1 type responses,
which lead to increases in IFN-γ, were shown to suppress Th2 and ultimately
lead to the inhibition of atopic immunopathology.
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A more recently identified Th subtype is Th17. Under normal functioning
conditions, Th17 cells aid in defending the host against extracellular pathogens.
This is accomplished by aiding in the recruitment of macrophages and
neutrophils to the infected tissue. However, when dysregulated Th17 cells can
lead to chronic inflammatory diseases such as multiple sclerosis, rheumatoid
arthritis, psoriasis, asthma and inflammatory bowel disease [176]. Recent studies
have linked the environmental factors such as diet and intestinal microbiota to
this dysregulation of cytokine regulation ultimately spurring autoimmunity and
disease [177]. Interestingly, studies have linked diets high in trans fatty acids
with increased expression of IL-17 and RORγt expression which are
characteristic of a Th17 response and intestinal inflammation in DSS treated
mice [178]. Additionally, a diet high in salt was linked with promotion of both Th17
differentiation and the induction of autoimmunity [179].
One particular strain of bacteria that has gained attention for both its relevance in
clinical populations for CRC, FAP and diarrheal disease is Enterotoxigenic
Bacteriodes fragilis (ETBF). ETBF bacteria are a subset of B. fragilis bacteria that
secrete the metalloprotease toxin, B. fragilis toxin (BFT). This 20 kDa zincdependent metalloprotease leads to the cleavage of E-cadherin thus increasing
permeability and exposing the submucosa of the colon to bacterial antigens from
the lumen. Additionally, the tumorigenesis induced by ETBF bacteria has been
found to be driven by Th17 response and increased STAT3 activity.
Like many biological processes, the balance between these competing pathways
is crucial in maintaining an optimal disease-free state. Excess of any one of
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these pathways under certain conditions can lead to a variety of diseases such
as asthma, rheumatoid arthritis, colitis, and cancer [180, 181]. It has also been
shown that by depleting the Tregs in ETBF-colonized C57BL/6 FOXP3(DTR)
mice, there was an effective shift toward enhanced colitis, but reduced
tumorigenesis. This was attributed to the shift in the mucosal cytokine profile
from IL17 to IFNγ [182]. A variety of factors have been found to influence Th17
cell differentiation. These factors include but are not limited to the following:
influence of Treg, PD-L1, AhR, COX-2/PGE2 [183].
Programmed death-ligand 1 (PD-L1)
A number of promising immunotherapeutic treatments such as ipilimumab (antiCTLA-4 therapy), pembrolizumab (anti-PD-1 therapy), nivolumab (anti-PD-1
therapy), atezolizumab (anti-PD-L1 therapy), avelumab (anti-PD-L1 therapy), and
durvalumab (anti-PD-L1 therapy) have recently been developed and successfully
applied to the treatment of several different types of cancer such as melanoma,
Hodgkin lymphoma, urothelial carcinoma and non-small cell lung cancer. Of
these immune therapies, one of the most common targets is the programmed
death ligand 1 (PD-L1) and its receptor programmed death 1 (PD-1) receptor.
The PD-1 receptor is expressed by T lymphocytes, B, natural killer T, and Treg
cells, where it functions as an inhibitory receptor which effectively diminishes the
immune

response

via

down-regulation

and

promotes

self-tolerance

by

suppressing T cell inflammatory activity. Under normal functioning conditions this
helps prevent autoimmune disease. However, this mechanism is often redirected
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by cancer cells, which highly express the PD-1 ligand, PD-L1, in order to prevent
the immune system recognition and attack.
With the recent rise in use of the checkpoint inhibitors such as anti-PD1 and antiCTLA-4 therapies, side effects classified as immune-related adverse events
(irAEs) ranging from pneumonitis and hepatitis to colitis have arisen [184]. More
specifically, it has been found that a new inflammatory bowel disease phenotype
that shares traits with both ulcerative colitis (UC) and crohn’s disease (CD) can
occur with use of these therapies [184]. These side effects are not surprising
considering that several studies have shown that polymorphisms in these
proteins are associated with autoimmune diseases such as type 1 diabetes
mellitus (T1DM), systemic lupus erythematosus (SLE) and rheumatoid arthritis
(RA) [185]. Interestingly, upregulation of PD-L1 has been found to restrain Th17
cell differentiation [186]. As noted previously, Th17 is one of the main drivers by
which ETBF bacteria drives inflammation-induced colon carcinogenesis [138].
Therefore, although PD-L1 has a deleterious role when expressed in the tumor
microenvironment, a more careful consideration of the endogenous role of PD-L1
in normal colon tissue must be addressed.
Role of COX-2 in PD-L1 expression and Th17 differentiation
Even though COX-2 was originally identified in 1989 by Needleman and
coworkers, COX-2 and COX-1 have been anti-inflammatory targets from the
ancient time - since 1500 BC [187]. COX-2 is typically expressed only under
conditions

where

prostaglandins

are

upregulated

which

occurs

during

inflammation and have thus been a key target for research relating to the
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treatment and prevention of diseases such as rheumatoid arthritis, osteoarthritis,
and cancers of the prostate, breast, lung and colon [188]. In addition to the more
traditional therapeutic applications of the COX-2/PGE2 pathway, recent research
has highlighted the influence of more mechanistic role of this pathway on PD-L1
expression and Th17 development. For instance, it has also been shown that
tumor cells can induce PD-L1 expression in macrophages and myeloid-derived
suppressor cells by altering PGE2 metabolism in hematopoietic cells and that
COX-2 inhibition could help to regulate these changes in PD-L1 expression [189].
Furthermore, COX-2 expression was also found to be positively correlated with
PD-L1 expression in melanoma and inhibition of COX-2 by celecoxib effectively
down-regulated PD-L1 expression in two melanoma cell lines [190]. Interestingly,
COX-2 expression was found to increase expression of IL-4 and IDO but was
also found to be inversely related to expression of IFN-γ in fibrosarcomas [191].
Thus, under circumstances of high local expression of COX-2 it is thought that
this induces immunosuppression and ultimately impairs the T cell effector
functions which are mediated by IFN-γ [191].
In addition to influencing PD-L1 expression, the PGE2/COX2 pathway has also
been found to influence Th17 differentiation. PGE2 has been shown to promote
the differentiation and pro-inflammatory functioning of Th17 cells in both mice
and humans by inducing EP2 and EP4 signaling altering

IFN-γ, and IL-10

production [192]. PGE2 was also found to be required for IL-17 production in the
presence of APC cells [192]. With the ever-expanding mechanistic influence of
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this pathway, it appears that the “gold-standard” for inflammation and the
prevention thereof still has a few mysteries that have yet to be unraveled.
With the above factors in mind, it is easy for one to grasp how complex the
balance in host immune response can be. Given the deleterious role of Th17 in
carcinogenesis induced by ETBF bacteria residing in the colon, identifying a
method by which this imbalance in T helper cell signaling can be restored in
order for the host to identify and effectively rid itself of ETBF, while limiting harm
to itself, would be an ideal scenario.

Modulation of gut microbiome dialogue with host
An important factor that should be considered when addressing dysbiosis of the
gut microbiome is the role that factors ranging from diet, whether an individual
was breast fed [193], antibiotic usage or whether they were exposed to
environmental carcinogens should be considered regarding the formation of
dysbiosis. For instance, the influence of dietary intake of refined sugars has
been found to increase levels of C. difficile and C. perringens which has been
linked to IBD[194]. Furthermore, individuals who consumed a more plant-based
agrarian diet versus Western-style diet rich in meat and fat were found to have
altered microbiomes [195, 196]. With the influence of dietary intake in mind, the
potential role of particular phytochemicals on the gut microbiome and its
interaction with the host is a key factor that needs to be investigated.
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Anthocyanin-rich foods have been a dietary staple seemingly since the dawn of
time. Known for their characteristically-rich purple, blue and red hues that
canvas/envelop a variety of fruits, vegetables, grains and flowers, anthocyanins
have been attributed to providing a variety of health promoting properties such
as

activities

including

anti-inflammatory

[94],

chemopreventive

and

chemotherapeutic [86, 130], obesity control, cardiovascular disease prevention,
and alleviation of the symptoms of diabetes [131].
As work presented in the preceding chapters has shown, Anthos works on a
variety of pathways including, phosphorylation status of Src and EGFR and
modulation of phase I/II enzyme expression in and ETBF bacterially-driven model
of CRC in ApcMin/+ mice. For this series of studies, we turned our attention to the
influence of Anthos on the inflammatory response to ETBF bacteria both within
the tumor and adjacent normal microenvironments and the influence of Anthos
dose on colon tumor number and tumor grade.
Methods
Anthos Isolation and Purity
The native bilberry Anthos mixture that was generously provided by 3P
Biotechnologies (Louisville, KY) was further enriched using C18 Sep-Pak
cartridges (Waters, Milford, MA) and eluted in acidified (0.1% HCl) ethanol. The
enriched extract was then dried using a Savant SC210A Speed-Vac
(ThermoFisher Scientific, Waltham, MA) and stored at -20 °C, under argon.
Purity was determined by HPLC-PDA-UV. Briefly, 15 µl samples were analyzed
using a Shimadzu Premier C18 reverse-phase column (250x4.6 mm i.d., 5 µm).
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Mobile phase A was composed of water: formic acid: acetonitrile (87:10:3) and
mobile phase B was composed of water: formic acid: acetonitrile (40:10:50). The
flow rate was 0.6 ml/min and the gradient condition was 0-5 min 5% B; 5-15 min
15% B; 15-20 min 25% B; 20-30 min 35% B; 30-40 min 45% B; 40-45 min 100%
B; 45-50 min 5% B. Detection of Anthos was at 520 nm by PDA-UV and total
Anthos concentration was calculated using a standard curve. The reference
anthocyanidins were purchased from Cayman Chemical Company (Ann Arbor,
MI).
In vivo Anthos dose escalation study
Animal experiments were performed in agreement with an approved protocol by
the Institutional Animal Care and Use Committee at the University of Louisville.
Breeding colonies were established in collaboration with Dr. Nejat K. Egilmez’s
lab [138] at the University of Louisville using C57BL/6J Min/+ (ApcMin/+) mice that
were originally attained from Jackson Laboratories (Bar Harbour, ME). Mice were
genotyped for the APC mutation using PCR according to the protocol established
by Jackson Laboratories. Mice were fed a standard chow diet and received water
ad libitum and were maintained on a standard light/dark cycle for the duration of
the study. At 5-6 weeks of age, animals were administered antibiotic. Four days
later the animals were administered ETBF to promote tumorigenesis and one
week following ETBF inoculation, animals began their respective treatment
regimen. The dose escalation study featured three doses, namely, low (8.6
mg/kg/day, i.e. 60 mg/kg/wk), medium (17.1 mg/kg/day, i.e. 120 mg/kg/wk) and
high (34.3 mg/kg/day, i.e. 240 mg/kg/wk) dosages. Male and female ApcMin/+
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mice (n=5 combined) were randomly assigned to each treatment or vehicle
control group and were treated via oral gavage three times per week for 4 weeks.
Animals were culled in the fed state at 12 weeks, colon tumors were counted and
tissues were harvested.

Pathology
Following excision, colon tumor and mesenteric lymph tissue were immediately
fixed in a solution of 10% formalin. After 48 hours, samples were transferred to a
solution of 70% ethanol. Samples were embedded in paraffin and sectioned by
the pathology core research laboratory, department of pathology and laboratory
medicine at the University of Louisville. Slides were embedded in paraffin,
sectioned and stained with H&E and subsequently evaluated by pathologist, Dr.
Mostafa Fraig. Digital slides were captured using a Leica Aperio digital pathology
slide scanner (Leica Biosystems, Wetzlar, Germany).
Western-blot analysis
For western-blot analysis, 40 µg of protein from in vitro and in vivo tissue lysates
was by 4 – 12 % polyacrylamimide - SDS

gel electrophoresis and

electrotransferred to polyvinylidene difluoride membranes by semi-dry transfer
(Biorad Trans-blot SD, Hercules, CA). Blots were blocked with 4% dry powder
milk or BSA for 1 h and then incubated with primary antibodies p21, IFN-γ, TLR4, phosphor-p38, phosphoVEGF, IFN-β, VEGF and COX-2 which were all
acquired

from Santa Cruz Biotech (Santa Cruz, CA) and PD-L1 which was

acquired from Proteintech (Rosemont, IL) at 4ºC overnight and secondary
antibodies (Santa Cruz Biotech, Santa Cruz, CA). conjugated to peroxidase for 1
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h at room temperature. Blots were then developed with an ECL detection system.
Densitometric analysis was then performed using ImageJ 1.x software [134].

Results

Effect of Anthos on tumor inhibition
Following our previous findings, we pursued a detailed dose-escalation study to
determine the influence of Anthos dosage on tumor count. Three doses were
tested - low (8.6 mg/kg/day, i.e. 60 mg/kg/wk), medium (17.1 mg/kg/day, i.e. 120
mg/kg/wk) and high (34.3 mg/kg/day, i.e. 240 mg/kg/wk). Controls included a
vehicle control and an ApcMin/+ mice without ETBF bacteria control. Results from
this study (Figure 23) showed a clear significant dose- dependent decrease in
colon tumor counts in Anthos-treated groups. Significant differences in tumor
counts were noted between control and low dose animals (P=0.003), control and
medium dose animals (P=0.0004), control and high dose animals (P<0.0001).
Additionally, significant inter-treatment group differences were noted for medium
and high doses (P=0.0001) and low and high doses (P<0.0001). The difference
between low and medium treatment groups was not statistically significant
(P=0.054). No significant difference in tumor number was noted between male
and female animals within any treatment group.
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Anthos:
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-Medium
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A.
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4 wk

1 wk

Male

Female
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Figure 23. In vivo Anthos dose escalation study: ApcMin/+ mice inoculated
with ETBF were treated via oral gavage, three doses a week for 4 weeks with low
(8.6 mg/kg), medium (17.1 mg/kg) and high (34.3 mg/kg) dosages or vehicle
control. (A) Study overview. (B) tumor numbers. Black triangles represent males
and black circles represent females. *** signifies P<0.001, ** signifies P<0.01,
and * signifies P<0.05.

112

Animal
Gender
number
1
F
2
F
3
F
4
F
5
M
Avg tumor number

Control
20
25
24
15
23
21

Dosage group
Low
Medium
9
10
12
12
15
10
14
11
12
7
12
10

High
4
3
2
1
5
3

Table 5. Tumor numbers for in vivo Anthos dose escalation study
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Figure 24. Anthos-treated ApcMin/+ mice inoculated with ETBF featured
fewer, more well differentiated tumors, with immune response:
Representative photographs of histological analysis of colon adjacent normal and
tumor samples taken from Anthos-treated (4E, 4F) and vehicle control (4C, 4D)
as compared to normal colon tissue (4A, 4B). Paraffin sections of colons were
stained with H&E. Arrows in 4C and 4D highlight representative tumors (4C) and
necrotic patches (4D) observed in vehicle control mice. Arrows in 4E and 4F
represent lymphoid aggregates adjacent to normal (4E) and tumor and normal
colon tissue (4F). No lymphoid aggregates were observed in vehicle control
mice. Scale bars = 1 mm for all figure panels.
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Mechanism
In vivo look at inflammation
Building upon the findings regarding the influence of Anthos on the
phosphorylation status of Src and EGFR, STAT3, STAT5 and downstream
expression of key targets cyclin D1 and cyclin D2 that were presented in the
previous chapter, we next sought to determine the influence of Anthos treatment
on the inflammatory tumor and adjacent normal microenvironments in the same
ETBF ApcMin/+ mouse model. Results from our western blot analysis (Figures 2527) of the inflammation pathways associated with CRC and immune checkpoint
function showed significant increases in the expression of IFN-γ (P=0.04),
phospho-p38 (P=0.03), and levels of TLR-4 (P=0.01), and significant decreases
in the expression of COX-2 (P=0.001), in adjacent normal tissue. In the tumor
tissue microenvironment, decreased levels of TLR-4 (P=0.01) were noted along
with decreased expression of COX-2 (P=0.03), and increased expression of p21
(P=0.03) in Anthos vehicle control animals. Interestingly, expression of the key
immune checkpoint protein, PD-L1, was significantly increased in adjacent
normal tissue (P=0.01) of animals treated with Anthos versus vehicle control and
significantly decreased in tumor tissue in these same Anthos versus control
animals (P=0.005).
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Adjacent Normal
Control
Control

Tumor

Anthos
Anthos

Control

Anthos

TLR4
TLR4
p-p38
p-p38
IFN-β
IFN-β

IFN-γ
IFN-γ
COX-2
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Y1068
Total
TotalEGFR
EGFR
pSTAT3
pSTAT3Y705
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STAT3
STAT3

PD-L1
PD-L1
β-actin
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Figure 25. In vivo changes in PD-L1 related expression and upstream
pathways following treatment with Anthos: changes in the phosphorylation
and expression of EGFR along with corresponding downstream pathway targets
including STAT3, PD-L1, COX-2 and IFN-γ related pathways in a) adjacent
normal and b) tumor colon tissue taken from ETBF-inoculated ApcMin/+ mice
after treatment with Anthos or vehicle control as assessed using western blot
analysis with β-actin loading control.
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*
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*
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pEGFR Y845
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*
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IFN-β
VEGF
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Cyclin
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*

*

*
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**
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COX-2
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* Fold change
-10
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Figure 26. Representative heatmap for in vivo changes in PD-L1 related
expression and upstream pathways following treatment with Anthos:
representative heat map legend depicts the average fold change and significance
level in either phosphorylation status or expression levels between Anthos
treated and vehicle control animals within either adjacent normal (n=3) or tumor
colon tissue (n=3).
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Table 6. Raw densitometry values calculated for PD-L1/inflammation
pathway western blot analysis: values determined using ImageJ software

Target
EGFR
pEGFR
(Y1068)
pSTAT3
STAT3
COX-2
TLR-4
p-p38
IFN-β
IFN-γ
PD-L1

Adjacent Normal
Fold
Control Anthos
change
18661 20531
1

Control Anthos
18388

20599

Fold
change
1
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Figure 27. Tentative pathways for modulation of PD-L1 expression: outline
of EGFR and IFN-γ driven expression of PD-L1 proposed for adjacent normal
and tumor tissue samples. Pathway is a modified version of the Qiagen EGFR
and IFNγ signaling pathways.
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Figure 28. In vitro changes in PD-L1 expression and related EGFR
phosphorylation

status

following

Bilberry-derived

Anthos

and

anthocyanidin treatment: a) dose dependent changes in the phosphorylation
status of EGFR (Y1068) and downstream PD-L1 expression in HT-29 cells
treated with varying concentrations of bilberry-derived Anthos; b) influence of
indicated individual anthocyanidins (100 µM) on PD-L1 expression in HT-29
colon cancer cells as assessed using western blot analysis with β-actin and
GAPDH loading controls.
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In vitro impact of Anthos and individual anthocyanidins on PD-L1
expression
Following the promising findings in vivo, we wanted to confirm that Anthos
treatment decreased PD-L1 expression in vitro in established human colon
cancer cell lines, HT-29 and HCT-116. Results from our look at PD-L1
expression in these two colon cancer cell lines showed that Anthos treatment led
to dose-dependent decreases in PD-L1 expression (Figure 28). Follow-up work
assessing the influence of each individual anthocyanidin and comparing it to the
native Anthos mixture showed that the most impressive reduction in PD-L1
expression was achieved by petunidin (Figure 28) at the same dosage (100 µM).

Discussion
In the previous chapters (Chapters 2 and 3, we identified Anthos as a
promising chemopreventive agent against colorectal tumor development in
an ApcMin/+ ETBF mouse CRC model. We showed that Anthos functions by
decreasing

the

phosphorylation

of Src and

EGFR

thereby

modulating

phosphorylation status or expression of key downstream players including
STAT3, STAT5, COX-2, Cyclin D1 and Cyclin D2 in chapter 2. We also showed
that Anthos treatment led to modulation of the metabolic detoxification pathways
in chapter 3. In this chapter we therefore sought to determine the influence of
Anthos treatment on the inflammatory environment in colon adjacent normal and
tumor tissue in an ApcMin/+ ETBF model. We also sought to identify the doseresponse range for Anthos treatment in vivo.
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ETBF bacteria is the prototypical bacteria posited to serve as an “alpha-bug”
which is both directly pro-oncogenic and is also able to influence and remodel the
colonic microbiome in such a way that ultimately further promotes its own ability
to induce mucosal immune responses and changes within the colon epithelial
cells ultimately resulting in colon cancer [24]. ETBF bacteria are a subclass of the
B. fragilis bacteria that secrete the metalloprotease, B. fragilis toxin, which is
structurally related to the tetanus and diphtheria toxins. Ultimately, BFT leads to
the stimulation of E-cadherin cleavage thereby leading to increased colon
permeability, inflammation and β-catenin nuclear signaling [26]. It has also
been previously shown that Treg depletion leads to the mitigation of the Th17
response to ETBF bacteria in favor of a Th1 response [182]. Results from this
series of studies suggests that Anthos treatment leads to increased levels of
TLR4 and secreted IFN-γ and decreased expression of COX-2 in adjacent
normal colon tissue and increased expression of p21 and decreased levels of
TLR-4 in colon tumor tissue. Interestingly, we also showed that PD-L1
expression was significantly upregulated in normal colon tissue and significantly
decreased in colon tumor tissue samples taken from Anthos treated animals. The
findings presented in chapter 2, which show that Anthos alter the phosphorylation
status of EGFR and Src as well as downstream STAT3 in colon tumor tissues
taken from the ETBF treated ApcMin/+ mice support the decrease in PD-L1
expression noted in the same colon tumor tissue. This modulatory specificity,
which in effect, differentially modulates PD-L1 levels in colon tumor over normal
tissue provides an interesting application for Anthos treatment to not only the
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prevention of offsite toxicities associated with the current standard of care, but
also serve as a potential modulator of PD-L1 over-expression specific to colon
tumor tissue.

In the previous chapters we have shown that Anthos treatment at 120 mg/kg/wk
led to significant reductions in the number of colon tumors when compared to
vehicle control animals. In order to gain a better understanding of the influence of
Anthos dosage on tumor number we conducted a dose escalation study with
Anthos in ApcMin/+ mice treated with ETBF bacteria. Results from this study
showed a significant dose dependent decrease in tumors for all treatment
groups. Treatment at the highest dose of 240 mg/kg/wk led to over an 86%
reduction in colon tumor development (P< 0.001). The appearance of tumors in
all treatment groups were also much flatter and smaller in size than the tumors
from vehicle control animals.

The influence

of

Anthos on

the

inflammatory environment identified

in

this chapter highlights the potential influence of these factors under conditions of
environmental carcinogen exposure. It has been shown that polycyclic aromatic
hydrocarbon (PAH) exposure induces Th17 cell differentiation and IL-17
secretion in T cells in an AhR dependent mechanism [197]. As presented in
previous chapters, along with this chapter ETBF bacteria and benzo[a]pyrene
(B[a]P) were shown to also lead to increased levels of AhR expression in
vivo and in vitro, respectively. With this in mind, one could extend these findings
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to posit that the recent increases in autoimmune diseases such as IBD and T1D
could potentially be associated with dual environmental insults such as
carcinogen exposure and microbiome dysbiosis.

The effect of the combined insult of environmental carcinogens such as PAHs
and

microbiome dysbiosis is

still

essentially

unknown.

Given the increasing industrialization of our environment and exposure to
carcinogens such as B[a]P, additional research assessing whether a synergistic
carcinogenic dialogue exists between the ETBF bacteria and the ubiquitous
environmental carcinogen, B[a]P, is a key area of future research that is
needed. Additionally, further investigation into the exact nature of Anthos
upregulation of AhRR is needed. Classically, AhRR expression is upregulated
by AhR. Previous studies have found that different AhR ligands differentially
induce

distinctly

different,

ligand

specific AhR dependent

gene

products

[198]. AhR has also recently been identified as a player in intestinal barrier
function, homeostasis, and intestinal immune cells [199]. Interestingly, it has
also been shown that activation of AhR by a high affinity ligand during Th17
development led to significant increases in not only the proportion of T cells but
also their production of cytokines [200]. This is particularly interesting considering
our findings in chapter 3, which showed how Anthos treatment influences the
AhR pathway, in relation to its role in altering phase I/II enzyme expression.
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Although it was not in the scope of this chapter, the influence of Anthos on the
gut microbiome is the next area of investigation that needs to be addressed.
Although our preliminary look at the influence of Anthos on the total ETBF
bacteria population in vitro suggests that Anthos does not directly influence the
total CFUs of the ETBF bacteria in the absence of a cellular/immunological
environment (unpublished data). However, the results presented here suggest
that Anthos most likely influences the immunological balance in the colon
adjacent normal and tumor microenvironment and may therefore, by extension,
influence the host immune response against this toxigenic bacteria. Future work
assessing the microbiomes of Anthos and vehicle treated animals using fecal
and mucosal biopsy samples should aid in elucidating the influence of Anthos
treatment on gut microbiota. Additionally, kinetic studies assessing the
modulation of T helper cell populations in adjacent normal and tumor tissue in
relation to the microbiome composition over time would also be needed to
determine how these immune and bacterial populations change as a function of
time with Anthos treatment.

Overall, the findings from our survey of inflammatory environment changes
brought about by Anthos treatment in ApcMin/+ mice that received ETBF bacteria
suggests that Anthos treatment may lead to positive chemopreventive
modulation of the inflammatory environment under similar conditions thus
reinforcing the benefits of berry-derived compounds on the treatment and
prevention of colorectal cancer.
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Abbreviations:
CRC: colorectal cancer ,IBD: inflammatory bowel disease, Th: T helper cell, TLR:
toll-like receptor, IL: interleukin, IFN: interferon, PD-L1: Programmed deathligand 1, PD-1: programmed death 1 receptor, irAEs: immune-related adverse
events, T1DM: type 1 diabetes mellitus, SLE: systemic lupus erythematosus, RA:
rheumatoid arthritis, CD: crohn’s disease, UC: ulcerative colitis, PGE2:
prostaglandin E2, EP: Prostaglandin E2 receptor, AhR: aryl hydrocarbon
receptor, AhRR: : aryl hydrocarbon receptor repressor, APC: adenomatous
polyposis coli, COX-2: cyclo-oxygenase-2, Cy: cyanidin, Dp: delphinidin, Pt:
petunidin, Mv: malvidin, Pe: peonidin, HPLC: high performance liquid
chromatography, PDA: photodiode array detector, UV: ultraviolet, ETBF:
enterotoxigenic Bacteriodes fragilis, BFT: B. fragilis toxin, H&E: Hematoxylin and
eosin stain.
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CHAPTER 5:
SUMMARY AND FUTURE DIRECTIONS
Overall goals and specific aims
The overarching goal of my doctoral work was to determine how Anthos
modulates the chemopreventive effects against bacteria- and carcinogeninduced colorectal cancer (CRC). In order to accomplish this task, the specific
aims were set forth for the project and are as follows:
Aim 1: Determine anti-proliferative efficacy of optimal mixture of Anthos against
colon cancer cells in vitro.
Aim 2: Determine efficacy of Anthos against colorectal cancer using a bacteriadriven ApcMin/+ ETBF mouse model.
Aim 3: Determine the mechanistic influence of Anthos on ETBF and the
environmental carcinogen, B[a]P in CRC.

Major findings from this dissertation
Although much work has been conducted on the use of plant bioactives as a
means of preventing and treating CRC, major limitations in bioavailability,
stability and ultimately dosage have prevented its translation to the clinic/patient
population. Results from this work show that Anthos treatment leads to the
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ultimate prevention of CRC via several mechanisms including modulation of the
phosphorylation state of Src and EGFR and the downstream players in these
pathways, modulation of the expression of phase I and detoxifying phase II
enzymes and potential harnessing of the gut’s ability to protect itself from the
invasion of cancer-causing ETBF bacteria/dysbiosis.
Modulation of Src/EGFR
Prior to this work, it had been shown that APC deficiency was associated with an
increase in EGFR activity and c-Src expression in ApcMin/+ mouse adenomas and
intestinal enterocytes [146]. Furthermore, In addition to increasing the secretion
of chloride and permeability of intestinal epithelial cells, BFT also activates
STAT3 and TH17 responses and leads to increased COX-2 [147]. Additionally,
overexpression of COX-2 has been noted in colon tumor tissue and plays a role
in the pathogenesis of FAP, ETBF and ultimately colon cancer [148, 149].
However, no work had been conducted to assess the impact of Anthos or
anthocyanins on Src in any cancer model or Anthos on EGFR in a CRC model.
Results from our look at EGFR, Src, STAT3 and STAT5 phosphorylation status
and expression of downstream proteins Cyclin D1, Cyclin D2 and COX-2 showed
a significant decrease in Src phosphorylation (Y418), EGFR phosphorylation
(Y845) and the downstream mediator STAT5a/b (Y694 and Y699), both in
adjacent normal and colon tumor tissue taken from ETBF treated ApcMin/+ mice
that received Anthos treatment. Furthermore, phosphorylation status of EGFR at
Y1068 and Y1173 along with the downstream mediator STAT3 (Y705) was
shown to decrease in tumor tissue in Anthos treated mice. Key regulators of cell
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cycle progression and inflammation, including Cyclin D1, Cyclin D2 and COX-2,
were shown to be favorably modulated by Anthos, with the most dramatic
reductions in expression observed in tumor tissue samples. These highly novel
findings provide great insight into how Anthos treatment is leading to such
significant decreases in colon tumor numbers in this model.
Phase I/II enzyme balance
The role of the gut microbiome in the development of CRC has gained attention
recently. However, little was previously known about the role of bacteria in
modulating the balance between phase I and phase II enzyme expression in the
liver and colon. Results from this series of studies showed that the ETBF bacteria
led to significantly decreased expression of the phase II enzymes UGT1A6 and
GSTM1 in in the liver while increasing the expression of the phase I enzymes
CYP1A1 and CYP1B1 in the colon. Anthos and ExoAnthos treatment was also
shown to decrease expression of phase I enzymes while increasing phase II
enzyme expression in the colon and liver compared to ETBF treated control
animals. Additionally, modulation of key transcription factor and regulators
including AhR and AhRR, were shown to be induced in ETBF treated animals.
Furthermore, Anthos and ExoAnthos treatment appeared to lead to positive
changes in AhR, AhRR, ARNT1, and VDR expression in ETBF treated animals.
Importantly, no significant differences in expression were noted for phase II
enzymes in colon tumor tissue taken from Anthos versus vehicle control animals
thereby alleviating potential concerns over increased degradation/excretion of
chemo therapeutic drugs. An interesting and highly novel use for this finding
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would be to potentially use Anthos treatment as a way to prevent issues of offsite
toxicity for chemotherapeutic drugs such as irinotecan, given the significant
increases in phase II enzyme expression that were noted in normal colon tissue
gathered from Anthos-treated animals.
In addition to examining the impact of Anthos treatment on the balance of phase
I/II enzyme expression using a bacterially driven ApcMin/+ colon cancer model, we
also determined the influence of Anthos treatment on enzyme balance when cells
are undergoing insult by the ubiquitous environmental carcinogen, B[a]P in vitro.
Results from this series of studies showed that Anthos treatment led to a dosedependent decrease back to baseline in cells treated with the carcinogen. These
results combined with the highly novel findings regarding the influence of the
ETBF bacteria on the enzyme balance suggest that the combined insult by gut
bacterial dysbiosis and environmental carcinogens such as B[a]P could provide
the perfect toxic storm and ultimately lead to the development of CRC.
Furthermore, Anthos treatment appeared to reverse these alterations both in vitro
and in vivo shifting the equilibrium toward a detoxification state.
Inflammation
Given the significant role that inflammation plays in CRC, we sought to determine
the influence of Anthos treatment on cytokine and immunoregulatory expression
in colon adjacent normal and tumor tissue. Results from this work show novel
and highly significant modulation of the immune checkpoint protein, PD-L1 by
Anthos in vivo. Modulation of this key protein may be a result of Anthos role in
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decreasing the phosphorylation status of Src and EGFR, which ultimately was
shown to alter STAT3 phosphorylation status in in vivo colon tumor tissue, a key
regulator of PD-L1 transcription. In vitro work with the human colon cancer cell
line, HT-29, confirmed that Anthos treatment led to a dose-dependent decrease
in phosphorylation of EGFR (Y1068) and expression of PD-L1. Upregulation of
PD-L1 in normal colon tissue may be induced by the increased IFN-γ expression
that was noted in this tissue. Although a more intensive study of the immune
regulatory environment is needed to more conclusively assess the true influence
that Anthos has on the colon immune response, the survey presented here
provides a highly intriguing look at how Anthos may be working in this bacteriallydriven model of CRC. This combined with the highly significant decreases in
colon tumor numbers in Anthos treated animals further confirm this beneficial
influence which may be of great use in the clinical setting as both a protective as
well as therapeutic treatment.

Influence of Anthos dose
Given the intriguing results that we gathered from our initial in vivo Anthos and
ExoAnthos studies, we carried out a dose-escalation study. The follow-up dose
escalation study of Anthos in ApcMin/+ mice treated with ETBF bacteria showed
that there was a clear dose-dependent decrease in the number of colon tumors
in mice treated with varying doses of Anthos. At the highest dose of 240
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mg/kg/week which equates to daily dose of about 34 mg/kg led to greater than
86% reduction in the formation of colon adenomas.
Although identifying all of the mechanisms by which Anthos work to modulate the
development of CRC is beyond the scope of my project, the findings contained
within this dissertation make important strides toward identifying the intricate and
highly interdependent mechanisms by which this ultimate goal is achieved. From
ancient times, plant-derived compounds such as anthocyanins have been key
staples both within our diets and as medicinal remedies. Unfortunately, the multifaceted approach by which these compounds work is sometimes lost due to their
seemingly mundane origins. With this in mind, the author of this dissertation
hopes that one of the major messages that the reader will derive from this work is
the strength and complexity that natural compounds such as Anthos exert
against diseases such as CRC. Furthermore, the studies presented in this
dissertation are merely the first step toward understanding how Anthos work,
therefore, additional studies are indeed warranted, thus leading us to the final
étape of this dissertation; future directions.
Future Directions
Future directions for this work would include conducting an in vivo experiment to
assess the potential dialogue between B[a]P and dysbiosis of the gut microbiome
induced by ETBF bacteria and how Anthos treatment may alter this hypothesized
interaction. The results presented in this dissertation suggest that B[a]P and
ETBF appear to shift the phase I/II enzyme equilibrium in a similar manner and
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thus may have a detrimental synergistic activity that could promote the formation
of the active carcinogen BPDE. Additional work assessing the impact of Anthos
treatment in non-transformed colon cells treated with B[a]P along with the
formation of BPDE-DNA adducts would also be the logical next steps for this
work. Ultimately, research into this area is made especially pressing given the
recent rise in CRC in younger individuals.
Additional in vitro work to assess the role of Anthos in modulating T helper cell
balance would also be an important future project to undertake. Linking PD-L1
and the known side effect of colitis with our findings in our in vivo ETBF ApcMin/+
mouse model treated with Anthos could be a key finding in overcoming the
current limitations of this breakthrough immunotherapy treatment. The ultimate
goal of this research is clinical translation of these findings. Therefore,
conducting a clinical trial with these compounds is also planned by our laboratory
for the future given the highly promising in vitro and in vivo results presented in
this dissertation.

133

REFERENCES
[1] M. Arnold, M.S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray,
Global patterns and trends in colorectal cancer incidence and mortality, Gut, 66
(2017) 683.
[2] G. Murphy, S.S. Devesa, A.J. Cross, P.D. Inskip, K.A. McGlynn, M.B. Cook,
Sex Disparities in Colorectal Cancer Incidence by Anatomic Subsite, Race and
Age, International journal of cancer. Journal international du cancer, 128 (2011)
1668-1675.
[3] N. Shivappa, A. Zucchetto, M. Montella, D. Serraino, S.E. Steck, C. La
Vecchia, J.R. Hebert, Inflammatory potential of diet and risk of colorectal cancer:
a case-control study from Italy, The British journal of nutrition, 114 (2015) 152158.
[4] A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer
statistics, CA: a cancer journal for clinicians, 61 (2011) 69-90.
[5] S. Pathy, R. Lambert, C. Sauvaget, R. Sankaranarayanan, The incidence and
survival rates of colorectal cancer in India remain low compared with rising rates
in East Asia, Diseases of the colon and rectum, 55 (2012) 900-906.
[6] A.B. Kunnumakkara, S. Guha, B.B. Aggarwal, Curcumin and colorectal
cancer: Add spice to your life, Current Colorectal Cancer Reports, 5 (2009) 5.
[7] O. Manousos, N.E. Day, D. Trichopoulos, F. Gerovassilis, A. Tzonou, A.
Polychronopoulou, Diet and colorectal cancer: A case-control study in Greece,
International journal of cancer, 32 (1983) 1-5.
[8] P. Terry, E. Giovannucci, K.B. Michels, L. Bergkvist, H. Hansen, L. Holmberg,
A. Wolk, Fruit, Vegetables, Dietary Fiber, and Risk of Colorectal Cancer, JNCI:
Journal of the National Cancer Institute, 93 (2001) 525-533.
[9] J. Lee, A. Shin, J.H. Oh, J. Kim, Colors of vegetables and fruits and the risks
of colorectal cancer, World Journal of Gastroenterology, 23 (2017) 2527-2538.
[10] E. Vogtmann, Y.-B. Xiang, H.-L. Li, E.B. Levitan, G. Yang, J.W. Waterbor, J.
Gao, H. Cai, L. Xie, Q.-J. Wu, B. Zhang, Y.-T. Gao, W. Zheng, X.-O. Shu, Fruit
and vegetable intake and the risk of colorectal cancer: Results from the Shanghai
Men's Health Study, Cancer causes & control : CCC, 24 (2013) 1935-1945.
134

[11] H. Wu, Q. Dai, M.J. Shrubsole, R.M. Ness, D. Schlundt, W.E. Smalley, H.
Chen, M. Li, Y. Shyr, W. Zheng, Fruit and vegetable intakes are associated with
lower risk of colorectal adenomas, The Journal of nutrition, 139 (2009) 340-344.
[12] R.L. Siegel, S.A. Fedewa, W.F. Anderson, K.D. Miller, J. Ma, P.S.
Rosenberg, A. Jemal, Colorectal Cancer Incidence Patterns in the United States,
1974-2013, Journal of the National Cancer Institute, 109 (2017).
[13] J. Terzić, S. Grivennikov, E. Karin, M. Karin, Inflammation and Colon
Cancer, Gastroenterology, 138 (2010) 2101-2114.e2105.
[14] S.L. Schmit, H.S. Rennert, G. Rennert, S.B. Gruber, Coffee Consumption
and the Risk of Colorectal Cancer, Cancer epidemiology, biomarkers &
prevention : a publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology, 25 (2016) 634639.
[15] G. Yang, W. Zheng, Y.B. Xiang, J. Gao, H.L. Li, X. Zhang, Y.T. Gao, X.O.
Shu, Green tea consumption and colorectal cancer risk: a report from the
Shanghai Men's Health Study, Carcinogenesis, 32 (2011) 1684-1688.
[16] J.N. Poynter , S.B. Gruber , P.D.R. Higgins , R. Almog , J.D. Bonner , H.S.
Rennert , M. Low , J.K. Greenson , G. Rennert Statins and the Risk of Colorectal
Cancer, New England Journal of Medicine, 352 (2005) 2184-2192.
[17] L.A. Garcia-Rodriguez, C. Huerta-Alvarez, Reduced risk of colorectal cancer
among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory
drugs, Epidemiology (Cambridge, Mass.), 12 (2001) 88-93.
[18] M. Howsam, J.O. Grimalt, E. Guinó, M. Navarro, J. Martí-Ragué, M.A.
Peinado, G. Capellá, V. Moreno, G. for the Bellvitge Colorectal Cancer,
Organochlorine Exposure and Colorectal Cancer Risk, Environmental Health
Perspectives, 112 (2004) 1460-1466.
[19] N. Kazerouni, R. Sinha, C.-H. Hsu, A. Greenberg, N. Rothman, Analysis of
200 food items for benzo[a]pyrene and estimation of its intake in an
epidemiologic study, Food and Chemical Toxicology, 39 (2001) 423-436.
[20] A.M. El-Tawil, Colorectal cancer and pollution, World Journal of
Gastroenterology : WJG, 16 (2010) 3475-3477.
[21] L. Rushton, HOW MUCH DOES THE ENVIRONMENT CONTRIBUTE TO
CANCER?, Occupational and Environmental Medicine, 60 (2003) 150.

135

[22] E. Oddone, C. Modonesi, G. Gatta, Occupational exposures and colorectal
cancers: A quantitative overview of epidemiological evidence, World Journal of
Gastroenterology : WJG, 20 (2014) 12431-12444.
[23] G.P. Pfeifer, M.F. Denissenko, M. Olivier, N. Tretyakova, S.S. Hecht, P.
Hainaut, Tobacco smoke carcinogens, DNA damage and p53 mutations in
smoking-associated cancers, Oncogene, 21 (2002) 7435-7451.
[24] C.L. Sears, D.M. Pardoll, Perspective: Alpha-Bugs, Their Microbial Partners,
and the Link to Colon Cancer, The Journal of Infectious Diseases, 203 (2011)
306-311.
[25] S. Wu, K.C. Lim, J. Huang, R.F. Saidi, C.L. Sears, Bacteroides fragilis
enterotoxin cleaves the zonula adherens protein, E-cadherin, Proceedings of the
National Academy of Sciences of the United States of America, 95 (1998) 1497914984.
[26] S. Wu, P.J. Morin, D. Maouyo, C.L. Sears, Bacteroides fragilis enterotoxin
induces c-Myc expression and cellular proliferation, Gastroenterology, 124
(2003) 392-400.
[27] F. Housseau, C.L. Sears, Enterotoxigenic Bacteroides fragilis (ETBF)mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model
of colon carcinogenesis, Cell cycle (Georgetown, Tex.), 9 (2010) 3-5.
[28] C.M. Dejea, P. Fathi, J.M. Craig, A. Boleij, R. Taddese, A.L. Geis, X. Wu,
C.E. DeStefano Shields, E.M. Hechenbleikner, D.L. Huso, R.A. Anders, F.M.
Giardiello, E.C. Wick, H. Wang, S. Wu, D.M. Pardoll, F. Housseau, C.L. Sears,
Patients with familial adenomatous polyposis harbor colonic biofilms containing
tumorigenic bacteria, Science (New York, N.Y.), 359 (2018) 592-597.
[29] Y. Imamura, T. Morikawa, X. Liao, P. Lochhead, A. Kuchiba, M. Yamauchi,
Z.R. Qian, R. Nishihara, J.A. Meyerhardt, K.M. Haigis, C.S. Fuchs, S. Ogino,
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075
BRAF wild-type colorectal cancers, Clinical cancer research : an official journal of
the American Association for Cancer Research, 18 (2012) 4753-4763.
[30] W. Li, T. Qiu, Y. Ling, L. Guo, L. Li, J. Ying, Molecular pathological
epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF
mutations, Oncotarget, 6 (2015) 39607-39613.
[31] C.E. Atreya, Z. Sangale, N. Xu, M.R. Matli, E. Tikishvili, W. Welbourn, S.
Stone, K.M. Shokat, R.S. Warren, PTEN expression is consistent in colorectal
cancer primaries and metastases and associates with patient survival, Cancer
medicine, 2 (2013) 496-506.

136

[32] Y. Chen, Y. Shi, J. Lin, Y.B. Ye, X.J. Wang, G. Chen, Z.Q. Guo, Combined
Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic
Colorectal Cancer, Medicine, 94 (2015) e1698.
[33] M. Han, G. Wu, P. Sun, J. Nie, J. Zhang, Y. Li, Association of genetic
polymorphisms in PTEN and additional interaction with alcohol consumption and
smoking on colorectal cancer in Chinese population, International Journal of
Clinical and Experimental Medicine, 8 (2015) 21629-21634.
[34] J.L. Boulay, G. Mild, A. Lowy, J. Reuter, M. Lagrange, L. Terracciano, U.
Laffer, R. Herrmann, C. Rochlitz, SMAD7 is a prognostic marker in patients with
colorectal cancer, International journal of cancer, 104 (2003) 446-449.
[35] A.J. Levine, A.I. Phipps, J.A. Baron, D.D. Buchanan, D.J. Ahnen, S.A.
Cohen, N.M. Lindor, P.A. Newcomb, C. Rosty, R.W. Haile, P.W. Laird, D.J.
Weisenberger, Clinicopathologic Risk Factor Distributions for MLH1 Promoter
Region Methylation in CIMP-Positive Tumors, Cancer epidemiology, biomarkers
& prevention : a publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology, 25 (2016) 68-75.
[36] S.P. Cleary, M. Cotterchio, M.A. Jenkins, H. Kim, R. Bristow, R. Green, R.
Haile, J.L. Hopper, L. LeMarchand, N. Lindor, P. Parfrey, J. Potter, B.
Younghusband, S. Gallinger, Germline MutY human homologue mutations and
colorectal cancer: a multisite case-control study, Gastroenterology, 136 (2009)
1251-1260.
[37] M. Lüchtenborg, M.P. Weijenberg, G.M.J.M. Roemen, A.P. de Bruïne, P.A.
van den Brandt, M.H.F.M. Lentjes, M. Brink, M. van Engeland, R.A. Goldbohm,
A.F.P.M. de Goeij, APC mutations in sporadic colorectal carcinomas from The
Netherlands Cohort Study, Carcinogenesis, 25 (2004) 1219-1226.
[38] M.A. Hildebrandt, M.E. Reyes, M. Lin, Y. He, S.V. Nguyen, E.T. Hawk, X.
Wu, Germline Genetic Variants in the Wnt/beta-Catenin Pathway as Predictors of
Colorectal Cancer Risk, Cancer epidemiology, biomarkers & prevention : a
publication of the American Association for Cancer Research, cosponsored by
the American Society of Preventive Oncology, 25 (2016) 540-546.
[39] R.N. Jorissen, M. Christie, D. Mouradov, A. Sakthianandeswaren, S. Li, C.
Love, Z.Z. Xu, P.L. Molloy, I.T. Jones, S. McLaughlin, R.L. Ward, N.J. Hawkins,
A.R. Ruszkiewicz, J. Moore, A.W. Burgess, D. Busam, Q. Zhao, R.L. Strausberg,
L. Lipton, J. Desai, P. Gibbs, O.M. Sieber, Wild-type APC predicts poor
prognosis in microsatellite-stable proximal colon cancer, British journal of cancer,
113 (2015) 979-988.

137

[40] W.S. Samowitz, M.L. Slattery, C. Sweeney, J. Herrick, R.K. Wolff, H.
Albertsen, APC mutations and other genetic and epigenetic changes in colon
cancer, Molecular cancer research : MCR, 5 (2007) 165-170.
[41] M.S. Pino, D.C. Chung, The chromosomal instability pathway in colon
cancer, Gastroenterology, 138 (2010) 2059-2072.
[42] E.R. Fearon, B. Vogelstein, A genetic model for colorectal tumorigenesis,
Cell, 61 (1990) 759-767.
[43] S. Markowitz, J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R.S.
Fan, E. Zborowska, K.W. Kinzler, B. Vogelstein, et al., Inactivation of the type II
TGF-beta receptor in colon cancer cells with microsatellite instability, Science
(New York, N.Y.), 268 (1995) 1336-1338.
[44] Y. Samuels, V.E. Velculescu, Oncogenic mutations of PIK3CA in human
cancers, Cell cycle (Georgetown, Tex.), 3 (2004) 1221-1224.
[45] S.J. Baker, E.R. Fearon, J.M. Nigro, S.R. Hamilton, A.C. Preisinger, J.M.
Jessup, P. vanTuinen, D.H. Ledbetter, D.F. Barker, Y. Nakamura, R. White, B.
Vogelstein, Chromosome 17 deletions and p53 gene mutations in colorectal
carcinomas, Science (New York, N.Y.), 244 (1989) 217-221.
[46] K.M. Haigis, K.R. Kendall, Y. Wang, A. Cheung, M.C. Haigis, J.N. Glickman,
M. Niwa-Kawakita, A. Sweet-Cordero, J. Sebolt-Leopold, K.M. Shannon, J.
Settleman, M. Giovannini, T. Jacks, Differential effects of oncogenic K-Ras and
N-Ras on proliferation, differentiation and tumor progression in the colon, Nature
genetics, 40 (2008) 600-608.
[47] J.N. Poynter, K.D. Siegmund, D.J. Weisenberger, T.I. Long, S.N. Thibodeau,
N. Lindor, J. Young, M.A. Jenkins, J.L. Hopper, J.A. Baron, D. Buchanan, G.
Casey, A.J. Levine, L.L. Marchand, S. Gallinger, B. Bapat, J.D. Potter, P.A.
Newcomb, R.W. Haile, t.C.C.F.R.I. Laird, W. Peter, Molecular characterization of
MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry
and mismatch repair germline mutation screening, Cancer epidemiology,
biomarkers & prevention : a publication of the American Association for Cancer
Research, cosponsored by the American Society of Preventive Oncology, 17
(2008) 3208-3215.
[48] C.R. Boland, A. Goel, Microsatellite Instability in Colorectal Cancer,
Gastroenterology, 138 (2010) 2073-2087.e2073.
[49] C.C. Pritchard, W.M. Grady, Colorectal cancer molecular biology moves into
clinical practice, Gut, (2010).

138

[50] C.H. Kim, J.W. Huh, H.R. Kim, Y.J. Kim, CpG island methylator phenotype is
an independent predictor of survival after curative resection for colorectal cancer:
A prospective cohort study, J Gastroenterol Hepatol, (2017).
[51] D.L. Worthley, B.A. Leggett, Colorectal cancer: molecular features and
clinical opportunities, The Clinical biochemist. Reviews / Australian Association of
Clinical Biochemists, 31 (2010) 31-38.
[52] S.D. Markowitz, M.M. Bertagnolli, Molecular origins of cancer: Molecular
basis of colorectal cancer, The New England journal of medicine, 361 (2009)
2449-2460.
[53] S. Ogino, A. Goel, Molecular classification and correlates in colorectal
cancer, The Journal of molecular diagnostics : JMD, 10 (2008) 13-27.
[54] J.R. Jass, Classification of colorectal cancer based on correlation of clinical,
morphological and molecular features, Histopathology, 50 (2007) 113-130.
[55] C.G. Moertel, T.R. Fleming, J.S. Macdonald, D.G. Haller, J.A. Laurie, P.J.
Goodman, J.S. Ungerleider, W.A. Emerson, D.C. Tormey, J.H. Glick, et al.,
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma,
The New England journal of medicine, 322 (1990) 352-358.
[56] J.A. Martenson, G. Hyland, C.G. Moertel, J.A. Mailliard, J.R. O'Fallon, R.T.
Collins, R.F. Morton, H.H. Tewfik, R.L. Moore, A.R. Frank, R.E. Urias, R.L.
Deming, Olsalazine is contraindicated during pelvic radiation therapy: Results of
a double-blind, randomized clinical trial, International Journal of Radiation
Oncology*Biology*Physics, 35 (1996) 299-303.
[57] C.G. Moertel, T.R. Fleming, J.S. Macdonald, D.G. Haller, J.A. Laurie,
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy,
Journal of Clinical Oncology, 11 (1993) 2386-2390.
[58] A. Moriarity, J. O’Sullivan, J. Kennedy, B. Mehigan, P. McCormick, Current
targeted therapies in the treatment of advanced colorectal cancer: a review,
Therapeutic Advances in Medical Oncology, 8 (2016) 276-293.
[59] A. Prat, E. Casado, J. Cortes, New approaches in angiogenic targeting for
colorectal cancer, World J Gastroenterol, 13 (2007) 5857-5866.
[60] H. Linardou, H. Gogas, Toxicity management of immunotherapy for patients
with metastatic melanoma, Annals of Translational Medicine, 4 (2016) 272.
[61] S. De Dosso, C. Sessa, P. Saletti, Adjuvant therapy for colon cancer:
present and perspectives, Cancer treatment reviews, 35 (2009) 160-166.

139

[62] G. Recondo, Jr., E. Díaz-Cantón, M. de la Vega, M. Greco, G. Recondo, Sr.,
M.E. Valsecchi, Advances and new perspectives in the treatment of metastatic
colon cancer, World Journal of Gastrointestinal Oncology, 6 (2014) 211-224.
[63] L. Migliore, F. Migheli, R. Spisni, F. Coppede, Genetics, cytogenetics, and
epigenetics of colorectal cancer, Journal of biomedicine & biotechnology, 2011
(2011) 792362.
[64] P. Gervaz, P. Bucher, P. Morel, Two colons-two cancers: paradigm shift and
clinical implications, Journal of surgical oncology, 88 (2004) 261-266.
[65] E. Half, D. Bercovich, P. Rozen, Familial adenomatous polyposis, Orphanet
journal of rare diseases, 4 (2009) 22.
[66] K.W. Jasperson, T.M. Tuohy, D.W. Neklason, R.W. Burt, Hereditary and
familial colon cancer, Gastroenterology, 138 (2010) 2044-2058.
[67] P. Galiatsatos, W.D. Foulkes, Familial Adenomatous Polyposis, Am J
Gastroenterol, 101 (2006) 385-398.
[68] P. Polakis, The adenomatous polyposis coli (APC) tumor suppressor,
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1332 (1997) F127F147.
[69] K. Aoki, M.M. Taketo, Adenomatous polyposis coli (APC): a multi-functional
tumor suppressor gene, Journal of cell science, 120 (2007) 3327-3335.
[70] A. Sameer, Colorectal Cancer: Molecular Mutations and Polymorphisms,
Frontiers in Oncology, 3 (2013).
[71] M.L. Bisgaard, K. Fenger, S. Bulow, E. Niebuhr, J. Mohr, Familial
adenomatous polyposis (FAP): frequency, penetrance, and mutation rate,
Human mutation, 3 (1994) 121-125.
[72] M.L. Falcone Ferreyra, S.P. Rius, P. Casati, Flavonoids: biosynthesis,
biological functions, and biotechnological applications, Frontiers in Plant Science,
3 (2012) 222.
[73] J.B. Harborne, C.A. Williams, Advances in flavonoid research since 1992,
Phytochemistry, 55 (2000) 481-504.
[74] B. Yousuf, K. Gul, A.A. Wani, P. Singh, Health Benefits of Anthocyanins and
Their Encapsulation for Potential Use in Food Systems: A Review, Crit Rev Food
Sci, 56 (2016) 2223-2230.
[75] C.R. Welch, Q. Wu, J.E. Simon, Recent Advances in Anthocyanin Analysis
and Characterization, Current analytical chemistry, 4 (2008) 75-101.
140

[76] R.L. Prior, X. Wu, Anthocyanins: Structural characteristics that result in
unique metabolic patterns and biological activities, Free Radical Research, 40
(2006) 1014-1028.
[77] M. Landi, M. Tattini, K.S. Gould, Multiple functional roles of anthocyanins in
plant-environment interactions, Environmental and Experimental Botany, 119
(2015) 4-17.
[78] H. Kausar, J. Jeyabalan, F. Aqil, D. Chabba, J. Sidana, I.P. Singh, R.C.
Gupta, Berry anthocyanidins synergistically suppress growth and invasive
potential of human non-small-cell lung cancer cells, Cancer Lett, 325 (2012) 5462.
[79] D. Del Rio, G. Borges, A. Crozier, Berry flavonoids and phenolics:
bioavailability and evidence of protective effects, The British journal of nutrition,
104 Suppl 3 (2010) S67-90.
[80] K.S. Gould, C. Lister, Flavonoid Functions in Plants, in: O.M. Andersen, K.R.
Markham (Eds.) FLAVONOIDS Chemistry, Biochemistry and Applications
CRC Press, Boca Raton, 2006, pp. 397-442.
[81] A. Scalbert, G. Williamson, Dietary intake and bioavailability of polyphenols,
The Journal of nutrition, 130 (2000) 2073s-2085s.
[82] J.M. Gee, M.S. DuPont, M.J. Rhodes, I.T. Johnson, Quercetin glucosides
interact with the intestinal glucose transport pathway, Free radical biology &
medicine, 25 (1998) 19-25.
[83] T. Miyazawa, K. Nakagawa, M. Kudo, K. Muraishi, K. Someya, Direct
intestinal absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin3,5-diglucoside, into rats and humans, J Agric Food Chem, 47 (1999) 1083-1091.
[84] S. Talavéra, C. Felgines, O. Texier, C. Besson, A. Gil-Izquierdo, J.-L.
Lamaison, C. Rémésy, Anthocyanin Metabolism in Rats and Their Distribution to
Digestive Area, Kidney, and Brain, Journal of Agricultural and Food Chemistry,
53 (2005) 3902-3908.
[85] A.R. Rechner, C. Kroner, Anthocyanins and colonic metabolites of dietary
polyphenols inhibit platelet function, Thrombosis Research, 116 (2005) 327-334.
[86] N. Katsube, K. Iwashita, T. Tsushida, K. Yamaki, M. Kobori, Induction of
apoptosis in cancer cells by Bilberry (Vaccinium myrtillus) and the anthocyanins,
J Agric Food Chem, 51 (2003) 68-75.
[87] C. Zhao, M.M. Giusti, M. Malik, M.P. Moyer, B.A. Magnuson, Effects of
commercial anthocyanin-rich extracts on colonic cancer and nontumorigenic
colonic cell growth, J Agric Food Chem, 52 (2004) 6122-6128.
141

[88] D.Y. Shin, W.S. Lee, J.N. Lu, M.H. Kang, C.H. Ryu, G.Y. Kim, H.S. Kang,
S.C. Shin, Y.H. Choi, Induction of apoptosis in human colon cancer HCT-116
cells by anthocyanins through suppression of Akt and activation of p38-MAPK,
International journal of oncology, 35 (2009) 1499-1504.
[89] N. Karthi, T. Kalaiyarasu, S. Kandakumar, P. Mariyappan, V. Manju,
Pelargonidin induces apoptosis and cell cycle arrest via a mitochondria mediated
intrinsic apoptotic pathway in HT29 cells, RSC Advances, 6 (2016) 45064-45076.
[90] J.-M. Yun, F. Afaq, N. Khan, H. Mukhtar, Delphinidin, an Anthocyanidin in
Pigmented Fruits and Vegetables, Induces Apoptosis and Cell Cycle Arrest in
Human Colon Cancer HCT116 Cells, Molecular carcinogenesis, 48 (2009) 260270.
[91] M.R. Webb, K. Min, S.E. Ebeler, Anthocyanin Interactions with DNA:
Intercalation, Topoisomerase I Inhibition and Oxidative Reactions, Journal of
food biochemistry, 32 (2008) 576-596.
[92] M.Y. Park, J.M. Kim, J.S. Kim, M.G. Choung, M.K. Sung, Chemopreventive
Action of Anthocyanin-rich Black Soybean Fraction in APC (Min/+) Intestinal
Polyposis Model, Journal of cancer prevention, 20 (2015) 193-201.
[93] H. Cai, T.H. Marczylo, N. Teller, K. Brown, W.P. Steward, D. Marko, A.J.
Gescher, Anthocyanin-rich red grape extract impedes adenoma development in
the Apc(Min) mouse: pharmacodynamic changes and anthocyanin levels in the
murine biophase, European journal of cancer (Oxford, England : 1990), 46
(2010) 811-817.
[94] L. Li, L. Wang, Z. Wu, L. Yao, Y. Wu, L. Huang, K. Liu, X. Zhou, D. Gou,
Anthocyanin-rich fractions from red raspberries attenuate inflammation in both
RAW264.7 macrophages and a mouse model of colitis, Scientific reports, 4
(2014) 6234.
[95] D. Cooke, M. Schwarz, D. Boocock, P. Winterhalter, W.P. Steward, A.J.
Gescher, T.H. Marczylo, Effect of cyanidin-3-glucoside and an anthocyanin
mixture from bilberry on adenoma development in the ApcMin mouse model of
intestinal carcinogenesis--relationship with tissue anthocyanin levels,
International journal of cancer, 119 (2006) 2213-2220.
[96] E.J. Freireich, E.A. Gehan, D.P. Rall, L.H. Schmidt, H.E. Skipper,
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster,
dog, monkey, and man, Cancer chemotherapy reports, 50 (1966) 219-244.
[97] S. Thomasset, D.P. Berry, H. Cai, K. West, T.H. Marczylo, D. Marsden, K.
Brown, A. Dennison, G. Garcea, A. Miller, D. Hemingway, W.P. Steward, A.J.

142

Gescher, Pilot study of oral anthocyanins for colorectal cancer chemoprevention,
Cancer prevention research (Philadelphia, Pa.), 2 (2009) 625-633.
[98] R.A. Mentor-Marcel, G. Bobe, C. Sardo, L.S. Wang, C.T. Kuo, G. Stoner,
N.H. Colburn, Plasma cytokines as potential response indicators to dietary
freeze-dried black raspberries in colorectal cancer patients, Nutrition and cancer,
64 (2012) 820-825.
[99] L.S. Wang, M. Arnold, Y.W. Huang, C. Sardo, C. Seguin, E. Martin, T.H.
Huang, K. Riedl, S. Schwartz, W. Frankel, D. Pearl, Y. Xu, J. Winston, 3rd, G.Y.
Yang, G. Stoner, Modulation of genetic and epigenetic biomarkers of colorectal
cancer in humans by black raspberries: a phase I pilot study, Clinical cancer
research : an official journal of the American Association for Cancer Research,
17 (2011) 598-610.
[100] S. Roth, M.R. Spalinger, C. Gottier, L. Biedermann, J. Zeitz, S. Lang, A.
Weber, G. Rogler, M. Scharl, Bilberry-Derived Anthocyanins Modulate Cytokine
Expression in the Intestine of Patients with Ulcerative Colitis, PloS one, 11 (2016)
e0154817.
[101] L. Biedermann, J. Mwinyi, M. Scharl, P. Frei, J. Zeitz, G.A. Kullak-Ublick,
S.R. Vavricka, M. Fried, A. Weber, H.U. Humpf, S. Peschke, A. Jetter, G.
Krammer, G. Rogler, Bilberry ingestion improves disease activity in mild to
moderate ulcerative colitis - an open pilot study, Journal of Crohn's & colitis, 7
(2013) 271-279.
[102] S. Kamiloglu, E. Capanoglu, C. Grootaert, J. Van Camp, Anthocyanin
Absorption and Metabolism by Human Intestinal Caco-2 Cells--A Review,
International journal of molecular sciences, 16 (2015) 21555-21574.
[103] C. Thery, L. Zitvogel, S. Amigorena, Exosomes: composition, biogenesis
and function, Nat Rev Immunol, 2 (2002) 569-579.
[104] R.M. Johnstone, A. Bianchini, K. Teng, Reticulocyte maturation and
exosome release: transferrin receptor containing exosomes shows multiple
plasma membrane functions, Blood, 74 (1989) 1844-1851.
[105] S.R. Vaiselbuh, Exosomes in Cancer Research, Cancer Research
Frontiers, 1 (2015) 11-24.
[106] J. Zhang, S. Li, L. Li, M. Li, C. Guo, J. Yao, S. Mi, Exosome and Exosomal
MicroRNA: Trafficking, Sorting, and Function, Genomics, Proteomics &
Bioinformatics, 13 (2015) 17-24.
[107] J. Kowal, M. Tkach, C. Thery, Biogenesis and secretion of exosomes,
Current opinion in cell biology, 29 (2014) 116-125.
143

[108] G. Raposo, W. Stoorvogel, Extracellular vesicles: exosomes, microvesicles,
and friends, The Journal of cell biology, 200 (2013) 373-383.
[109] C. Théry, M. Boussac, P. Véron, P. Ricciardi-Castagnoli, G. Raposo, J.
Garin, S. Amigorena, Proteomic Analysis of Dendritic Cell-Derived Exosomes: A
Secreted Subcellular Compartment Distinct from Apoptotic Vesicles, The Journal
of Immunology, 166 (2001) 7309-7318.
[110] B.K. Thakur, H. Zhang, A. Becker, I. Matei, Y. Huang, B. Costa-Silva, Y.
Zheng, A. Hoshino, H. Brazier, J. Xiang, C. Williams, R. Rodriguez-Barrueco,
J.M. Silva, W. Zhang, S. Hearn, O. Elemento, N. Paknejad, K. ManovaTodorova, K. Welte, J. Bromberg, H. Peinado, D. Lyden, Double-stranded DNA
in exosomes: a novel biomarker in cancer detection, Cell Res, 24 (2014) 766769.
[111] H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, J.O. Lotvall,
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells, Nature cell biology, 9 (2007) 654-659.
[112] A. Clayton, J.P. Mitchell, J. Court, M.D. Mason, Z. Tabi, Human tumorderived exosomes selectively impair lymphocyte responses to interleukin-2,
Cancer research, 67 (2007) 7458-7466.
[113] C. Thery, Exosomes: secreted vesicles and intercellular communications,
F1000 biology reports, 3 (2011) 15.
[114] I. Parolini, C. Federici, C. Raggi, L. Lugini, S. Palleschi, A. De Milito, C.
Coscia, E. Iessi, M. Logozzi, A. Molinari, M. Colone, M. Tatti, M. Sargiacomo, S.
Fais, Microenvironmental pH is a key factor for exosome traffic in tumor cells,
The Journal of biological chemistry, 284 (2009) 34211-34222.
[115] R. Munagala, F. Aqil, J. Jeyabalan, R.C. Gupta, Bovine milk-derived
exosomes for drug delivery, Cancer Lett, 371 (2016) 48-61.
[116] F. Aqil, H. Kausar, A.K. Agrawal, J. Jeyabalan, A.H. Kyakulaga, R.
Munagala, R. Gupta, Exosomal formulation enhances therapeutic response of
celastrol against lung cancer, Experimental and molecular pathology, 101 (2016)
12-21.
[117] A.K. Agrawal, F. Aqil, J. Jeyabalan, W.A. Spencer, J. Beck, B.W. Gachuki,
S.S. Alhakeem, K. Oben, R. Munagala, S. Bondada, R.C. Gupta, Milk-derived
exosomes for oral delivery of paclitaxel, Nanomedicine : nanotechnology,
biology, and medicine, (2017).
[118] V.N. Tudyka, S.K. Clark, Surgical treatment in familial adenomatous
polyposis, Annals of Gastroenterology, 25 (2012) 201-206.
144

[119] J. Burn, A.-M. Gerdes, F. Macrae, J.-P. Mecklin, G. Moeslein, S.
Olschwang, D. Eccles, D.G. Evans, E.R. Maher, L. Bertario, M.-L. Bisgaard, M.G.
Dunlop, J.W.C. Ho, S.V. Hodgson, A. Lindblom, J. Lubinski, P.J. Morrison, V.
Murday, R. Ramesar, L. Side, R.J. Scott, H.J.W. Thomas, H.F. Vasen, G. Barker,
G. Crawford, F. Elliott, M. Movahedi, K. Pylvanainen, J.T. Wijnen, R. Fodde, H.T.
Lynch, J.C. Mathers, D.T. Bishop, Long-term effect of aspirin on cancer risk in
carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised
controlled trial, The Lancet, 378 (2011) 2081-2087.
[120] C. Carroll, K. Cooper, D. Papaioannou, D. Hind, H. Pilgrim, P. Tappenden,
Supplemental calcium in the chemoprevention of colorectal cancer: a systematic
review and meta-analysis, Clinical therapeutics, 32 (2010) 789-803.
[121] R.M. Bostick, Effects of supplemental vitamin D and calcium on normal
colon tissue and circulating biomarkers of risk for colorectal neoplasms, The
Journal of steroid biochemistry and molecular biology, 148 (2015) 86-95.
[122] T. Qin, M. Du, H. Du, Y. Shu, M. Wang, L. Zhu, Folic acid supplements and
colorectal cancer risk: meta-analysis of randomized controlled trials, Scientific
reports, 5 (2015) 12044.
[123] K.R. Patel, V.A. Brown, D.J. Jones, R.G. Britton, D. Hemingway, A.S.
Miller, K.P. West, T.D. Booth, M. Perloff, J.A. Crowell, D.E. Brenner, W.P.
Steward, A.J. Gescher, K. Brown, Clinical pharmacology of resveratrol and its
metabolites in colorectal cancer patients, Cancer research, 70 (2010) 7392-7399.
[124] R.A. Sharma, H.R. McLelland, K.A. Hill, C.R. Ireson, S.A. Euden, M.M.
Manson, M. Pirmohamed, L.J. Marnett, A.J. Gescher, W.P. Steward,
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients
with colorectal cancer, Clinical cancer research : an official journal of the
American Association for Cancer Research, 7 (2001) 1894-1900.
[125] M. Shimizu, Y. Fukutomi, M. Ninomiya, K. Nagura, T. Kato, H. Araki, M.
Suganuma, H. Fujiki, H. Moriwaki, Green tea extracts for the prevention of
metachronous colorectal adenomas: a pilot study, Cancer epidemiology,
biomarkers & prevention : a publication of the American Association for Cancer
Research, cosponsored by the American Society of Preventive Oncology, 17
(2008) 3020-3025.
[126] K.F. Adams, P.D. Lampe, K.M. Newton, J.T. Ylvisaker, A. Feld, D.
Myerson, S.S. Emerson, E. White, J.D. Potter, J.W. Lampe, Soy protein
containing isoflavones does not decrease colorectal epithelial cell proliferation in
a randomized controlled trial, The American journal of clinical nutrition, 82 (2005)
620-626.

145

[127] M.A. Nunez-Sanchez, R. Garcia-Villalba, T. Monedero-Saiz, N.V. GarciaTalavera, M.B. Gomez-Sanchez, C. Sanchez-Alvarez, A.M. Garcia-Albert, F.J.
Rodriguez-Gil, M. Ruiz-Marin, F.A. Pastor-Quirante, F. Martinez-Diaz, M.J.
Yanez-Gascon, A. Gonzalez-Sarrias, F.A. Tomas-Barberan, J.C. Espin, Targeted
metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine
and colon tissues from colorectal cancer patients, Molecular nutrition & food
research, 58 (2014) 1199-1211.
[128] K. Cooper, H. Squires, C. Carroll, D. Papaioannou, A. Booth, R.F. Logan,
C. Maguire, D. Hind, P. Tappenden, Chemoprevention of colorectal cancer:
systematic review and economic evaluation, Health technology assessment
(Winchester, England), 14 (2010) 1-206.
[129] M.A. Nunez-Sanchez, A. Gonzalez-Sarrias, M. Romo-Vaquero, R. GarciaVillalba, M.V. Selma, F.A. Tomas-Barberan, M.T. Garcia-Conesa, J.C. Espin,
Dietary phenolics against colorectal cancer--From promising preclinical results to
poor translation into clinical trials: Pitfalls and future needs, Molecular nutrition &
food research, 59 (2015) 1274-1291.
[130] J. Jeyabalan, F. Aqil, R. Munagala, L. Annamalai, M.V. Vadhanam, R.C.
Gupta, Chemopreventive and therapeutic activity of dietary blueberry against
estrogen-mediated breast cancer, J Agric Food Chem, 62 (2014) 3963-3971.
[131] J. He, M.M. Giusti, Anthocyanins: natural colorants with health-promoting
properties, Annual review of food science and technology, 1 (2010) 163-187.
[132] L.-S. Wang, G.D. Stoner, Anthocyanins and their role in cancer prevention,
Cancer Letters, 269 (2008) 281-290.
[133] F. Aqil, J. Jeyabalan, H. Kausar, R. Munagala, I.P. Singh, R. Gupta, Lung
cancer inhibitory activity of dietary berries and berry polyphenolics, Journal of
Berry Research, 6 (2016) 105-114.
[134] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25
years of image analysis, Nat Meth, 9 (2012) 671-675.
[135] G. Zhang, B. Svenungsson, A. Karnell, A. Weintraub, Prevalence of
enterotoxigenic Bacteroides fragilis in adult patients with diarrhea and healthy
controls, Clinical infectious diseases : an official publication of the Infectious
Diseases Society of America, 29 (1999) 590-594.
[136] K.-J. Rhee, S. Wu, X. Wu, D.L. Huso, B. Karim, A.A. Franco, S. Rabizadeh,
J.E. Golub, L.E. Mathews, J. Shin, R.B. Sartor, D. Golenbock, A.R. Hamad, C.M.
Gan, F. Housseau, C.L. Sears, Induction of Persistent Colitis by a Human
Commensal, Enterotoxigenic Bacteroides fragilis, in Wild-Type C57BL/6 Mice,
Infection and immunity, 77 (2009) 1708-1718.

146

[137] S. Wu, J. Powell, N. Mathioudakis, S. Kane, E. Fernandez, C.L. Sears,
Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of
interleukin-8 through mitogen-activated protein kinases and a tyrosine kinaseregulated nuclear factor-kappaB pathway, Infection and immunity, 72 (2004)
5832-5839.
[138] T. Gu, M. De Jesus, H.C. Gallagher, T.P. Burris, N.K. Egilmez, Oral IL-10
suppresses colon carcinogenesis via elimination of pathogenicCD4+ T-cells and
induction of antitumor CD8+ T-cell activity, OncoImmunology, (2017) e1319027.
[139] G. Warnes, B. Bolker, T. Lumley, gplots: Various R programming tools for
plotting data. R package version 2.6.0.
[140] R. Team, RStudio: Integrated Development for R., RStudio, Inc., Boston,
MA, 2016.
[141] D. Sarkar, Lattice: multivariate data visualization with R, Springer Science
& Business Media2008.
[142] F. Aqil, J. Jeyabalan, A.K. Agrawal, A.H. Kyakulaga, R. Munagala, L.
Parker, R.C. Gupta, Exosomal delivery of berry anthocyanidins for the
management of ovarian cancer, Food & function, 8 (2017) 4100-4107.
[143] L. Muller, P. Bednar, P. Bartak, K. Lemr, J. Sevcik, Estimation of partition
coefficients by MEKC part 2: anthocyanins, Journal of separation science, 28
(2005) 1285-1290.
[144] R. Munagala, F. Aqil, J. Jeyabalan, A.K. Agrawal, A.M. Mudd, A.H.
Kyakulaga, I.P. Singh, M.V. Vadhanam, R.C. Gupta, Exosomal formulation of
anthocyanidins against multiple cancer types, Cancer Lett, 393 (2017) 94-102.
[145] T.C. Wallace, M.M. Giusti, Anthocyanins, Advances in Nutrition, 6 (2015)
620-622.
[146] A.E. Moran, D.H. Hunt, S.H. Javid, M. Redston, A.M. Carothers, M.M.
Bertagnolli, Apc deficiency is associated with increased Egfr activity in the
intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice, The Journal of
biological chemistry, 279 (2004) 43261-43272.
[147] L. Chung, E. Thiele Orberg, A.L. Geis, J.L. Chan, K. Fu, C.E. DeStefano
Shields, C.M. Dejea, P. Fathi, J. Chen, B.B. Finard, A.J. Tam, F. McAllister, H.
Fan, X. Wu, S. Ganguly, A. Lebid, P. Metz, S.W. Van Meerbeke, D.L. Huso, E.C.
Wick, D.M. Pardoll, F. Wan, S. Wu, C.L. Sears, F. Housseau, Bacteroides fragilis
Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of
Colonic Epithelial Cells, Cell host & microbe, 23 (2018) 203-214.e205.

147

[148] H. Sano, Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S.
Kimura, H. Kato, M. Kondo, T. Hla, Expression of Cyclooxygenase-1 and -2 in
Human Colorectal Cancer, Cancer research, 55 (1995) 3785-3789.
[149] R.A. Gupta, R.N. DuBois, Colorectal cancer prevention and treatment by
inhibition of cyclooxygenase-2, Nature Reviews Cancer, 1 (2001) 11.
[150] S.P. Claus, H. Guillou, S. Ellero-Simatos, The gut microbiota: a major
player in the toxicity of environmental pollutants?, 3 (2017) 17001.
[151] L.A. Beamish, A.R. Osornio-Vargas, E. Wine, Air pollution: An
environmental factor contributing to intestinal disease, Journal of Crohn's &
colitis, 5 (2011) 279-286.
[152] P.-L. Wei, S.-Y. Lin, Y.-J. Chang, Cigarette Smoking and Colorectal
Cancer: From Epidemiology to Bench, Journal of Experimental & Clinical
Medicine, 3 (2011) 257-261.
[153] D.L. Diggs, A.C. Huderson, K.L. Harris, J.N. Myers, L.D. Banks, P.V.
Rekhadevi, M.S. Niaz, A. Ramesh, Polycyclic aromatic hydrocarbons and
digestive tract cancers: a perspective, Journal of environmental science and
health. Part C, Environmental carcinogenesis & ecotoxicology reviews, 29 (2011)
324-357.
[154] R.S. Clark, S.T. Pellom, B. Booker, A. Ramesh, T. Zhang, A. Shanker, M.
Maguire, P.D. Juarez, M.J. Patricia, M.A. Langston, M.Y. Lichtveld, D.B. Hood,
Validation of research trajectory 1 of an Exposome framework: Exposure to
benzo(a)pyrene confers enhanced susceptibility to bacterial infection,
Environmental research, 146 (2016) 173-184.
[155] J. Sun, I. Kato, Gut microbiota, inflammation and colorectal cancer, Genes
& diseases, 3 (2016) 130-143.
[156] B.C. Casto, L.A. Kresty, C.L. Kraly, D.K. Pearl, T.J. Knobloch, H.A. Schut,
G.D. Stoner, S.R. Mallery, C.M. Weghorst, Chemoprevention of oral cancer by
black raspberries, Anticancer research, 22 (2002) 4005-4015.
[157] H.S. Aiyer, R.C. Gupta, Berries and ellagic acid prevent estrogen-induced
mammary tumorigenesis by modulating enzymes of estrogen metabolism,
Cancer prevention research (Philadelphia, Pa.), 3 (2010) 727-737.
[158] G.K. Russell, R.C. Gupta, M.V. Vadhanam, Effect of phytochemical
intervention on dibenzo[a,l]pyrene-induced DNA adduct formation, Mutat Res,
774 (2015) 25-32.
[159] A. Srovnalova, M. Svecarova, M.K. Zapletalova, P. Anzenbacher, P.
Bachleda, E. Anzenbacherova, Z. Dvorak, Effects of anthocyanidins and
148

anthocyanins on the expression and catalytic activities of CYP2A6, CYP2B6,
CYP2C9, and CYP3A4 in primary human hepatocytes and human liver
microsomes, J Agric Food Chem, 62 (2014) 789-797.
[160] G. Lala, M. Malik, C. Zhao, J. He, Y. Kwon, M.M. Giusti, B.A. Magnuson,
Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats,
Nutrition and cancer, 54 (2006) 84-93.
[161] C.Y. Li, S. Lee, S. Cade, L.-J. Kuo, I.R. Schultz, D.K. Bhatt, B. Prasad, T.K.
Bammler, J.Y. Cui, Novel Interactions between Gut Microbiome and Host DrugProcessing Genes Modify the Hepatic Metabolism of the Environmental
Chemicals Polybrominated Diphenyl Ethers, Drug Metabolism and Disposition,
45 (2017) 1197.
[162] G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder,
S. Sarkar, Drug Resistance in Cancer: An Overview, Cancers, 6 (2014) 17691792.
[163] B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang, B. Baradaran, The
Different Mechanisms of Cancer Drug Resistance: A Brief Review, Advanced
Pharmaceutical Bulletin, 7 (2017) 339-348.
[164] J.P. Hernandez, L.C. Mota, W.S. Baldwin, Activation of CAR and PXR by
Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism,
Intermediary Metabolism, and Cell Proliferation, Current pharmacogenomics and
personalized medicine, 7 (2009) 81-105.
[165] S. Wu, K.J. Rhee, E. Albesiano, S. Rabizadeh, X. Wu, H.R. Yen, D.L.
Huso, F.L. Brancati, E. Wick, F. McAllister, F. Housseau, D.M. Pardoll, C.L.
Sears, A human colonic commensal promotes colon tumorigenesis via activation
of T helper type 17 T cell responses, Nat Med, 15 (2009) 1016-1022.
[166] S. Sakurai, T. Shimizu, U. Ohto, The crystal structure of the AhRR-ARNT
heterodimer reveals the structural basis of the repression of AhR-mediated
transcription, The Journal of biological chemistry, 292 (2017) 17609-17616.
[167] L. Cheng, L. Qian, G.S. Wang, X.M. Li, X.P. Li, Genetic association of
aromatic hydrocarbon receptor and its repressor gene polymorphisms with risk of
rheumatoid arthritis in Han Chinese populations, Medicine, 96 (2017) e6392.
[168] Y. Zhang, M. Elgizouli, B. Schottker, B. Holleczek, A. Nieters, H. Brenner,
Smoking-associated DNA methylation markers predict lung cancer incidence,
Clinical epigenetics, 8 (2016) 127.
[169] S.E. Bojesen, N. Timpson, C. Relton, G. Davey Smith, B.G. Nordestgaard,
AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and
mortality, Thorax, 72 (2017) 646-653.
149

[170] M. Mandl, M.K. Lieberum, R. Depping, A HIF-1alpha-driven feed-forward
loop augments HIF signalling in Hep3B cells by upregulation of ARNT, Cell death
& disease, 7 (2016) e2284.
[171] S. Chen, M.F. Yueh, C. Bigo, O. Barbier, K. Wang, M. Karin, N. Nguyen,
R.H. Tukey, Intestinal glucuronidation protects against chemotherapy-induced
toxicity by irinotecan (CPT-11), Proceedings of the National Academy of
Sciences of the United States of America, 110 (2013) 19143-19148.
[172] L.T. Stiemsma, L.A. Reynolds, S.E. Turvey, B.B. Finlay, The hygiene
hypothesis: current perspectives and future therapies, Immunotargets and
Therapy, 4 (2015) 143-157.
[173] D. Cutler, G. Miller, The Role of Public Health Improvements in Health
Advances: The Twentieth-Century United States, Demography, 42 (2005) 1-22.
[174] M. Scudellari, News Feature: Cleaning up the hygiene hypothesis,
Proceedings of the National Academy of Sciences, 114 (2017) 1433.
[175] J.I. Keenan, F.A. Frizelle, Bacteria flying under the radar: linking a bacterial
infection to colon carcinogenesis, Infectious agents and cancer, 9 (2014) 31.
[176] L.A. Tesmer, S.K. Lundy, S. Sarkar, D.A. Fox, Th17 cells in human
disease, Immunological Reviews, 223 (2008) 87-113.
[177] P.R. Burkett, G. Meyer zu Horste, V.K. Kuchroo, Pouring fuel on the fire:
Th17 cells, the environment, and autoimmunity, The Journal of Clinical
Investigation, 125 (2015) 2211-2219.
[178] Y. Okada, Y. Tsuzuki, H. Sato, K. Narimatsu, R. Hokari, C. Kurihara, C.
Watanabe, K. Tomita, S. Komoto, A. Kawaguchi, S. Nagao, S. Miura, Trans fatty
acids exacerbate dextran sodium sulphate-induced colitis by promoting the upregulation of macrophage-derived proinflammatory cytokines involved in T helper
17 cell polarization, Clinical and Experimental Immunology, 174 (2013) 459-471.
[179] M. Kleinewietfeld, A. Manzel, J. Titze, H. Kvakan, N. Yosef, R.A. Linker,
D.N. Muller, D.A. Hafler, Sodium Chloride Drives Autoimmune Disease by the
Induction of Pathogenic Th17 Cells, Nature, 496 (2013) 518-522.
[180] C.M. Wilke, K. Bishop, D. Fox, W. Zou, Deciphering the role of Th17 cells in
human disease, Trends in Immunology, 32 (2011) 603-611.
[181] S. Nakae, Y. Iwakura, H. Suto, S.J. Galli, Phenotypic differences between
Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17,
Journal of leukocyte biology, 81 (2007) 1258-1268.

150

[182] A.L. Geis, H. Fan, X. Wu, S. Wu, D.L. Huso, J.L. Wolfe, C.L. Sears, D.M.
Pardoll, F. Housseau, Regulatory T cell response to enterotoxigenic Bacteroides
fragilis colonization triggers IL-17-dependent colon carcinogenesis, Cancer
discovery, 5 (2015) 1098-1109.
[183] H. Li, J.A. Bradbury, R.T. Dackor, M.L. Edin, J.P. Graves, L.M. DeGraff,
P.M. Wang, C.D. Bortner, S. Maruoka, F.B. Lih, D.N. Cook, K.B. Tomer, A.M.
Jetten, D.C. Zeldin, Cyclooxygenase-2 Regulates Th17 Cell Differentiation during
Allergic Lung Inflammation, American Journal of Respiratory and Critical Care
Medicine, 184 (2011) 37-49.
[184] M. Bertha, E. Bellaguara, T. Kuzel, S. Hanauer, Checkpoint Inhibitor–
Induced Colitis: A New Type of Inflammatory Bowel Disease?, ACG Case
Reports Journal, 4 (2017) e112.
[185] S. Dai, R. Jia, X. Zhang, Q. Fang, L. Huang, The PD-1/PD-Ls pathway and
autoimmune diseases, Cellular Immunology, 290 (2014) 72-79.
[186] Y. Zhang, C.A. Ma, M.G. Lawrence, T.J. Break, M.P. O’Connell, J.J. Lyons,
D.B. López, J.S. Barber, Y. Zhao, D.L. Barber, A.F. Freeman, S.M. Holland, M.S.
Lionakis, J.D. Milner, PD-L1 up-regulation restrains Th17 cell differentiation in
STAT3 loss- and STAT1 gain-of-function patients, The Journal of experimental
medicine, 214 (2017) 2523-2533.
[187] C.J. Hawkey, COX-2 chronology, Gut, 54 (2005) 1509.
[188] R.E. Harris, Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of
cancers of the colon, breast, prostate, and lung, Inflammopharmacology, 17
(2009) 55-67.
[189] V. Prima, L.N. Kaliberova, S. Kaliberov, D.T. Curiel, S. Kusmartsev,
COX2/mPGES1/PGE<sub>2</sub> pathway regulates PD-L1 expression in
tumor-associated macrophages and myeloid-derived suppressor cells,
Proceedings of the National Academy of Sciences, 114 (2017) 1117-1122.
[190] G. Botti, F. Fratangelo, M. Cerrone, G. Liguori, M. Cantile, A.M. Anniciello,
S. Scala, C. D’Alterio, C. Trimarco, A. Ianaro, G. Cirino, C. Caracò, M.
Colombino, G. Palmieri, S. Pepe, P.A. Ascierto, F. Sabbatino, G. Scognamiglio,
COX-2 expression positively correlates with PD-L1 expression in human
melanoma cells, Journal of Translational Medicine, 15 (2017) 46.
[191] C. Göbel, F. Breitenbuecher, H. Kalkavan, P.S. Hähnel, S. Kasper, S.
Hoffarth, K. Merches, H. Schild, K.S. Lang, M. Schuler, Functional expression
cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity,
Cell Death &Amp; Disease, 5 (2014) e1568.

151

[192] K. Boniface, K.S. Bak-Jensen, Y. Li, W.M. Blumenschein, M.J. McGeachy,
T.K. McClanahan, B.S. McKenzie, R.A. Kastelein, D.J. Cua, R. de Waal Malefyt,
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic
AMP and EP2/EP4 receptor signaling, The Journal of experimental medicine,
206 (2009) 535-548.
[193] P.D. Houghteling, W.A. Walker, Why is initial bacterial colonization of the
intestine important to infants' and children's health?, Journal of pediatric
gastroenterology and nutrition, 60 (2015) 294-307.
[194] A.M. Berg, C.P. Kelly, F.A. Farraye, Clostridium difficile Infection in the
Inflammatory Bowel Disease Patient, Inflammatory Bowel Diseases, 19 (2013)
194-204.
[195] L.G. Albenberg, G.D. Wu, Diet and the Intestinal Microbiome: Associations,
Functions, and Implications for Health and Disease, Gastroenterology, 146
(2014) 1564-1572.
[196] P. Smith-Brown, M. Morrison, L. Krause, P.S.W. Davies, Dairy and plant
based food intakes are associated with altered faecal microbiota in 2 to 3 year
old Australian children, Scientific reports, 6 (2016) 32385.
[197] M. van Voorhis, S. Knopp, W. Julliard, J.H. Fechner, X. Zhang, J.J.
Schauer, J.D. Mezrich, Exposure to Atmospheric Particulate Matter Enhances
Th17 Polarization through the Aryl Hydrocarbon Receptor, PloS one, 8 (2013)
e82545.
[198] A.A. Soshilov, M.S. Denison, Ligand promiscuity of aryl hydrocarbon
receptor agonists and antagonists revealed by site-directed mutagenesis,
Molecular and cellular biology, 34 (2014) 1707-1719.
[199] B. Lamas, J.M. Natividad, H. Sokol, Aryl hydrocarbon receptor and
intestinal immunity, Mucosal Immunology, 11 (2018) 1024-1038.
[200] M. Veldhoen, K. Hirota, A.M. Westendorf, J. Buer, L. Dumoutier, J.C.
Renauld, B. Stockinger, The aryl hydrocarbon receptor links TH17-cell-mediated
autoimmunity to environmental toxins, Nature, 453 (2008) 106-109.

152

CURRICULUM VITAE

Ashley Marie Mudd
Graduate Research Assistant
Department of Pharmacology and Toxicology
580 S. Hancock St.
Louisville, KY 40292
EDUCATION:
University of Louisville
M.S. and Ph.D. in Pharmacology and Toxicology
Cumulative Grade Point Average: 3.8
2014-present
Brown University
A.M. in Chemistry
Cumulative Grade Point Average: 3.8
Graduation Month/Year: June 2012
Wilson College
Chemistry (with honors in the major) & Spanish Double Major
Biology, Business and Economics Minors
Cumulative Grade Point Average: 3.9
Graduation Month/Year: June 2009
Mercersburg Academy
Graduation Month/Year: May 2005

RESEARCH AND PROFESSIONAL EXPERIENCE:

Graduate Research Assistant, University of Louisville (2014-present)
Working in the lab of Dr. Ramesh Gupta, my research focuses on utilizing Anthos
and ExoAnthos in the treatment and prevention of breast and colorectal cancer
as well as familial adenomatous polyposis. Additionally, my doctoral project
focuses on studying the interaction between the gut bacteria (Enterotoxigenic b.
fragilis) and the environmental pollutant, B[a]P in the development of CRC and
how, mechanistically, the blueberry-derived non-toxic anthocyanidins (Anthos)
impacts this dialogue. The results attained from this project will be a simple yet
153

elegant game changer for the prevention of colorectal cancer caused by
imbalance of the gut bacteria and exposure to cancer causing pollutants.
Scientist and Project lead, NuLabel Technologies (10/2012-06/2014)
Responsible for developing both the research and business aspects of my
project. During this time, I also co-authored three patents.
Visiting Scholar, Department of Molecular Biology, Cell Biology and
Biochemistry, Brown University (05/2013-06/2014)
Research focusing on discovering the biological phosphorylation networks in
immune cells, especially T cell signaling pathway quantitative phosphoproteomic
study.

Research Assistant, Department of Chemistry, Brown University (2010)
My research focused on profiling cell wall carbohydrate changes using GC-MS
during pollen development. I was responsible for developing extraction, sample
preparation and GC-MS methods.
Honors Undergraduate Research, Wilson College (2008-2009)
Independent research project that focused on investigating the relationship
between levels of β-carotene and Tetrachloroisophthalonitrile Fungicide Residue
levels in D.carota and R. sativus.
Internship with the Crawford Beck Vineyard Inc. (Summer 2008)
Responsible for creating a vineyard expansion plan involving the selection of
variety, clone, rootstock, site, and trellising system based upon market forces,
soil chemistry, degree growing days, as well as other factors.

TEACHING EXPERIENCE:
Teaching Assistant Undergraduate Organic Chemistry CHEM 350 and
CHEM 360
Brown University, Fall 2010-Spring 2012
Responsible for teaching 1-2 laboratory classes per week for the undergraduate
first (CHEM 350) and second semester (CHEM 360) organic chemistry classes.
During this time, I have instructed students how to use GC, prepare and run
basic gravity column chromatography, perform fractional, simple and steam
distillations, TLC, IR, refractometer, melting point apparatus and how to interpret
the results from the above. I have also helped students interpret Mass Spectra
and NMR (proton and 13C) spectra, as well as how to prepare the samples for
each method. Furthermore, I have also been responsible for grading lab reports,
lab quizzes, student laboratory notebooks, and lecture exams.

154

Peer Teacher First Year Seminar Solving 21st Century Problems: Theory to
Practice, Honors Section
Wilson College, Fall 2007
Worked with faculty member to develop the course, co-taught lectures, and
participated in grading.
Peer Teacher First Year Seminar on Sustainable Living, Honors
Section
Wilson College, Fall 2006
Worked with faculty member from the Biology department to develop the course,
co-taught lectures, and participated in grading.

ACADEMIC AND PROFESSIONAL HONORS:
--Currently a recipient of funding on the UofL NIEHS T32 training program in
Environmental Health Sciences award
-University of Louisville 1st place Louisville Women in Medicine and Science
Research Award (Fall 2015)
-University of Louisville IPIBS Fellowship recipient (Fall 2014-Summer 2016)
-Honors in Chemistry
-Wilson College Davison Greenawalt Grove Award for Distinction in Senior
Research in the Physical and Life Sciences (Spring 2009)
-Wilson College Margaret Strode Haines Award for “outstanding qualities of
scholarship, interest in the humanities and strength of mind, body and spirit”
(Spring 2009)
-Phi Beta Kappa honor society
-Wilson College Mary-Eleanor Maule Travel Grant (Spring 2009)
-Grant from the Pennsylvania Academy of Science for my Senior Research
project entitled: An Inquiry into the Existence of a Relationship between βcarotene and Tetrachloroisophthalonitrile Fungicide Residue levels in D.carota
(2008-2009)
-Scholarship to attend the 2008 International Diffuse Reflectance Conference
(IDRC)
-Peer Teacher Recognition Award (Spring 2008)
-Wilson College Mary-Eleanor Maule Travel Grant for Spanish (Spring 2008)

155

-National Science Foundation SEBCLAR scholarship (Fall 2007)
-Scholarship to attend Mises University at the Ludwig von Mises Institute of
Austrian
Economics (Summer 2007)
-Liberty Fund weekend colloquia (Fall 2006-Spring 2009)
-Wilson College Robert Shannon McElwain Prize in Mathematics awarded
(Spring 2007)
-Wilson College Organic Chemistry Award (Spring 2007)
-Wilson College Peer Teacher Recognition Award (Spring 2007)
-2006-2007 Intercollegiate Studies Institute Honors Fellow
-Wilson College Phoenix Scholar (2006-2009)
-Wilson College’s Honors Program (2006-2009)
-College Board Advanced Placement Scholar with Distinction (Spring 2005)
-Mercersburg Academy Colonel Wills First Place Prize in the Study of Economics
(Spring 2005)
-Maintained Honors-High Honors Academic Status while attending The
Mercersburg Academy (Spring 2005)

PUBLICATIONS:
Yang, L., Li, C., Mudd, A., Gu, X. LncRNA PVT1 predicts prognosis and
regulates tumor growth in prostate cancer. Biosci. Biotechnol. Biochem., 2017,
81(12) 2301-2306
Belmont, J., Gu, T., Mudd, A., Salomon, A. A PLC-γ1 Feedback Pathway
Regulates Lck Substrate Phosphorylation at the T Cell Receptor and SLP-76
Complex. J. Proteome Res., 2017 16(8), 2729-2742
Munagala, R., Aqil, F., Jeyabalan, J., Agrawal, A., Mudd, A. M., Kyakulaga, A. H.,
Vadhanam, M. V., Gupta, R. C. Exosomal formulation of anthocyanidins against
multiple cancer types. Cancer Lett., 393 (2017) pp. 94-102
Manuscripts under review/currently preparing manuscripts regarding:
156

Mudd, A. M., Gupta, R.C. et al., Influence of Anthos on EGFR, Src and
downstream signaling and Modulation of inflammatory environment and PD-L1
expression
Mudd, A. M., Gupta, R.C. et al., The role of anthocyanidins in reequilibrating
metabolic shifts induced by dysbiosis of the gut microbiome and the ubiquitous
environmental carcinogen, Benzo[a]pyrene.

PATENTS:
Mudd, A.M., Munnelly, H., Lux, B., Shear Stress-Resistant Systems and Uses
Thereof. Patent US20160331087 A1 (Issued Nov 17, 2016)
Cho, D., Mudd, A.M., Sonshine, D., Two-Component Hybrid Labeling System for
Use in Repeat Labeling. U.S. Patent US20140072748 A1 Sept 12, 2013 (Issued
March 13, 2014)
Lux, B., Mudd, A.M., Munnelly, H., Articles de conditionnement refermables et
leurs procédés de fabrication et d'utilisation. WO 2015073566 A1 Nov 12, 2014.
(Issued May 21, 2015)
ABSTRACTS/POSTER PRESENTATIONS:
Barbour, C. E., Mudd, A. M., Kyakulaga, A., Gupta, R. C. (2018, August) Role of
anthocyanidins on immune checkpoint protein, PD-L1 in HCT116 and HT-29
colorectal cancer cells. Abstract submitted for poster session at annual UofL R25
NCI summer scholar poster session, Louisville, KY.
Mudd, A. M., Gu, T., Jeyabalan, J., Munagala, R., Egilmez., N. K., Gupta, R. C.
(2018, April) Novel mechanistic insight into the prevention and treatment of
colorectal cancer and familial adenomatous polyposis by anthocyanidins.
Abstract accepted for presentation at annual American Association for Cancer
Research (AACR) meeting Chicago, IL.
Mudd, A. M., Gu, T., Jeyabalan, J., Munagala, R., Egilmez., N.K., Gupta, R. C.
(2017,
March)
Prevention and Treatment of Colorectal Cancer by BilberryDerived Anthocyanidin
s (Anthos) and Nano-Anthos. Abstract submitted for poster session at Berry
Health Benefits Symposium, Pismo Beach, CA.
Mudd, A. M., Gu, T., Jeyabalan, J., Munagala, R., Egilmez., N. K., Gupta, R. C.
(2016, October) Prevention and treatment of familial adenomatous polyposis

157

(FAP) and colorectal cancer by bilberry-derived anthocyanidins Abstract
submitted for poster session at annual Research Louisville, Louisville, KY.
Mudd, A. M., Munagala, R., Gupta, R. C. (2015, October) Exosomal formulations
enhance therapeutic response of anthocyanidins against breast cancer. Abstract
submitted for poster session at annual Research Louisville, Louisville, KY.
Gupta, R. C., Aqil, F., Vadhanam, M. V., Jeyabalan, J., Agrawal, A., Mudd, A. M.,
Kyakulaga, A., Karukonda, D., Spencer, W., Munagala, R. (2016, May) Milkderived exosomes – a platform nanocarrier to enhance anti-proliferative, antiinflammatory and anti-cancer activities of small drug molecules against multiple
human cancers. Abstract accepted for presentation at Annual meeting of ISEV,
Rotterdam, Netherlands.

Mudd, A. M., Santai, C. (2009, March) An Inquiry into the Existence of a
Relationship between β-carotene and Tetrachloroisophthalonitrile Fungicide
Residue levels in D.carota. Abstract accepted for presentation at annual meeting
of the Pennsylvania Academy of Science, Harrisburg, PA
Professional Memberships
American Association for Cancer Research
American Chemical Society
Pennsylvania Academy of Science
Phi Beta Kappa Honor Society

158

